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I. General Introduction 
 
1. Adenylyl Cyclases 
 
1.1 Mammalian Adenylyl Cyclases 
The modulation of AC activity is the key step in intracellular cAMP regulation 
by extracelluar stimuli. In mammals, the major ACs are integral plasma membrane 
proteins;  they  catalyze  the  synthesis  of  cAMP  and  pyrophosphate  (PPi)  by 
conversion of adenosine 5’-triphosphate (ATP) (1-4). In intracellular signaling 
pathways adenosine 3’,5’-cyclic monophosphate (cAMP) is a key player as second 
messenger in the response to first messenger signaling molecules such as 
neurotransmitters, hormones, and odorants. Until recently, the signaling by this 
archetypal second messenger was thought to be straightforward, but fifty years after 
its discovery by Earl Sutherland, cAMP regulation has become very complex. By 
direct activation of nucleotide-gated ion channels and stimulation of protein 
phosphorylation via activation of protein kinase A (PKA), cAMP is known to be 
involved in modulation of membrane potential and the rate of cell division (5-7).  
Independently of any phosphorylation, cAMP also induces protein-protein 
interactions, e.g. in signaling of Rap1 proteins (8, 9). The high complexity of 
synthesis and degradation of the second messenger is also due to a multiplicity of 
phosphodiesterases and adenylyl cyclase (AC) isoforms. 
 
ACs act as effector enzymes integrating extracelluar signals by G-protein 
coupled receptors (GPCRs) to a variety of intracellular signaling pathways (10, 11).  
The classic receptor-G-protein-AC signal transduction cascade is characterized by a 
large excess of G-proteins compared to receptor and effector molecules. Therefore, 
G-proteins are the major amplification factor of the GPCR signal (12, 13), and the AC 
molecules are the limiting component for maximum second messenger production in 
response to hormone stimulation (14, 15). Although ACs do not contribute 
extensively to the amplification of intracellular signaling, they participate in diverse 
manners to integrate signaling pathways and cross-talks in different cell systems (16, 
17). 
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Mammalian ACs are transmembrane proteins with the exception of one 
soluble form of AC (sAC) identified in testis (18). Nine different AC isoforms have 
been identified in mammals that differ in tissue distribution, activation and inhibition 
by different mediators (19, 20). 
 
1.2 Bacterial Adenylyl Cyclase Exotoxins 
In addition to mACs, several microorganisms such as Bacillus anthracis, 
Bordetella pertussis and Pseudomonas aeroginosa, release AC toxins that play an 
important role in disrupting several host intracellular signaling pathways. These 
exotoxins enter host cells via different mechanisms and cause a dramatic increase in 
cAMP levels (21-23).  
  
1.2.1 Anthrax Adenylyl Cyclase Toxin, Edema Factor 
One such toxin is Edema Factor, released by Bacillus anthracis that alters 
water homeostasis and causes edema by increasing cAMP levels (24, 25). Though 
mACs and EF are structurally distinct, both these enzymes are important cAMP 
modulators and they both constitute potential drug targets. By regulating cAMP 
levels, mACs play an important role in several diseases such as congestive heart 
failure, and bronchial asthma (19, 20).  By increasing cAMP levels, EF contributes 
significantly to cutaneous and systemic forms of anthrax (26, 27). 
 
Anthrax disease 
Anthrax, caused by Bacillus anthracis, is a deadly epizootic disease primarily 
affecting cattle and consequently humans that come in contact with infected animals 
or animal products (28, 29). Occupational exposure to infected animals or their 
products - such as skin and meat - is the usual pathway for humans. Persons, who 
work with imported animal hides, tissues or furs from high incidence areas and 
workers, who are exposed to dead animals and animal products, are at the highest 
risk to become infected, especially in countries where anthrax is more common. 
Human anthrax is more common in developing countries of Asia and Africa 
compared to the developed countries (30).  
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Anthrax cases have been described as early as 16th century BC in Egypt and 
several publications describing anthrax were published in the 1800s (31, 32). More 
recently, anthrax spores were used during the terrorist attacks in the US in 2001 
giving a new meaning to the word bioterrorism (33). 
Bacillus anthracis is a large Gram-positive bacterium that forms spores when 
coming in contact with oxygen (Fig. 1). The spores which carry the virulent factors 
are highly resistant to a wide range of climatic and environmental conditions such as 
high temperature, UV light and high pH (34-36). The spores carry three exotoxins 
namely Edema Factor (EF), Lethal Factor (LF) and Protective Antigen (PA) and a 
poly-γ-D glutamyl capsule, all of which are released when the spores come in contact 
with host cells. Crystallographic, biochemical, kinetic and structural studies have 
greatly improved our understanding of the mode of action of these toxins. 
 
Fig. 1: a) Coloured scanning, electron micrograph (SEM) of bacillus anthracis (37), b) Gram-
stain of bacillus anthracis (38), c) Original photomicrograph of Bacillus anthracis by Robert 
Koch (38). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. 2.1.1 Anthrax – infection, diagnosis, treatment and prevention 
a 
a 
C 
C 
b 
Chapter I                                                                               Introduction and aim of the work 
 
                                                                                                                                                                               
 5 
Anthrax is primarily classified into three types depending on the mode of entry 
of the spores into the host. These anthrax forms are (a) cutaneous anthrax, (b) 
inhalational anthrax and (c) gastrointestinal anthrax. There are also some minor and 
rare forms of anthrax such as anthrax sepsis and renal and ophthalmic forms of 
anthrax  (32). 
 
Cutaneous anthrax 
Cutaneous anthrax is the most common manifestation of anthrax in humans, 
accounting for more than 95 percent of cases occurs due to introduction of 
endospores into the body through a cut, break or abrasion on the skin. In most 
cases, cutaneous anthrax in humans is due to the handling of infected animals or 
their products. There have also been reports of some rare cases of cutaneous 
anthrax due to biting of flies that have fed on anthrax-infected animals. The 
incubation period of spores is typically between 1-12 days (39). The signs and the 
symptoms appear with the development of papule on the skin which slowly turns into 
a vesicle showing necrosis, edema and a characteristic black eschar (lesion) (Fig. 2). 
The cutaneous form of anthrax can be effectively treated with antibiotics and can be 
fatal if left untreated. About 20 percent of untreated cases of cutaneous anthrax will 
result in death. Anthrax is not spread from person to person by casual contact, 
coughing and sneezing; the only way anthrax can be transmitted is by direct contact 
with the drainage from an open sore (32, 40, 41). 
 
Inhalational anthrax 
Inhalational anthrax, also called pulmonary anthrax, is the most lethal form of 
anthrax. The spores inhaled and, after a brief journey to the lungs, reach the alveolar 
sac. the immune cells, macrophages, become aware of the presence of anthrax 
endospores and start to engulf them (42). The macrophages travel to the lymph 
gland where the immunity against the future infection is prepared. However, the 
spores are not destroyed but germinate to vegetative bacteria called bacilli. The 
Initial symptoms start with fever and cough. Within a few hours, more serious 
symptoms such as dyspnea (shortness of breath), cyanosis (blue coloration of the 
skin) and respiratory failure develop leading to septicemia, shock and death. Current 
models for inhalational anthrax assume that bacilli, multiply and lyse cells, then 
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spread through lymph nodes causing extensive septicemia (Fig. 3). Inhalational 
anthrax cases have a high mortality rate and broad-spectrum antibiotic therapies 
have not been very helpful (40, 43, 44). 
 
Gastrointestinal anthrax (GI anthrax) 
The gastrointestinal form of anthrax accounts for less than 5% of all anthrax 
infections. Gastrointestinal anthrax occurs due to ingestion of spores through 
contaminated food or water. This form of anthrax has a high mortality rate. Two 
subforms i.e. the oropharyngeal form where spores get deposited in the upper GI 
tract, and the intestinal or abdominal form with deposition of spores in the lower GI 
tract, have been reported. The latter form is characterized by an acute inflammation 
of the intestinal tract. First symptoms of nausea, loss of appetite, vomiting and fever 
are followed by abdominal pain, vomiting of blood and severe watery or bloody 
diarrhea. Intestinal anthrax results in death in 25-60 percent in cases (45). Extensive 
edema and necrosis occurs in both forms of GI anthrax. If detected early, GI anthrax 
can be treated with antibiotics. Once spores invade the bloodstream, they cause 
toxemia, septicemia and death (46).  
 
 
 
Fig. 2: Cutaneous anthrax; examples for the cratered center surrounded by dying 
tissue, a (47), b (48), c (49) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a b c 
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Fig. 3: Inhalational anthrax - Chest X-rays may show a widened mediastinum and 
pleural effusions (50). 
 
 
 
 
 
 
 
 
 
 
 
Diagnosis, treatment and prevention 
The symptoms of systemic anthrax infection resemble septic shock and kill the 
patient within days. For example, inhalational form of anthrax is a deadly disease; the 
bacilli and their exotoxins diffuse through the body before the immune system has 
had a chance to eradicate the invaders. Laboratory diagnosis of anthrax includes 
Gram and polychrome methylene blue staining of the specimen from potentially 
infected patients to identify the polypeptide capsules of Bacillus anthracis. Bacillus 
anthracis from body fluids can also be cultured in blood agar and identified as large 
colonies, white or grey in color. It can also be diagnosed by measuring specific 
antibodies in the blood of infected persons. The anthrax skin test is performed by 
injecting an attenuated strain and is positive in 85% of cases immediately after 
infection (32, 51, 52). 
 
The first vaccine for anthrax was developed by Louis Pasteur by injection of 
an attenuated Bacillus anthracis strain. Protective antigen (PA) was discovered as 
one of the toxins responsible for virulence by Gladstone (53). By the 1950s, the AVA 
vaccine was developed with PA and small amounts of Edema factor (EF) and lethal 
factor (LF) from an attenuated strain adsorbed to aluminum hydroxide. AVA, the only 
vaccine for anthrax approved for use in humans, was licensed by the FDA in the 
1970s. AVA with the trade name BioThrax® is manufactured by Bioport Corp 
(Lansing, MI, USA), parent company of Emergent Biosolutions (Rockville, MD, USA). 
Due to problems related to purity, differences in reactivity and manufacturing, a next 
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generation vaccine called rPA is being clinically tested to determine its safety and 
reactivity. rPA is a recombinant protective antigen purified from an asporogenic 
Bacillus anthracis strain. rPA was clinically tested by VaxGen Inc (Brisbane, CA, 
USA) and later acquired by Emergent Biosolutions (Rockville, MD) in 2006 (54). Due 
to the rapid growth of Bacillus anthracis in vital organs the pathogenesis of anthrax is 
mediated by the combination of bacteremia and toxemia (55-57). Anthrax bacteria 
are sensitive to a broad spectrum of antibiotics; thus antibiotics are the primary 
treatment of this infectious disease. However, antibiotics are ineffective against either 
toxemia or antibiotic-resistant strains (58-60). In addition to vaccines, post-exposure 
treatment for anthrax is aggressive and comprises timely antibiotic therapy with 
penicillin, doxycyclin and other broad spectrum antibiotics such as fluoroquinolone 
compounds. 
 
Approaches to develop next-generation drugs and vaccines for anthrax are 
exploring new avenues such as inhibitor design for receptor binding, toxin assembly, 
endocytosis, and enzymatic activity of toxins and targeting virulence of the poly-γ-D 
glutamyl acid capsule (61-63). 
 
Prevention is effective by surveillance and regular check-up of humans 
working closely associated with animals and military personnel working in higher-risk 
areas where anthrax spores may be used for potential biological warfare. Timely 
immunization of animals and humans is also a key to preventing anthrax infections in 
case of a suspicious exposure to anthrax spores (64, 65). 
 
1.2.1.2 Anthrax – Biological warfare and incidence in developing countries 
 
Bacillus anthracis spores have been used as bioweapons and several 
significant incidents occurred during the last few centuries. Ideal characteristics of 
biological weapons are quick low-cost-production in large quantities, easy cultivation 
of the microbes, high infectivity, high potency, fast-acting without a long lag time 
between dispersal and debilitating illness and delivery as an aerosol. Often, the 
biological weapons can be manufactured quickly and easily – the primary difficulty is 
not the production of the biological agent but delivery in an infective form to a 
vulnerable target (66-68). Anthrax spores were purportedly used to kill millions of 
people and cattle during the movement of Huns across Eurasia in 80 AD (69). In 
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1941, the British Government tested the effect of anthrax spores as a bioweapon in 
Gruinard Island near Scotland. The island was uninhabited until 1986 after several 
attempts were made to sterilize the soil (70). In 1979, 96 cases of anthrax including 
68 deaths resulted due to accidental release of anthrax spores from a military facility 
in Russia (71). In 1993, an attenuated strain of anthrax was sprayed from the top of a 
building by the Aum Shinrikyo, a doomsday cult in Tokyo (72-74). In 2001, anthrax 
spore-laced letters caused widespread panic among people in the United States and 
worldwide. The event of the 2001 bioterrorism-related anthrax attack in the United 
States highlighted an urgent need for a valuable, more effective adjunct to 
conventional antibiotic treatment to improve survival rate and quality of life of patients 
suffering from anthrax due to future acts of bioterrorism (75). For cases of pulmonary 
anthrax antibiotic treatment used for victims of this attack resulted in a survival rate of 
slightly better than 50%. Due to its high potency, hardiness and resistance to a wide 
range of conditions, anthrax is classified as Category A bioterrorism agent by the US 
Centers for Disease Control and Prevention (CDC). It is estimated that a 50 kg of 
anthrax aerosol spray would result in millions of deaths and, therefore, the potential 
devastating effects of anthrax cannot be underestimated (76). 
 
Naturally occurring anthrax is still a major problem in several countries such as 
India, Turkey, Greece and countries in the African continent. Until 2006, at least 205 
cases of anthrax have been reported in parts of Southern India especially in the 
under-developed regions (76, 77). Actually, there is no doubt that, lack of awareness 
and lack of vaccinations for both humans and livestock are the primary reasons for 
high incidence of anthrax infection. 
 
In view of the potential use of anthrax as a bioweapon and the high incidence 
of naturally occurring infections, there is an urgent need for the development of 
efficient, accessible and cost-effective drugs, vaccines and other therapeutics to 
prevent and cure anthrax. 
 
 
 
 
 
 
Chapter I                                                                               Introduction and aim of the work 
 
                                                                                                                                                                               
 10 
1.2.1.3 Anthrax tripartite toxin and mechanism of toxin translocation into host 
cells 
Virulence factors of Bacillus anthracis are encoded on two plasmids: - pXO1 
which contains genes responsible for synthesizing the exotoxins EF, lethal factor 
(LF), and protective antigen (PA), and pXO2 which carries genes that synthesize the 
poly-γ-D glutamyl capsule. Bacillus anthracis toxin is a member of the bacterial binary 
A-B toxin family where the B moiety acts as a transporter helping the A moiety to 
translocate into the cytosol. The A moiety exerts its deleterious effects after it enters 
the cytosol. In the case of B.anthracis, PA acts as a transporter protein and 
translocates EF and LF into the host cell (28, 78) (29, 79, 80) . 
 
Protective antigen (PA) is an 83 kDa protein that binds to specific receptors 
referred to as ANTXR1 (tumor endothelial marker 8) and ANTXR2 (Capillary 
morphogenesis protein 2), on host cells. Both ANTXR1 and ANTXR2 are widely 
expressed in cells and consist of regions similar to the von Willebrand factor type A 
domain and the Integrin I domain, thus binding to collagen and collagen/laminin 
respectively. LRP6, a cell surface protein, can also act as a coreceptor. By 
interacting directly or indirectly with ANTXR1 and ANTXR2, LRP6 can stimulate PA 
binding to ANTXR1 and ANTXR2 (81-87). After PA83 is bound to ANTXR1 or 
ANTXR2, it is cleaved by a member of the furin family of proteases. The N terminal 
region of PA83 is cleaved, releasing PA20 extracellularly, and PA63 is bound to the 
receptors (88). PA63 then self oligomerizes to form a ring-shaped heptamer referred 
to as prepore conformation. EF and LF bind competitively with high affinity to the 
PA63 heptameric prepore conformation. Several studies have shown that a 
maximum of three molecules of EF and/or LF can be accommodated by the PA63 
heptamer. 
  
The recognition sites of the interaction of EF and LF with PA63 heptamer have 
been mapped and both EF and LF are positioned with their N termini at the entrance 
of the PA63 prepore and therefore can translocate in the N- to C terminal direction. 
The PA63 heptamer with bound LF and or EF then undergoes receptor-mediated 
endocytosis and is transferred into an intracellular acidic compartment. The low pH in 
the endosomal compartment results in structural rearrangements, giving rise to the 
PA63 pore conformation that can now insert itself in the endosomal membrane. The 
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PA63 pore is typically a 14-strand transmembrane β barrel with a water-filled central 
cavity of about 15 Å in diameter (79, 88-90). EPR (Electron Paramagnetic 
Resonance) studies have shown that seven F427 residues from the PA63 heptamer 
form a “Φ” (phi) clamp exposing their aromatic rings in the lumen. The Φ clamp 
causes partial unfolding and translocation of EF and LF through the pore coupled to 
a positive membrane potential across the membrane (91). 
 
Fig. 4: Schematic representation of PA binding, assembly, endocytosis and 
translocation of EF and LF inside the cytosol. 
PA83 binds to specific receptors on the membrane. Furin endoproteases 
present on the cell membrane cleave PA83, releasing PA20 extracellularly, and 
PA63 bound to the receptor. PA63 self-oligomerizes to form a ring-shaped heptamer 
termed the prepore complex that can bind to EF and or LF. Prepore complex with 
bound EF and or LF is then endocytosed to an intracellular acidic compartment. The 
lower pH in the endosome triggers structural rearrangements causing a change in 
conformation from prepore to pore causing partial unfolding and translocation of EF 
and LF into the cytosol. 
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1.2.1.4 Anthrax toxin components and their function 
Protective antigen (PA), 83 kDa protein, is divided into four domains. Domain 
1 has a recognition site for Furin-like family endoproteases and part of domain 1 is 
cleaved giving rise to PA20 that is released extracellularly and PA63 which can self 
oligomerize. Domain 2 undergoes pH-dependent conformational changes and helps 
in oligomerization, conversion from prepore to pore forms and translocation of EF 
and LF into the cytosol. Domain 2 from seven PA63 monomers forms the 
transmembrane β barrel and consists of the Φ clamp for unfolding and translocation 
of EF and LF. Furthermore, it has been shown that K397 from one PA domain 2 can 
form a salt bridge with D426 of the neighboring PA domain 2 thus giving rise to a 
loop bringing the F427 residues closer to form the Φ clamp. Mutational studies have 
shown that Domain 3 is also important for oligomerization of PA63. Domain 4 
consists of the receptor-binding domain and is important for the interaction of PA with 
its cellular receptors ANTXR1 and ANTXR2 (92-95). 
 
Lethal factor (LF) is a 90 kDa zinc-dependent metalloprotease that can cleave 
the proline-rich N-terminal of mitogen–activated protein kinase (MAPK) kinases 
(MEKs).  LF can cleave and inactivate all MEKs except MEK 2. Since MEKs serve as 
important substrates for downstream signaling, proteolytic inactivation of MEKs by LF 
inhibits the MAP kinase signal transduction pathways that include p38, JNK and 
ERK. The crystal structure of LF with bound substrate and inhibitor has shown the 
presence of four domains. The N-terminal domain 1, or LF-N, is the protective 
antigen binding domain and has residues similar to EF-N. Domain 2 and Domain 3 
serve as sites for substrate recognition. The C terminal domain 4 consists of the zinc 
metalloprotease site (79, 96, 97). Though several studies have shown that EF and LF 
can bind only to PA63 heptamers, recent evidence suggests that LF and LF-N (N-
terminal region of LF) can bind to PA63 monomer, albeit with lower affinity. It has 
also been shown that PA20 interacts with LF-N, though a functional role for this 
interaction has not been determined (89, 98). It has also been demonstrated that low 
concentrations of LF bind to PA63 and higher concentrations inhibit PA63 assembly 
(99). 
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Edema Factor (EF) is a 93 kDa calmodulin (CaM)-activated adenylyl cyclase 
that can convert ATP to cAMP (23). Increased cAMP levels can cause several 
changes by activating downstream targets such as PKA, in turn disrupting 
intracellular signaling pathways and impairing host defences (43). EF is thought to be 
primarily responsible for the cutaneous form of anthrax (23, 100). A detailed analysis 
of the structure and intracellular activation of EF will be discussed in the following 
sections. 
 
ET (EF with PA) and LT (LF with PA) can together or separately impair host 
defences by promoting bacterial invasion (101). Both ET and LT suppress innate 
immune responses and impair human neutrophil activity (102, 103). ET and LT inhibit 
the generation of superoxides and reactive oxygen species (ROS) by NADPH 
oxidase activity of human neutrophils needed to cause bacterial killing (104). ET 
increased cAMP levels of lymphocytes can cause changes in important gene 
expression resulting in suppression of the immune response. ET can also inhibit 
chemotaxis in endothelial cells by activating downstream effectors such as Epac and 
RAP1 (105). Also, the PA binding domain of EF is not essential for potency of ET 
(106). Furthermore, ET can inhibit platelet aggregation and cause hemorrhage, an 
important symptom of anthrax (107).  Anthrax toxin can induce hemolysis in the 
presence of polymorphonuclear cells (PMNs), an activity primarily mediated by PA, 
with synergistic effects provided by LF and EF (108). EF and LF are capable of 
inducing hemolysis (lysis of blood cells) in the presence of neutrophils (108). 
 
1.2.1.5 Edema Factor – structure and intracellular activation 
EF can be possesses two domains, a 30 kDa N-terminal protective antigen 
binding domain and a 63 kDa CaM sensitive adenylyl cyclase domain or EF3 (26, 
109). The PA-binding domain is homologous to the N terminal region of LF (110). 
EF3 can be further divided into N terminal EF3 (EF3-N) and a C terminal EF3 (EF3-
C). EF3-N is homologous to AC exotoxins from Bordetella pertussis and 
Pseudomonas aeuroginosa. It is resistant to protease digestion. EF3-C is sensitive to 
protease digestion in the absence of CaM (109). 
 
After PA-mediated entry of EF into the cells, EF binds to calmodulin (CaM). 
CaM is a highly conserved calcium sensor protein. CaM has a molecular weight of 
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16.5 kDa and consists of N- and C-terminal globular domains which are connected 
by a flexible, central α-helix (Fig. 5), and is ubiquitously expressed in cells. CaM 
binds and modulates activities in a large number of targets that include enzymes, 
pumps and ion channels in a calcium-dependent manner, thus playing an important 
role in several intracellular processes such as signal transduction and gene 
transcription (111, 112). 
 
X-ray and NMR studies have shown that CaM exists as a flexible dumbbell- 
shaped structure with two globular end domains; each globular domain comprises 
two helix-loop-helix calcium-binding motifs. Calcium binding to CaM induces 
conformational changes from a closed state with a highly negatively charged surface 
to an open conformation. In the closed state, the two helices of each Ca2+-binding 
helix-loop-helix motif are almost anti-parallel, whereas in the open conformation the 
two helices are nearly perpendicular. These conformational rearrangements lead to 
the exposure of a large, hydrophobic binding pocket (113, 114).  
 
 
 
Fig. 5: A) 3-d-structure of Ca2+-free calmodulin (115). B) 3-d-structure of 
calmodulin in complex with Ca2+-ions (blue spheres) (116, 117).  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
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CaM binding causes large conformational changes in the structure of EF. The 
structure of EF is crucially dependent on binding of its cofactor. In the absence of 
calmodulin, EF shows no catalytic activity. 
 
The crystal structure of EF with and without CaM and inhibitor, solved by Drum 
et al (2001), showed that the C terminus of EF consists of three domains, CA, CB 
and a helical domain. A linker region connects CA to the helical domain and CA and 
CB together form the catalytic core of the enzyme. In the CaM-free EF structure, CA, 
the helical domain and switch C form a contiguous, positively charged surface that is 
likely to make initial electrostatic contacts with the highly negatively charged CaM. 
The unusually large binding surface between EF and CaM stabilize the various 
structural rearrangements that activate EF. EF activation by CaM is a multistep 
process, which is initially mediated by CaM-binding residues that are exposed in the 
CaM-free state. One such residue, Lys 525, has been identified as a binding 'hot 
spot' through alanine-scanning mutagenesis of EF residues located in the interface 
between helix H and CaM. Whereas mutations in nearby residues Lys 523, Gln 526 
and Val 529 have little effect on CaM activation, the Lys525Ala mutation markedly 
increases (200-fold) the CaM concentration for half-maximum response (EC50), with 
only a small reduction in the velocity of the enzyme-catalysed reaction at infinite 
concentration of substrate (Vmax). 
 
CaM is almost completely wrapped by a clamp formed by CA, linker and the 
helical domain in such a manner that it causes a 30˚ rotation and a 15 Å movement 
of the helical domain. In addition, three regions, switch A, B and C in EF also 
undergo large conformational changes due to CaM binding. Switch A (residues 502-
551) consists of amino acid residues important for CaM- and nucleotide binding. 
Switch B (residues 578-591) contains residues important for ATP binding and 
catalysis. Switch C (residues 630-659) consists of residues from the linker region and 
swings almost 33 Å when CaM binds to EF. The EF-CaM interaction is stabilized and 
strengthened by a large number of both hydrophobic and hydrophilic contacts. FRET 
(Fluorescence resonance energy transfer) experiments have also shown that CaM 
binds to EF in an extended conformation unlike its binding to a number of other 
proteins (109, 118). 
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There are several mechanisms by which activators are known to activate 
enzymes. The activation of EF by CaM is conceptually most similar to the activation 
of G  proteins by regulator of G-protein signalling. In this case, as in EF, the catalytic 
machinery is present near the site of catalysis, but is disordered in the inactive state. 
The most surprising aspect of EF activation by CaM is that the conformational 
switches associated with activation do not involve residues that participate in 
chemical catalysis. The catalytic base, the metal-binding site, and all of the amino 
acids thought to be involved in stabilizing the pentavalent transition state are virtually 
identical in the active and inactive states of the enzyme. These residues 
are significantly more exposed to solvent (and substrate) in the inactive state than in 
the active state. The switch that gives rise to a 1,000-fold increase in enzyme activity 
involves residues that bind and position the substrate, not those that perform the 
catalytic reaction (25). 
 
Fig. 6: Schematic illustration of EF and EF3 proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N – terminal domain 30 kDa 
Homology to N terminal 
domain of LF 
C – terminal domain (EF 
Approx. 60 kDa catalytic domain 
CaM – sensitive AC activity 
EF – 92.5 kDa soluble protein 
N – terminal domain (EF3-N) 43 kDa 
Homology to ACs from B. pertussis 
and P. aeruginosa 
C – terminal domain (EF3-C) 
Approx. 20 kDa 
+ 
+ 
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Fig. 7: Crystal structure of EF (a) EF alone (b) EF with bound CaM and 3’dATP 
(25). 
 
CA and CB domains of EF are shown in green and the helical domain is 
shown in yellow. Switch A, B and C regions are shown in blue, orange and magenta 
respectively. CaM is shown in red and metal ions and 3’-d-ATP are shown in purple. 
CaM is wrapped by the helical domain and the switch A, C and CA regions. The CA 
and CB domains form the catalytic core of EF (25). 
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1.2.1.6 Catalytic mechanism of EF 
Following activation of EF by CaM, EF catalyzes conversion of ATP to cAMP. 
Several crystal structures of EF with bound CaM and nucleotide/inhibitor have been 
solved that greatly helped to improve our understanding of the ATP binding and 
catalysis processes. The first crystal structure of EF with bound CaM and 3’-d-ATP 
published by Drum et al., (2002) indicates a single metal ion-mediated catalytic 
mechanism (Fig. 8, A) unlike the mammalian ACs where two-metal-ion-catalysis is 
observed. Drum et al., (2002) observed that the single metal ion is coordinated by a 
pair of aspartate residues (D491 and D493) and interacts with the oxygens of the α 
and β phosphates of the substrate analog 3’-d-ATP. Furthermore, H351 serves as a 
catalytic base and is thought to interact with the 3’-OH of the substrate to promote 
nucleophilic attack (25). In support of this hypothesis, Gupta et al., (2005) have 
shown in their kinetic studies that when H351 was mutated to alanine, aspargine or 
phenyl alanine, AC activity was reduced several-fold, indicating the importance of 
histidine 351 in catalysis by EF (119, 120). 
 
A major difference of two-metal-ion catalysis from the proposed mechanism of 
EF by Drum and co-workers is the presence of additional metal ion, instead of 
histidine, to facilitate the deprotonation of the 3’-OH. One key feature for enzymes 
that use two-metal–ion catalysis utilizes two closely spaced aspartate residues to 
coordinate the catalytic metal ions. Interestingly, EF also has the same setup, raising 
the possibility that EF may also use two-metal–ion catalysis. Shen et al., (2005) 
refined the first model and found that EF contains two metal ions similar to 
mammalian ACs and DNA polymerases. Metal ion A is coordinated by the conserved 
aspartate residues and H577. Metal ion B is coordinated by D493 and the non-
bridging oxygens of all three phosphates of ATP. Furthermore, it was shown that 
H351 does not act as a catalytic base because it was at least 6 Å away from the 3’-
OH of the substrate making it unlikely to be able to accept a proton from the 3’-OH 
during the cyclization reaction. Site directed mutagenesis studies have shown that 
when H351 was mutated to lysine, there was no change in AC activity or the pH 
optimum, further confirming that H351 is not the catalytic base but may act to 
stabilize the 3’-OH group.  
 
To promote the ATP cyclization reaction, EF needs to bind ATP, facilitate the 
deprotonation of 3’-OH, stabilize pentacoordinated phosphorane intermediate, and 
Chapter I                                                                                Introduction and aim of the work                            
                                                                                                                                                                               
 20 
effectively release cAMP and PPi. It is proposed that EF uses N583 to restrain the 
rotational freedom of ribose, thus holding 3’-OH in place for its nucleophilic attack 
during the catalysis (Fig. 8, D). The protonated histidine 351 is used to stabilize the 
OH ion near the 3’-OH group. A variant of this mechanism is that EF uses neutral 
histidine 351 to deprotonate a neutral water molecule. This OH ion in turn facilitates 
the deprotonation of 3’-OH of ATP. A suitable catalytic metal ion, MgA, near the 3’-
OH of ATP is coordinated by D491, D493 and H577 residues. This metal can also 
facilitate the deprotonation of 3’-OH by stabilizing the negative charge on the 
resulting 30-oxyanion. The action of MgA ion and histidine 351 can be additive (117). 
 
Using the energy term, the free energy cost (∆G) associated with the proton 
transfer of 3’-OH is proportional to the difference between pKa of the 3’-OH group 
and local pH of the solution. The catalytic role of H351 is to increase local pH, 
whereas the role of the catalytic metal is to decrease the pKa component to make 
∆G small or even negative. In addition, this metal ion, MgA, also stabilize the reaction 
intermediate by moving towards the nonbridging oxygen of α-phosphate during the 
nucleophilic attack step of the catalytic reaction (117).  
 
A second metal ion, MgB, is coordinated by D493 and nonbridging oxygens of 
all three phosphates of ATP. This metal ion can facilitate the bond breakage between 
α and β-phosphates by stabilizing the developing negative charges. Several positive 
residues (R329, K353, K372 and K346) are also involved in stabilizing the reaction 
intermediate and the departure of PPi. The side chain of N583 forms hydrogen bond 
with the ribose ring and holds the 3’-OH group in place for nucleophilic attack (117). 
 
Shen et al (2004) have also demonstrated an alternate binding mode of ATP 
to the catalytic core of EF. They showed that AMPCPP (adenosine 5’-(α, β-
methylene)-triphosphate) binds to EF differently compared to 3’-d-ATP and 2’d-3’-
ANT-ATP. The ribose ring of AMPCPP is rotated 105˚ and the adenine ring is rotated 
by 180˚ in the catalytic site of EF (65, 121). 
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Fig. 8: Catalytic mechanism of EF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Catalytic mechanism of EF (A) A ball and stick model of the EF active site. EF is shown in 
green, side chains of important residues in blue and ligand in black (25); (B) Proposed 
catalytic mechanism of EF. Single metal ion-mediated catalysis is shown. (25); (C) Simulated 
model based on the EF-CaM-3’-d-ATP catalytic site. EF is in green, ligand in black and Mg 
ions are shown in orange (117); (D) Proposed two metal ion catalytic mechanism of EF 
(117). 
 
 
 
 
 
 
 
 
 
D
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1.2.1.7 Challenges, limitations and future directions of anthrax research with 
special focus on EF 
With a better understanding of the detrimental effects of anthrax, it will 
become possible to develop highly specific control measures to prevent and treat 
anthrax infections. The efficacy of the AVA vaccine currently used is a cause for 
major concern since adverse side effects have been reported in some cases. 
Another disadvantage of AVA vaccine is that it is available only for military personnel. 
Antibiotic treatment is effective only against the cutaneous forms of anthrax. 
Therefore, there is a need for better vaccinations, drugs and other therapeutics to 
prevent anthrax infection not only in military personnel but also in humans and 
animals that are at a higher risk of contracting the infection. 
 
With recent evidence that LF binds to monomeric PA, the question arises as to 
whether monomeric PA could translocate LF and EF into the cytosol. To this end, it 
has been shown that LF binds to monomeric PA with low affinity and would probably 
require PA heptamer for its translocation. Another important challenge faced by 
researchers is the lack of crystal structure of PA heptamer since it is a 
transmembrane protein. Solving the crystal structure of the PA heptamer would 
substantially improve our understanding of the PA prepore formation, binding of LF 
and EF, and help develop PA-based inhibitors. With the current model of the PA 
heptamer, it is known that the Φ clamp formed by the PA heptamer facilitates the 
translocation of EF and LF; however, it is not clear how these proteins unfold and 
refold in the cytosol. 
 
Using various approaches to study the anthrax toxins, several steps in the 
intoxication mechanism can be blocked and studied for future rational drug design. 
For example, the binding sites of EF on PA have been mapped, so it would be 
interesting to study inhibitors that would block protein-protein interaction, EF-PA 
interaction, thus preventing entry of EF into the cytosol. Once inside the cell, 
inhibitors can be developed to block two important processes of EF. One is CaM- 
dependent activation of EF, the second is the catalytic activity of EF. The crystal 
structure of EF-CaM shows that EF makes extensive contacts with CaM and CaM 
changes the conformation of EF from a closed to an open conformation, thus 
exposing the substrate binding site. An important challenge here is to understand the 
specificity of this interaction, since CaM is a ubiquitously expressed protein that binds 
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to several other protein targets. Although several small molecules have been 
designed to block the catalytic activity of EF both in vitro and in vivo, there is a critical 
need for more potent and cell-permeable inhibitors (122, 123). 
 
In summary, early detection, appropriate timely treatment and improved 
vaccines combined with a better understanding of the molecular basis of the 
biological action of anthrax toxins are critical for control and prevention of anthrax. 
 
1.3 Nucleotide-analogues as inhibitors for mammalian and bacterial adenylyl 
cyclases 
  Substrate analogues can be used as inhibitor for the catalytic activity of 
mammalian and bacterial ACs (124, 125). The classic adenylyl cyclase (AC) 
inhibitors are adenine nucleotides with a phosphate or a polyphosphate at the 3’-O-
ribosyl position (124, 126, 127). These compounds are also referred to as P-site 
inhibitors. P-site inhibitors are noncompetitive or uncompetitive AC inhibitors that 
bind to the AC-PPi conformation (128, 129). P-site inhibitors exhibit a moderate 
degree of specificity for mammalian AC isoforms (127). EF is highly sensitive to some 
of P-site inhibitors (61, 125). Furthermore, adefovir diphosphate (PMEApp), the 
active cellular metabolite of the adefovir dipivoxil, which is approved as a drug for the 
treatment of chronic hepatitis B virus infection, is also a potent EF and CyaA inhibitor. 
In addition 2',3'-N-methylanthraniloyl (MANT)-, anthraniloyl (ANT)- and 2,4,6-
trinitrophenyl (TNP)-substituted nucleotides  are environmental sensitive fluorescence 
probes that show an increase in fluorescence with a hydrophobic environment (Fig. 
9) (130). ANT- and MANT-nucleotides have been used successfully to study 
conformational changes in various nucleotide-binding proteins including G-protein 
and bacterial AC toxins (131, 132).  
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Fig. 9: Representative examples of AC inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.1 Anthraniloyl-substituted purine and pyrimidine nucleotides 
 These fluorescent probes possess protein-binding properties similar to those 
of natural nucleotides that are involved in many metabolic processes (125). The 
(M)ANT-fluorophore attached to the ribosyl ring (Fig. 10), has a compact nature. 
Therefore, it is readily accommodated in the substrate binding pocket of several 
enzymes (125, 130, 133, 134). For this reason, fluorescent nucleotide analogues 
play an important role in signal transduction research; they can serve as substrate, 
inhibitor or as regulatory molecules for key enzymes in signaling pathways (61, 135). 
(M)ANT-nucleotides are extremely valuable for characterization of nucleotide-binding 
processes. The environmental sensitivity of the (M)ANT-fluorophore often allows the 
detection of conformational changes of nucleotide-binding proteins, as they are 
involved in activation of heterotrimeric G-proteins or in activation of the edema factor. 
Therefore, (M)ANT-fluorophores can serve as a monitor for protein-protein or protein-
Chapter I                                                                                Introduction and aim of the work                            
                                                                                                                                                                               
 25 
ligand interactions (130).  
In a project that originally aimed at developing a fluorescence assay for 
receptor/G-protein coupling by using fluorescent guanine nucleotides ( 2’,3’-O-(N-
methylanthraniloyl)-guanosine 5’-[γ-thio]triphosphate (MANT-GTPγS) and 2’,3’-O-(N-
methylanthraniloyl) guanosine 5’-[β,γ-imido]triphosphate (MANT-GMPPNP)), MANT-
nucleotides were serendipitously identified as potent competitive AC inhibitors (133). 
Now, they serve as a pharmacophor to develop optimized inhibitors with high 
selectivity for mammalian and bacterial adenylyl cyclases (130).  
 
Fig. 10: General chemical structure of (M)ANT-substituted nucleotides
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1.4 Fluorescence spectroscopic studies of adenylyl cyclases 
 Fluorescence spectroscopy is one of the most widely used analytical 
techniques in the biomedical sciences. Fluorescence has been successfully 
implemented for various biological applications due to its selectivity and specificity. 
Various measurement categories like fluorescence intensity, decay time, polarization, 
FRET, 2-photon excitation, imaging and time gated-analysis broaden the range of 
possible implementations in experimental science. As a disadvantage, fluorescence 
is sensitive to quenching, solvent effects, geometry and temperature (136). 
 
 One of the most important fluorescence applications is fluorescence 
resonance energy transfer (FRET). The phenomenon discovered by Theodor Förster 
in 1946 (137). FRET is a distance-dependent interaction between the electronically 
excited states of two fluorescent molecules in which excitation is nonradiatively 
transferred from a donor molecule to an acceptor molecule. This technique is used 
for studying conformational changes and dynamics of biological molecules that 
produce changes in molecular proximity. On that account it can be used for 
determination of molecular distances, binding assays and homogenous competitive 
assays (137). 
 
 MANT-nucleotides are fluorescent and this property was exploited to suggest 
conformational changes associated with activation in purified catalytic subunits of 
mammalian ACs (138, 139), and the Bordetella pertussis AC toxin Cya A (135).  We 
used FRET to characterize the interaction of the catalytic site of EF with mono- and 
bis-(M)ANT-nucleotides possesses various purine and pyrimidine bases to better 
understand the molecular mechanisms of EF inhibition and to provide the basis for 
the rational development of potent and selective EF inhibitors. At an excitation 
wavelength of 280 nm, tryptophan and tyrosine residues in proteins are excited, 
emitting light at 350 nm (137) which can  then excite the (M)ANT group of 
nucleotides (140), provided sufficient proximity between donor and acceptor. Such 
energy transfer results in increased fluorescence of the MANT-group at 420-450 nm 
in mAC and CyaA, reflecting the fact that the MANT-group is in a hydrophobic 
environment (135, 138, 139) (Fig. 11).   
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Fig. 11: schematic representation of FRET occur from EF to (M)ANT-
nucleotides 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5 The aim of this thesis 
The primary goal of this thesis was to systematically study the interactions of 
natural purine and pyrimidine nucleotides and several mono- and bis-
(propyl)(M)ANT-substituted analogues with EF in terms of catalysis, fluorescence 
changes and molecular modeling. We determined the inhibitory potencies of those 
nucleotide analogues on EF/CaM to better understand the molecular mechanisms 
of EF inhibition and to provide the basis for the rational development of potent and 
selective EF inhibitors. The effect of calcium and CaM on the Vmax and Km of EF 
and on the inhibitory potencies of MANT-nucleotides at EF was also examined. 
Potent and selective EF inhibitors could be useful compounds to treat EF toxemia 
and antibiotic-resistant Bacillus anthracis strains.  
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II. Purification of recombinant anthrax edema 
factor from Escherichia coli and calmodulin from 
bovine brain 
 
1. Abstract 
Protein purification is a first step of almost all in vitro protein studies. High 
quality of purified protein is critical in respect to activity and crystallization ability. 
Almost all proteins lose activity during manipulations. A great deal of strategy and 
consideration are required in choosing the right condition for extraction and 
purification in order to get the required results. Thus, the investigators need to have 
an answer prior to extraction and purification for some common questions which help 
in selecting the appropriate strategy of purification. In the present chapter, we sought 
to purify recombinant EF, EF3(F586A) from E. coli and their corresponding 
intracellular activator CaM from bovine brain at the maximum possible state of purity, 
with maintenance of the catalytic activity. The purified proteins were then used for 
further investigation of enzyme-ligand interactions in terms of catalysis, and 
fluorescence spectroscopy. The purifications of EF and EF3(F586A) were performed 
essentially as  described in references (14, 15), with important modifications in the 
purification protocol to obtain more pure protein with a reasonable yield. In 
conclusion, we successfully purified the recombinant full-length EF and EF3(F586A) 
from E. coli with the best appealing balance between the high purity and high yield of 
the purified protein together with retention of activity. 
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2.  Introduction 
Protein purification is a first step of almost all in vitro protein studies. High 
quality of purified protein is critical in respect to activity and crystallization ability. 
Almost all proteins lose activity during manipulations. However, even the protein 
stored at 4°C can lose activity and crystallization ability. That is why it is important to 
purify protein as quickly as possible (1, 2). A great deal of strategy and consideration 
are required in choosing the right condition for extraction and purification in order to 
get the required results. Thus, the investigators need to have an answer prior to 
extraction and purification for some common questions which help in selecting the 
appropriate strategy of purification. The first step is to describe the basic scenario for 
the purification. What is the intended use of the product? What kind of starting 
material is available and how should it be handled? What are the purity issues in 
relation to the source material and intended use of the final product? What has to be 
removed? What must be removed completely? What will be the final scale of 
purification? If there is a need for scale-up, what consequences will this have on the 
chosen purification techniques? What are the economical constraints and what 
resources and equipment are available? One has to determine the purpose for which 
the protein is required. For example, to carry out a full chemical and physical analysis 
of a protein may require several hundreds of milligrams of purified material, whereas 
a kinetic analysis of the reaction catalyzed by an enzyme could perhaps be done with 
a few milligrams and less than 1 mg would be required to raise a polyclonal antibody 
(3).  
 
Protein purification involves the separation of one species from perhaps 1000 
or more species of essentially the same general characteristics (they are all proteins) 
in a mixture of which it may constitute a small fraction of 1 % of the total. It is, 
therefore, necessary to fully exploit those properties in which proteins differ from one 
another in devising a purification schedule. There are some protein properties that 
have to be taken into consideration during purification, for example; solubility, charge, 
size and specific binding (4). Most purification schemes involve some form of 
chromatography. As a result, chromatography has become an essential tool in every 
laboratory where protein purification is needed. Different chromatography techniques 
with different selectivities can form powerful combinations for the purification of any 
biomolecule. As general, ion-exchange chromatography provides the most general 
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method for the isolation of proteins with retention of activity unless the protein has 
special characteristics that offer alternative strategies (5, 6). 
 
The most versatile system used for protein and biomolecule purification is the 
Fast Protein Liquid Chromatography system (FPLC). FPLC system is a form of liquid 
chromatography similar to high-performance liquid chromatography that is used to 
separate or purify proteins from complex mixtures. FPLC system is a complete 
system for laboratory scale chromatographic separations of proteins and other 
biomolecules. Liquid Chromatography is a term which refers to all chromatographic 
method with a liquid mobile phase. The stationary phase may be a liquid or a solid. 
FPLC is a type of liquid chromatography where the solvent velocity is controlled by 
pumps to control the constant flow rate of solvents. The solvents are accessed 
through tubing from an outside reservoir. Depending on the type of separation 
preferred, various columns are used. FPLC is commonly used in biochemistry and 
enzymology. The system was developed and marketed by Pharmacia (now GE 
Healthcare) in 1982 (7).  
 
EF is a bacterial adenylyl cyclase which, upon activation by its eukaryotic 
cofactor, CaM, causes a rapid increase in the intracellular cAMP levels of host cells 
(8). Anthrax edema toxin can differentially regulate lipopolysaccharide-induced 
production of tumour necrosis factor α and interleukin-6 by increasing intracellular 
cAMP in monocytes (9). The disruption of the cytokine network may contribute to 
clinical symptoms of anthrax, such as edema formation. 
 
In addition, the genes for PA, LF, and EF (called pagA, lef, and cya, 
respectively) reside on a 185-kb plasmid, pXO1, of B. anthracis. Strains lacking 
pXO1 do not produce toxin and are essentially avirulent. All three genes have been 
cloned and sequenced (4, 5, 21, 26). Efforts have been made to express and purify 
PA and LF from other expression hosts, such as Bacillus subtilis and Escherichia coli 
(10). Large amounts of biologically active PA and LF can now be obtained from E. 
coli with relative ease (10, 11). 
 
Calmodulin is a low molecular weight Ca2+-binding protein which serve to 
mediate numerous Ca2+-regulated enzyme systems and cellular processes (11). 
Norman, (1980) noted a correlation between octanol:water partition coefficients of 
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antipsychotic phenothiazine drugs and their ability to inhibit calmodulin activation of 
cyclic nucleotide phosphodiesterase, and suggested that these drugs probably bind 
to calmodulin through hydrophobic interaction (12). This was supported by the 
demonstration of a Ca 2+ -induced hydrophobic region on calmodulin in experiments 
using a fluorescent probe for hydrophobic sites (13). Based on this information, the 
rapid purification of calmodulin to homogeneity, and high yield, can be achieved in a 
single step using this hydrophobic interaction chromatography (11). 
 
In the present chapter, we sought to purify recombinant EF, EF3 (F586A) from 
E. coli and their corresponding intracellular activator CaM from bovine brain at the 
maximum possible state of purity, with maintenance of the catalytic activity. The 
purified proteins were then used for further investigation of enzyme-ligand 
interactions in terms of catalysis, and fluorescence spectroscopy. The purifications of 
EF and EF3(F586A) were performed essentially as  described in references (14, 15), 
with important modifications in the purification protocol to obtain more pure protein 
with a reasonable yield.  
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3. Materials and Methods 
 
3.1 Materials:  
The plasmids pProExH6-EF and pProExH6-EF3F586A for the expression of 
N-terminally hexahistidine-tagged (EF and EF3(F586A) mutant) were kindly 
donated by Dr. W.J.Tang (Ben-May institute for Cancer Research, University of 
Chicago, Chicago, IL, USA). Ampicillin, kanamycin, lysozyme enzyme, β- 
mercaptoethanol, Tris base, Tris-HCl, Mes buffer (low moisture content) and 
dithiothreitol (for molecular biology) were purchased from Sigma-Aldrich, Steinheim, 
Germany. Tryptone and yeast were purchased from BD Biosciences (Franklin 
Lakes, NJ, USA). [α−32P]ATP (800 Ci/mmol) was purchased from PerkinElmer, 
Rodgau Jügesheim, Germany. Aluminum oxide 90 active, (neutral, activity 1, 
particle size 0.06 - 0.2 mm) was purchased from Biomedicals (Eschwege, 
Germany). Bovine serum albumin (fraction V, highest quality) was bought from 
Sigma-Aldrich, Steinheim, Germany. Imidazole highest quality), CaCl2, MnCl2 
tetrahydrate and MgCl2 hexahydrate (highest quality) were purchased from Merck. 
For all experiments double-distilled water was used. 
 
3.2 EF/EF3(F586A) plasmid amplification and protein expression 
Plasmids pProExH6-EF and pProExH6-EF3F586A were transformed into E. 
coli BL21(DE3) cells that harbored pUBS520, a plasmid that encoded tRNAarg for the 
rare arginine  AGA and AGG codons. The resulting cells were grown over solid agar 
media (containing 50 µg/ml Ampicillin and 30 µg/ml kanamycin) for 24 hours at 37°C. 
 
Two freshly grown colonies were picked up. Each of the two colonies was 
further grown in 6 ml modified Lysogeny-Broth or Luria-Bertani (LB medium) 
(containing 50 µg/ml Ampicillin and 30 µg/ml kanamycin) at 30°C over night under 
vigorous agitation (250 rpm). The LB medium consists of the following components to 
yield the given final concentrations: 20 g/l tryptone, 10 g/l yeast extract and 5 g/l 
NaCl. At the next day, each of the overnight 6 ml cell cultures was transferred into 2L 
T7/ampicillin medium, in 5L conical flask, and allowed to grow for 6-8 hour at 30°C, 
under agitation (250 rpm), until cell density reached OD595 = 0.6. Thereafter, 
expression of recombinant EF/EF3(F586A) in E. coli were induced by addition of 
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isopropyl-1-thio galactopyranoside (IPTG). T7/ampicillin medium containing 16 g/L 
tryptone, 10 g/L yeast extract, 5 g/L NaCl and 50 µg/ml ampicillin. 19 hour after 
induction, the 4L E. coli culture was centrifuged at 10,000 x g (6800 rpm) at 4°C for 
10 minutes. The supernatant was discarded, and the pellets were stored at -80°C for 
the next day. The freezing at -80°C not only helped in the next step of the cell lysis 
but also provided a convenient break of the protocol.  
 
3.3 Lysis of E. coli 
We used both enzymatic and mechanical method for the disruption of the 
bacterial cell wall. The enzymatic method included lysozyme hydrolysis, which 
cleaves the glucosidic linkages in the bacterial cell wall. The inner cytoplasmic 
membrane then was disrupted by sonication. 
 
For preparation of lysis buffer, 4 ml of 1 M Tris-HCl buffer (pH 7.7), 1 ml of 4 M 
NaCl solution, 200 µl of 0.1 M phenyl methyl sulfonyl fluoride (PMSF) in absolute 
ethanol and 75 µl of 14.3 M β-mercaptoethanol solution were mixed with 150 ml of 
double-distilled water and then the volume was completed to 200 ml with water. 
PMSF was added to the lysis buffer as a last component, because it is unstable in 
aqueous solution. 
  
The pellets were picked up from -80°C freezer and allowed to thaw, 
transferred to the crushed ice and re-suspended in lysis buffer. The complete re-
suspension of the bacteria is very crucial for the complete lysis of the cells. 
Therefore, the lysate was passed through a syringe several times to ensure the 
homogeneity of the cell suspension (neither lysozyme nor sonication is effective 
against clumps). Two ml of the freshly prepared 10 mg/ml lysozyme solution was 
added to the cell suspension to yield 0.1 mg/ml final concentration. The cell 
suspension was decanted into 50 ml Falcon tubes for sonication. The sonication was 
performed with Bandelin Sonopuls GM 2070 sonicator - KE 76 Tip (Bandelin 
electronic, Berlin, Germany) with one-second-ON and one-second-OFF cycle using 
the maximum power of 100%, for a total run time of 12 min. We avoided continuous 
sonication, because it heated the sample up significantly, even if the sample was 
placed on ice all the time. After sonication, the lysate was left on ice for one hour, to 
allow for lysozyme to achieve the complete lysis of the bacterial cell wall. Then, the 
Chapter II (Protein Purification)                                                              Materials and Methods                          
 48 
cell lysate was centrifuged at 35,000 rpm with a Ti45 rotor (Beckman) for 30 min at 
4°C to ensure the complete removal of particulate cell debris and sustain the lifespan 
of Ni-column. The supernatant (containing the EF/EF3(F586A)) was decanted 
immediately after the end of centrifugation and the pellet was discarded. Four ml of 
0.1 M PMSF stock solution was added to the resultant supernatant immediately to 
inactivate any proteases. 
 
3.4 Chromatographic purification of EF 
Two different chromatographic steps with two different principles were used for 
purification of EF; the first step was based on the immobilized metal ion-affinity 
chromatographic (IMAC) technique using Ni2+ column (for the purification of 
hexahistidine-tagged proteins), and the second step was based on ion exchange 
chromatographic technique using resource-Q column as a strong anion exchange 
column. 
 
3.4.1 IMAC chromatographic purification using HisTrap fast-flow-rate Ni2+ 
column 
Chromatographic purification of the EF was started immediately after the last 
centrifugation step, because EF is highly sensitive to destruction by proteolytic 
enzymes even if stored at 4°C.  
 
The HisTrap Fast-flow-rate Ni2+ column, 5 ml, (GE Healthcare, Freiburg/Brsg., 
Germany) was connected to the ÄKTAdesign, FPLC system, (GE Healthcare, 
Freiburg/Brsg., Germany). Before loading the sample, a blank run was conducted to 
remove the impurities and other undesirable proteins that could still bind to the 
column matrix from previous runs. The blank run was applied as follows: the column 
was washed with 5 column-volumes of water, followed by 5 column-volumes washing 
with, high-salt buffer B (20 mM Tris-HCl, pH 7.7; 5 mM β-mercaptoethanol; 0.1 mM 
PMSF; and 500 mM NaCl), 5 column-volumes washing buffer C (20 mM Tris-HCl, pH 
7.7; 5 mM β-mercaptoethanol; 0.1 mM PMSF; 100 mM NaCl and 20 mM imidazole), 
5 column-volumes elution, low-salt-high-imidazole, buffer D (20 mM Tris-HCl, pH 7.7; 
5 mM β-mercaptoethanol; 0.1 mM PMSF; 50 mM NaCl and 200 mM imidazole). 
Finally, the column was equilibrated with 10-15 column-volumes of equilibration, 
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imidazole free, buffer A (20 mM Tris-HCl, pH 7.7; 5 mM β-mercaptoethanol; 0.1 mM 
PMSF; 100 mM NaCl) before sample loading. The flow rate, during the blank run, 
was adjusted to 5 ml per minute, which is the maximum flow rate of the column.  
 
The protein sample was prepared prior to loading onto Ni2+ column by addition 
of imidazole to the sample to yield 20 mM final concentration (the same imidazole 
final concentration in the washing buffer C). Then, the sample was diluted with an 
equal volume of the washing buffer C and filtered through 0.45 µm filter. The 
imidazole was included in the sample at a concentration equal to that of washing 
buffer  to ensure the best balance of high purity (low binding of unwanted proteins) 
and high yield (binding of all of the histidine-tagged EF protein). In fact, the ideal 
imidazole concentration in both the sample and washing buffer is protein-dependent. 
Thus, imidazole final concentration in both sample and washing buffer was optimized 
based on both our previous trial experiments, and as previously described by Shen et 
al., 2002. 
 
Thereafter, the sample was loaded onto the Ni2+ column, with a flow rate of 3 
ml per minute, followed by two washing steps of the column with 5 column-volumes 
of buffer B and buffer C respectively, with a flow rate of 5 ml per minute. Then, the EF 
was eluted from the column by elution with high-imidazole buffer D with a flow rate of 
4 ml per minute. The eluate was collected in 8 ml plastic tubes, 4 ml of the eluate per 
each tube. The 200 mM imidazole final concentration of the elution buffer was the 
ideal for elution of EF. This imidazole concentration was determined based on this 
fact, that the concentration of imidazole that gave ideal purification results was 
slightly higher for the column matrix we used (Ni-sepharose high performance) and 
our previous trial experiments (fractions collection during the gradient imidazole 
elution from 50 to 500 mM). The fractions of the area under the peak were collected 
and EF was identified by sodium dodecyl sulfate; polyacrylamide gel electrophoresis 
(SDS-PAGE). 
 
3.4.2 Anion exchange chromatographic purification of EF 
Resource Q (quaternary ammonium salt) strong anion exchange column, (6 
ml), (GE Healthcare, Freiburg, Germany) was used. The media of this column are 
based on a hydrophilic matrix made from monodispersed, rigid, polystyrene/divinyl 
benzene and substituted with quaternary ammonium groups. This combination 
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confers extreme chemical and physical stability to media. The small particle sizes 
allow fast binding and dissociation to facilitate high resolution. The column was 
washed with 5 column-volumes water to remove the 20% (v/v) ethanol used for 
column storage. Then, the column was equilibrated with the start (equilibration) buffer 
Ares.Q (20 mM Tris-HCl, pH 8.6; 1 mM ethylenediaminetetraacetic acid (EDTA); 0.1 
mM PMSF). The fractions containing EF protein, obtained after Ni2+ column, were 
diluted five-fold with the start buffer Ares.Q, in order to be adjusted to the starting pH 
and ionic strength and then loaded onto the column with a flow rate of 3 ml per 
minute. The column was washed with five column-volumes of equilibration buffer 
Ares.Q pH 8.6 to wash out all unbound materials from the column. The adsorbed EF 
protein was eluted at 2 ml/min with a linear NaCl gradient (400-450 mM). The NaCl 
gradient was mixed by using two buffers; salt-free buffer Ares.Q (20 mM Tris-HCl, pH 
8.6; 1 mM EDTA; 0.1 mM PMSF) and high-salt buffer Bres.Q (20 mM Tris-HCl, pH 8.6; 
1 mM EDTA; 0.1 mM PMSF; 1 M NaCl). EF eluted by adjusting the gradient to 40% 
(v/v) buffer Bres.Q per 480 ml of both buffer Ares.Q and Bres.Q.  
  
The Resource Q column was then washed with at least 5 column-volumes of 
high-salt buffer Bres.Q to remove the other unwanted proteins adsorbed into the 
column matrix due to unspecific binding. This procedure was followed by washes with 
5 column-volumes of buffer A and finally with 5 column-volumes water before storage 
in 20% (v/v) ethanol. 
 
The high-salt column wash with 1 M NaCl buffer B at the end of each 
separation should keep the Resource Q column in good condition. However, we 
cleaned the column after two separation cycles to improve the performance and 
increase the life-span of the column. During column cleaning, the flow rate was 
adjusted to 6 ml/min. and the direction of flow was reversed so that contaminants did 
not need to pass through the entire length of the column. The cleaning procedures 
included: washing with two column-volumes of 2 M NaCl followed by 4 column-
volumes of 1 M NaOH, 2 column-volumes 2 M NaCl, 2 column-volumes of water, and 
finally 4 column-volumes of start buffer. 
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3.5 Chromatographic purification of EF3(F586A) mutant 
  
3.5.1 IMAC chromatographic purification using HisTrap fast-flow-rate Ni2+ 
column 
 The IMAC chromatographic purification of EF3(F586A) was performed as 
described previously in EF purification. 
 
3.5.2 Cation exchange chromatographic purification of EF3(F586A) 
The HiPrep 16/10 SP XL column (GE Healthcare, Freiburg, Germany) was 
used in cation exchange chromatography. The media of this column are based on a 
hydrophilic matrix made from monodispersed, rigid, polystyrene/divinyl benzene and 
substituted with propyl sulphonyl groups.  
 
The column was washed with 5 column-volumes water to remove the 20% 
(v/v) ethanol used for column storage. Then, the column was equilibrated with the 
start (equilibration) buffer (20 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffer, 
pH 6.5; 1 mM EDTA; 0.1 mM PMSF; 1 mM dithiothreitol, proteases enzymes free, 
(DTT)). The fractions containing EF3(F586A) protein, obtained after Ni2+ column, 
were diluted five times with the start buffer, in order to be adjusted to the starting pH 
and ionic strength and then loaded onto the column with 3 ml per minute flow rate. 
The column was washed with five column-volumes of equilibration buffer, pH 6.5, to 
wash out all unbound materials from the column. The adsorbed EF3(F586A) was 
eluted at 2 ml/min with a linear NaCl gradient (500 mM). The NaCl gradient was 
generated by using two buffers; salt-free buffer (20 mM MES buffer, pH 6.5; 1 mM 
EDTA; 0.1 mM PMSF: 1 mM DTT) and high-salt buffer (20 mM mM MES buffer, pH 
6.5; 1 mM EDTA; 0.1 mM PMSF: 1 mM DTT; 1 M NaCl). EF eluted by adjusting the 
gradient to 50% of the high-salt buffer per 480 ml of both salt-free buffer and high-salt 
buffer.  
  
The HiPrep 16/10 SP XL column was then washed with at least 5 column-
volumes of high-salt buffer to remove the other unwanted proteins adsorbed to the 
column matrix due to unspecific binding. This procedure was followed by washes with 
5 column-volumes of the start buffer and finally with 5 column-volumes water before 
storage in 20% (v/v) ethanol. 
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3.6 Calmodulin purification from bovine brain 
Calmodulin was isolated and purified from bovine brain as described 
previously by Gopalakrishna and Anderson (11). The detailed procedures of isolation 
and purification will be discussed at this section. 
 
Bovine brains were purchased several weeks in advance, and cleaned of 
membranes and blood clots. The bovine brain was stored in plastic freezer bags at -
20 °C. It was removed from the freezer 8-12 h before the start of purification and 
allowed to thaw at room temperature.  
 
3.6.1 Extraction of calmodulin from bovine brain tissues 
Unless otherwise stated, all procedures were carried out at 4°C and 
centrifugations were conducted at 15,000 g for 30 min. Approximately 200 g of brain 
were homogenized by the tissue homogenizer (ULTRA-TURRAX-Typ Tp18 - 
Germany) with two volumes of buffer A (50 mM Tris-HCl, pH 7.5; 1 mM β-
mercaptoethanol; 1 mM EDTA 0.5; mM PMSF) per weight of brain. The homogenate 
was centrifuged at 15,000 g (9600) rpm at 4°C for 30 min using 4 °C refrigerated 
centrifuge (Sorvall RC 5B refrigerated centrifuge using GSA rotor). The pellet was 
discarded and the supernatant was filtered through gauze swabs to get rid of the 
lipids. The pH was adjusted to 4.3, the isoelecteric point of calmodulin, at which 
calmodulin precipitates by dropwise addition of 6 M acetic acid. 
 
The slurry was then transferred into the cold room and stirred for about 30 min. 
After that, the slurry was centrifuged at 15,000 g (9600) rpm at 4°C for 30 min, then 
the supernatant was discarded and the pellet was resuspended in 100 ml of buffer A, 
and the pH was adjusted to 7.5 by dropwise addition of Tris base. The slurry was 
centrifuged again at 15,000 for 30 min. The pellet was discarded and the 
concentration of CaCl2 in the supernatant was adjusted to 5 mM final concentration 
(i.e 0.0375/50 ml of final supernatant). 20 µl of the 0.5 M PMSF stock solutions was 
added to adjust the concentration of the PMSF in the final supernatant into 0.1 mM. 
The sample was frozen at -20°C for the next day. 
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3.6.2 Hydrophobic chromatography purification of calmodulin 
The solutions were removed from the freezer about 2 hour before starting the 
procedure. The FPLC refrigerator was also turned off about two hours before the 
start because the hydrophobic chromatographic procedure should be performed at 
room temperature and any decrease in temperature during purification steps could 
interfere with the hydrophobic binding of calmodulin to the Sephadex matrix. Hiprep 
16/10 phenyl FF (high sub) (GE Healthcare, Freiburg, Germany) was used. For the 
first-time use, the column was washed by 5 column-volumes of low-salt start buffer I 
(50 mM Tris-HCl, pH 7.5; 1 mM β-mercaptoethanol; 0.1 mM CaCl2), followed by five 
column-volumes of high-salt buffer I (50 mM Tris-HCl, pH 7.5; 1 mM β-
mercaptoethanol; 0.1 mM CaCl2; 500 mM NaCl) and equilibration with 10 column-
volumes of start buffer I before sample loading. All column preparation and 
equilibration steps were performed with a flow rate of 5 ml/min. The sample was 
loaded onto the column with a flow rate of 1.5 ml/min. This was followed by two 
washing steps with ten column-volumes of start buffer I and high-salt buffer I 
respectively with 2.5 ml/min flow rate. Finally, the adsorbed calmodulin was eluted 
from the column with a flow rate of 2.5 ml/min by elution buffer containing 50 mM 
Tris-HCl, pH 7.5; 1 mM β-mercaptoethanol; and 1 mM ethylene glycol tetraacetic acid 
(EGTA). The fractions at the area under the peak (containing calmodulin) were 
collected and further identified with SDS-PAGE depending on the molecular mass. 
 
3.7 Concentration and characterization of the purified proteins 
The fractions containing the purified proteins were pooled and the target 
protein was identified by SDS-PAGE (a 12% (m/v) polyacrylamide gel was used) 
depending on its molecular mass. The protein sample (7.5 µl) was mixed with 2.5 µl 
of the Laemmli dye (migration marker dye). Furthermore, the mixture was incubated 
with shaking at 95°C for 3 min. Samples (9 µl) and 5 µl of the proper protein standard 
were loaded into the wells and the electric current with a fixed 150 volt was applied 
for about 35 min. The gel slabs were washed from the loading buffer three times by 
double distilled water for 10 min, 10 min., and 30 min., respectively, and stained with 
Coomassie brilliant blue dye for at least one hour. Finally gels were washed with 
water for 5 min.  
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The purified proteins were concentrated using Jumbosep centrifugal devices 
with 60 ml sample reservoir (Pall Life Sciences, MI, USA). For the maximum 
retention, we selected a Jumbosep membrane insert with a molecular weight cutoff 
three times smaller than the molecular weight of the molecule to be retained. Thus, 
10K, 20K, and 30K cutoff membranes were used for the concentration of CaM, 
EF3(F586A), and EF respectively. The Jumbosep centrifugal devices were pre-
treated to reduce the non-specific adsorption to the device. For the pre-treatment the 
sample reservoir was filled with 60 ml of the 10% (m/v) glycerine and soaked over 
night at room temperature, then rinsed with deionised water and finally, filled with 
deionised water and twice centrifuged for 15 min. at 3,000 g. For the concentration of 
the protein sample, it was placed into the sample reservoir and centrifuged at 3,000 g 
for 40- 60 min. 
The concentration of the purified protein was estimated using ultraviolet light 
absorption at 280 nm using Beckman photometer (Beckman Instruments, Munich, 
Germany)(1 absorption unit = 1.16 mg/ml) and then determined accurately by 
Bradford protein assay, because it is simple, rapid and free from interference with 
common reagents except detergents. Seven different dilutions in duplicates of the 
standard protein (BSA), in a microtiter plate, were prepared for establishment of the 
standard curve. The protein samples were diluted 1-20-fold with distilled-deionized 
water. Two different dilutions of each sample were tested in duplicates. Then 50 µl of 
the Coomassie® Brilliant Blue G-250 dye were added per well and finally, the water 
was added to adjust the volumes 250 µl/well. After 5 min the absorbance was 
measured at 595 nm using Bio-Rad microtiter plate reader. The data were calculated 
and processed in Excel 2003. 
 
Adenylyl cyclase activity assay. For the determination of Km and Vmax 
values, 10 µl of ATP/Mn2+  at final concentration from 10 µM to 1 mM were added, 
and 20 µl of EF or EF3(F586A) (10 pM final concentration) in 75 mM Tris/HCl, pH 
7.4, containing 0.1% (m/v) bovine serum albumin. Tubes were preincubated for 2 
min at 25°C, and reactions were initiated by the addition of 20 µL of reaction 
mixture consisting of the following components to yield the given final 
concentrations; 100 mM KCl, 100 µM free Ca2+, 5 mM free Mn2+, 100 µM EGTA, 
100 µM cAMP, 100 nM CaM. Tubes were incubated for 10 min at 25°C, and 
reactions were stopped by the addition of 20 µL of 2.2 N HCl.  
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For the determination of the potency of AC toxin inhibitors, assay tubes 
contained 10 µl of MANT-ATP at final concentrations from 10 nM to 100 µM as 
appropriate to obtain saturated inhibition curves plus 20 µl of EF or EF3(F586A) 
(10 pM final concentration) in 75 mM Tris/HCl, pH 7.4, containing 0.1% (m/v) 
bovine serum albumin. Tubes were preincubated for 2 min at 25°C, and reactions 
were initiated by the addition of 20 µL of reaction mixture consisting of the 
following components to yield the given final concentrations; 100 mM KCl, 100 
µM free Ca2+, 5 mM free Mn2+, 100 µM EGTA, 100 µM cAMP, 100 nM CaM. ATP 
was added as non-labeled substrate at a final concentration of 40 µM and as 
radioactive tracer [α−32P]ATP (0.2 µCi/tube). Denaturated protein was sedimented 
by a 1-min centrifugation at 13,000 x g. [32P]cAMP was separated from 
[α−32P]ATP by transferring the samples to columns containing 1.4 g of neutral 
alumina. [32P]cAMP was eluted by the addition of 4 ml of 0.1 M ammonium 
acetate solution, pH 7.0. Blank values were about 0.02% of the total amount of 
[α−32P]ATP added; substrate turnover was < 3% of the total amount of 
[α−32P]ATP added. Samples collected in scintillation vials were filled up with 10 ml 
of double-distilled water and Čerenkov radiation was measured in a PerkinElmer 
Tricarb 2800TR liquid scintillation counter. Vmax and Km values reported in the 
results section were calculated using the Prism 4.02 software (Graphpad, San 
Diego, CA, USA). Free concentrations of divalent cations were calculated with 
WinMaxC (http://www.stanford.edu/~cpatton/maxc.html).  
 
Fluorescence resonance energy transfer (FRET) experiments for 
monitoring inhibitor binding to EF/EF3(F586A). Fluorescence experiments 
were performed using quartz UV ultra-microcuvettes from Hellma (Müllheim, 
Germany, type 105.251- QS, light path length 3 x 3 mm, center 15 mm, total 
volume 70 µl and type 105.250- QS, light path length 10 x 2 mm, center 15 mm, 
total volume 150 µl) in a thermostated multicell holder at 25°C in a Varian Cary 
Eclipse fluorescence spectrometer (Varian, Darmstadt, Germany). In case of 
150 µl cuvettes, 140 µl of buffer consisting of 100 mM KCl, 100 µM CaCl2, 10 
mM MnCl2 and 25 mM HEPES/NaOH, pH 7.4, was added into the cuvette. Five 
µl of 10 µM full-length EF/EF3(F586A) (final concentration 300 nM), 5 µl of 10 
µM CaM (final concentration 300 nM) and fluorescent 2’-MANT-3’-d-ATP (300 
nM each) was added. In case of experiments with 70 µl cuvettes, volumes were 
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adjusted stoichiometrically. The results obtained with 70 µl- and 150 µl-cuvettes 
were identical, with the 70 µl-cuvettes offering an opportunity to save 
EF/EF3(F586A) mutant protein. 
 
Steady-state fluorescence emission spectra of nucleotides were recorded 
at low speed in the scan mode from λem 300 nm to 550 nm with λex 280 nm. 
Fluorescence recordings were analyzed with the spectrum package of the 
Varian Cary Eclipse software version 1.1. Baseline fluorescence (buffer alone) 
and the baseline-corrected nucleotide-dependent emission of each 
concentration of the ligand (buffer + nucleotide) were subtracted from the 
spectra shown in Fig. 10.  
 
  
 
 
 
 
 
 
 
 
 
  
Chapter II (Protein Purification)                                                             Results and discussion                           
 57 
4. Results and discussion 
 
4.1 Purification and characterization of the Full length EF 
 Figs. 1 and 2 show examples of the unsatisfactory Ni2+ column and Resource 
Q column purification results of the initial purification trials that had been performed 
as described by Shen et al., 2002 without modifications. The resolution, the purity, 
and the yield After Ni2+ column were all very poor. It was clear at SDS-PAGE, that the 
target protein was strongly contaminated by other unwanted proteins. Unfortunately 
at the further purification of the sample on the Resource Q column, a multiple peak 
chromatogram without a characteristic peak was obtained. Also, the EF fractions of 
Resource Q column as analyzed by SDS-PAGE, were highly contaminated with other 
proteins.  This meant that the purification protocol applied was not ideal and needed 
further optimization. Hence, the following modifications were performed: The 
imidazole was included in the sample in a concentration equal to that of washing 
buffer  to ensure the best balance of high purity (low binding of unwanted proteins) 
and high yield (binding of all of the histidine-tagged EF protein molecules). The 
imidazole was included in the sample. Imidazole at low concentrations is commonly 
used in the binding and wash buffer to minimize binding of unwanted host cell 
proteins and for the same reason, it has to be also included in the sample (4). 
Moreover, the sample was diluted with the imidazole-containing washing buffer C to 
adjust the pH and the ionic strength of the sample, also to ensure the balance of the 
high purity and high yield. In addition, the final concentration of imidazole in elution 
buffer was increased from 150 mM to 200 mM because the HisTrap Fast-flow-rate 
Ni2+ column used at the EF initial step purification require a higher imidazole 
concentration in the elution buffer than the other commercially available IMAC 
columns. Finally, at the anion exchange chromatography step of the purification, the 
fractions containing EF collected from Ni2+ column were pooled and diluted with the 
start buffer Ares.Q before loading to resource Q column. Based on these modifications 
of the purification protocol ideal chromatograms (with sharp narrow single peak) were 
obtained during the purification of EF on both Ni2+ and resource Q columns as shown 
in Figs. 3 and 4. 
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Fig. 1: Initial results of the primary purification step of EF on Ni2+ column and 
SDS-PAGE of the collected fractions (before the important modifications). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
                                                         
 
 
 
The initial purification step of recombinant EF from E. coli on Ni2+ column, A) the 
chromatogram obtained during the separation of the sample on Ni2+ column. The separation 
was performed as described by Shen et al., 2002 without modifications B) the identification 
of the EF on 12% (m/v) SDS-PAGE. Lane 1, shows the protein standard (Fermentas, 
PageRuler protein standard SM0661, Germany), lanes A5-A9, the fractions of the 2nd peak 
(EF peak), and lane A3 the fraction of 1st peak. SDS-PAGE was performed as described in 
the Materials and Methods section. As shown, the resolution of the purification process was 
poor and the protein was heavily contaminated.  
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Fig. 2: Initial results of secondary purification step of EF on resource Q column 
and SDS-PAGE of the the collected fractions (before the important 
modifications). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The secondary purification step of recombinant EF from E. coli on resource Q column, A) the 
chromatogram obtained during the separation of the sample on Q column. The separation 
was performed as described by Shen et al., 2002 without modifications. B) the identification 
of the EF on 12% (m/v) SDS-PAGE. Lane 1, shows the protein standard (Fermentas, 
PageRuler protein standard SM0661, Germany), lanes 2 and 3, the fractions of the 1st peak 
and lanes 4-8, the fractions of 2nd peak (EF peak). SDS-PAGE was performed as described 
in the Materials and Methods section. As shown, the resolution of the purification process 
was poor and the protein was heavily contaminated.  
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Fig. 3: Final results of primary purification step of EF on Ni2+ column and SDS-
PAGE of the collected fractions (after the important modifications). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Final results of the primary purification step of recombinant EF from E. coli on Ni2+ column, 
A) the chromatogram obtained during the separation of the sample on Ni2+ column. The 
separation was performed as described by Shen et al., 2002 with the previously mentioned 
modifications. B) the identification of the EF on 12% (m/v) SDS-PAGE. Lane 3, shows the 
protein standard (Fermentas, PageRuler protein standard SM0661, Germany), lanes 1, 2, 4-
10, the fractions of the EF peak. The SDS-PAGE was performed as described in the 
Materials and Methods section. As shown, a single sharp peak chromatogram obtained and 
the protein approximately pure before the second step of purification. These results were 
reproduced at least 6 times. 
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Fig. 4: Final results of secondary purification step of EF on resource Q column 
and SDS-PAGE of the collected fractions (after the important modifications). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Final results of the secondary purification step of recombinant EF from E. coli on resource Q 
column, A) the chromatogram obtained during the separation of the sample on resource Q 
column. The separation was performed as described by Shen et al., 2002 with the previously 
mentioned modifications. B) the identification of the EF on 12% SDS-PAGE. Lane 2, shows 
the protein standard (Fermentas, PageRuler prestained protein standard SM0671, 
Germany), lanes 1, 3, 4, the fractions of the EF peak. Lanes 5-8, the fractions collected 
during the cleaning steps of the column. SDS-PAGE was performed as described in the 
Materials and Methods section. As shown, a single sharp peak chromatogram obtained and 
the protein approximately 98% pure. These results were reproduced at least 6 times. 
 
Furthermore, the yield was increased > 25 mg EF protein/L E. coli culture with a 
EF peak 
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highest purity > 98% as represented by 12% (m/v) SDS-PAGE (Fig. 3 and 4). Fig. 5 
shows kinetic analysis of the catalytic activity of EF in the presence of Ca2+ and its 
intracellular activator CaM by ATP/Mn2+ saturation assay.  The Vmax and Km values of 
EF are 232 ± 34 and 84.5 ± 8.3 respectively. Those values were obtained by 
nonlinear regression analysis of substrate-saturation experiment and are the means 
± standard deviation of at least three independent experiments performed in 
triplicates  
 
Fig. 5: Substrate saturation experiments of full length EF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The assay was performed as described under Materials and Methods section. Km and 
Vmax values were obtained by non-linear regression analysis of substrate-saturation 
experiments and are the means ± SD of at least 3 independent experiments performed 
in triplicates. For the determination of the Vmax and Km of EF, reaction mixtures contained 
100 µM free Ca2+, 5 mM free Mn2+, 100 µM EGTA, 0.2-1.0 µCi/tube [α−32P]ATP, 100 µM 
cAMP, 100 nM calmodulin and 10 pM enzyme in 75 mM Tris-HCl, pH 7.0. The unlabeled 
ATP/Mn2+ concentrations ranged from 100 nM to 700 µM as appropriate to obtain 
saturated curves. 
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4.2 Purification and characterization of EF3(F586A) 
EF3 is the truncated form of edema factor and is the CaM-sensitive adenylyl 
cyclase domain. EF3(F586A), in the slightly acidic MES buffer, pH 6.5, acquires a 
positive charge and hence could be easily purified on the strong cationic exchange 
column. EF3(F586A) mutant has been effectively purified using HisTrap Fast-flow-
rate Ni2+ column and HiPrep 16/10 SP XL column, resulting in > 98% pure protein as 
judged by SDS-PAGE as shown in Figs. 6 and 7. This preparation yields 
approximately 40 mg EF3(F586A) mutant/L E. coli culture. The mutant was 
expressed and purified essentially as described (Shen et al., 2002) with minor 
modifications as in the purification of full-length EF. Specifically, the imidazole 
concentration in the elution buffer for the Ni2+ column was 200 mM, and imidazole 
(20 mM) was included in the sample. The HisTrap fast flow rate affinity Ni column 
(5 ml) was used for immobilized matrix-affinity chromatography and the HiPrep 
16/10 SP XL column (GE Healthcare) was used for cation exchange 
chromatography.  
 
Fig. 8 shows kinetic analysis of the catalytic activity of EF3(F586A) in the 
presence of Ca2+ and its intracellular activator CaM by ATP/Mn2+ saturation assay.  
The Vmax and Km values of EF3(F586A) are 128 ± 5 and 92.0 ± 14.7 respectively. The 
Vmax value of that mutant was about half of that of wild-type EF, but the Km was not 
changed significantly. Those values were obtained by nonlinear regression analysis 
of substrate-saturation experiments and are the means ± standard deviation of at 
least three independent experiments performed in triplicates  
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Fig. 6: Separation of the recombinant EF3(F586A) from E. coli on Ni2+ column 
and SDS-PAGE of the collected fractions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results of the primary purification step of recombinant EF3(F586A) from E. coli on Ni2+ 
column, A) the chromatogram obtained during the separation of the sample on Ni2+ column. 
The separation was performed as described by Shen et al., 2002 with the previously 
mentioned modifications. B) the identification of the EF3(F586A) on 12% (m/v) SDS-PAGE. 
Lane 2, shows the protein standard (Fermentas, PageRuler prestained protein standard 
SM0671, Germany), lanes 1, 3, 4-9, the fractions of the EF3(F586A) peak. The SDS-PAGE 
was performed as described in the Materials and Methods section. As shown, a single sharp 
peak chromatogram obtained and the protein was already almost pure before the second 
step of purification. These results were reproduced at least 5 times. 
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Fig. 7: Separation of the recombinant EF3(F586A) from E. coli on HiPrep 16/10 
SP XL and SDS-PAGE of the collected fractions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
The results of the secondary purification step of recombinant EF3(F586A) from E. coli on 
HiPrep 16/10 SP XL column, A) chromatogram obtained during the separation of the sample 
on Ni2+ column. The separation was performed as described by Shen et al., 2002 with the 
previously mentioned modifications. B) identification of the EF3(F586A) on 12% (m/v) SDS-
PAGE. Lane 3, shows the protein standard (Fermentas, PageRuler prestained protein 
standard SM0671, Germany), lanes 1, 2, 4-9, the fractions of the EF3(F586A) peak. The 
SDS-PAGE was performed as described in the Materials and Methods section. As shown, a 
single sharp peak chromatogram obtained and the protein purity was > 98%. These results 
were reproduced at least 5 times. 
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Fig. 8: Substrate saturation experiments of EF3(F586A) mutant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The assay was performed as described under Materials and Methods section. Km and 
Vmax values were obtained by non-linear regression analysis of substrate-saturation 
experiments and are the means ± SD of at least 3 independent experiments performed 
in triplicates. For the determination of the Vmax and Km of EF3(F586A), reaction mixtures 
contained 100 µM free Ca2+, 5 mM free Mn2+, 100 µM EGTA, 0.2-1.0 µCi/tube 
[α−
32P]ATP, 100 µM cAMP, 100 nM calmodulin and 10 pM enzyme in 75 mM Tris-HCl, 
pH 7.0. The unlabeled ATP/Mn2+ concentrations ranged from 100 nM to 700 µM as 
appropriate to obtain saturated curves. 
 
 
4.3 Purification of calmodulin from bovine brain 
 This purification of CaM from bovine brain extract on phenyl-sepharose after 
isoelecteric precipitation is considered as a very good and easy method to obtain 
CaM in a high yield and purity. The yield was about 35 mg CaM per 200 g of bovine 
brain with a purity > 95% as judged by the 12% (m/v) SDS-PAGE as shown in Fig. 9. 
The biological activity of the purified CaM was very good, when tested with the 
purified EF and EF3(F586A) mutant as shown in Figs. 5 and 8.  The purified CaM 
exhibited the same activity as the commercially available CaM.   
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Fig. 9: Purification of calmodulin from bovine brain extract on Hiprep 16/10 
phenyl FF and SDS-PAGE of the collected fractions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results of the CaM purification from bovine brain extract on HiPrep 16/10 phenyl FF 
column, A) the chromatogram obtained during the separation of the sample on HiPrep 16/10 
phenyl FF column. B) the identification of the CaM on 12% SDS-PAGE. Lane 4, shows the 
protein standard (Fermentas, PageRuler prestained protein standard SM0441, Germany), 
lanes 1-3, the fractions of the CaM peak. Lanes 5 and 6, the fractions collected during 
cleaning of the column. The separation and SDS-PAGE was performed as described in the 
Materials and Methods section. As shown, a single sharp peak chromatogram obtained and 
the protein approximately pure. These results reproduced at least 5 times. 
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Fig. 10: Analysis of MANT-nucleotide binding to the catalytic site of EF3 and 
EF3(F586A) using FRET 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FRET experiments were performed as described under “Materials and Methods”. The 
assay buffer consisted of 75 mM HEPES/NaOH, 100 µM CaCl2, 100 mM KCl and 5 mM 
MnCl2, pH 7.4. Nucleotide was added to the buffer to yield 300 nM final concentrations. 
EF3/EF3(F586A) (300 nM final concentration) was added followed by the addition of CaM 
(1 µM final concentration). Emission was scanned at an excitation wavelength of 280 nm 
after each addition. The buffer and the MANT-nucleotide basal fluorescence was 
subtracted from the fluorescence after addition of EF3/EF3(F586A) (purple line) and CaM 
(blue line). Shown are superimposed recordings of a representative experiment. Similar 
data were obtained in 5 independent experiments. a.u., arbitrary unit  
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4.4 Analysis of the interaction of MANT-nucleotides with EF3 in 
FRET experiments  
At an excitation wavelength of 280 nm, tryptophan and tyrosine residues in 
proteins are excited, emitting light at 350 nm (16) which can then excite the 
(M)ANT group of nucleotides (17), provided sufficient proximity between donor and 
acceptor. Such energy transfer results in increased fluorescence of the MANT-
group at 420-450 nm in mAC and CyaA, reflecting the fact that the MANT-group is 
in a hydrophobic environment (18-20). Previous studies with mAC showed that in 
the presence of Mn2+, FRET signals were much larger than in the presence of Mg2+ 
(19). Preliminary studies with EF3 showed that the Mn2+-preference also applies to 
the toxin (data not shown). Therefore, all subsequent FRET studies with EF3 were 
conducted in the presence of Mn2+ (see Materials and Methods). 
 
In the absence of CaM, EF3 exhibits a strong emission peak at 350 nm 
when excited at 280 nm under steady-state conditions (Fig. 10A). Upon addition of 
the EF activator CaM, an additional prominent fluorescence peak with an emission 
maximum at 440 nm appeared with MANT-ATP (Fig. 10A), reflecting FRET from 
tryptophan and tyrosine residues to the MANT-group. In EF3(F586A), the 
endogenous tryptophan and tyrosine fluorescence was similar as in EF3, but the 
FRET signal (difference in fluorescence at an emission wavelength of 440 nm in 
the presence and absence of calmodulin) was reduced by 64% (Fig. 10B).  
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5. Summary and conclusion 
 
We successfully purified the recombinant full length EF and EF3(F586A) from 
E. coli with a very good balance between the high purity and high yield of the purified 
protein together with retention of activity. These results were obtained based on the 
modifications that were applied to the EF purification protocol of Shen et al., 2002.  
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III. Molecular Analysis of the Interaction of Anthrax 
Adenylyl Cyclase Toxin, Edema Factor, with 2’(3’)-O-
(N- (methyl)anthraniloyl)-Substituted Purine and 
Pyrimidine Nucleotides 
 
1. Abstract 
 Bacillus anthracis causes anthrax disease and exerts its deleterious 
effects by the release of three exotoxins, i.e. lethal factor, protective antigen and 
edema factor EF), a highly active calmodulin-dependent adenylyl cyclase (AC). 
However, conventional antibiotic treatment is ineffective against either toxemia 
or antibiotic- resistant strains. Thus, more effective drugs for anthrax treatment 
are needed. Previous studies from our laboratory showed that mammalian 
membranous AC (mAC) exhibits broad specificity for purine and pyrimidine 
nucleotides (Mou et al., Mol Pharmacol 70: 878 (2006)). Here, we investigated 
structural requirements for EF inhibition by natural purine and pyrimidine 
nucleotides and nucleotides modified with N-methylanthraniloyl  (MANT)- or 
anthraniloyl groups at the 2’(3’)-O-ribosyl position. MANT-CTP was the most 
potent EF inhibitor (Ki, 100 nM) among 16 compounds studied. MANT-
nucleotides inhibited EF competitively. Activation of EF by calmodulin resulted in 
effective fluorescence resonance energy transfer (FRET) from tryptophan and 
tyrosine residues located in the vicinity of the catalytic site to MANT-ATP, but 
FRET to MANT-CTP was only small. Mutagenesis studies revealed that F586 is 
crucial for FRET to MANT-ATP and MANT-CTP and that the mutations N583Q, 
K353A and K353R differentially alter the inhibitory potencies of MANT-ATP and 
MANT-CTP. Docking approaches relying on crystal structures of EF indicate 
similar binding modes of the MANT nucleotides with subtle differences in the 
region of the nucleobases. In conclusion, like mAC, EF accommodates both 
purine and pyrimidine nucleotides. The unique preference of EF for the base 
cytosine offers an excellent starting point for the development of potent and 
selective EF inhibitors. 
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2.  Introduction 
The spore-forming bacterium Bacillus anthracis exerts its deleterious effects 
by production of three major exotoxins, i.e. EF, protective antigen, and lethal factor 
(1). EF and lethal factor enter host cells via a complex with membrane-associated 
protective antigen, which acts as a pH-dependent protein transporter. Lethal factor, a 
specific zinc-metalloprotease, inactivates mitogen-activated protein kinase (2). EF 
possesses ~800 amino acid residues and an apparent molecular weight of ~89 kDa 
and is a CaM-dependent AC (3). After entering host cells, EF forms a complex with 
CaM, a mammalian regulatory protein that mediates many aspects of calcium-
regulated signaling (4). The binding of CaM induces a major conformational change 
in the catalytic domain of EF (3). This rearrangement renders EF highly efficient at 
catalyzing the conversion of ATP into cAMP, disrupting intracellular signaling 
pathways through excessive activation of cAMP-dependent signaling pathways (5). 
 
We resolved several crystal structures of nucleotide-EF-CaM complexes and 
characterized the amino acids that are important for binding of the substrate ATP 
and catalysis (3-5). Additionally, we showed that mAC and bacterial AC toxins are 
potently inhibited by MANT-substituted nucleoside 5’-triphosphates (6-9). MANT-
nucleotides are fluorescent, and we exploited this property to suggest 
conformational changes associated with activation in purified catalytic subunits of 
mAC (7, 8) and the Bordetella pertussis AC toxin, CyaA (9). In addition, by 
combining crystallographic and molecular modeling approaches, we developed a 
three-site pharmacophore model for mAC and CyaA, with binding domains for the 
base, the MANT-group and the polyphosphate chain (8-11). Those studies revealed 
that the catalytic sites of mAC and CyaA exhibit substantial conformational flexibility, 
accommodating both purine and pyrimidine nucleotides. Despite this flexibility, the 
structure/activity relationships of MANT-nucleotides at mAC and CyaA are quite 
different, offering the opportunity to design potent and isoform-selective AC 
inhibitors. 
 
In contrast to mAC (6-8, 10) and CyaA (9), a detailed analysis of MANT-
nucleotide/EF interactions has not yet been presented. Therefore, in the present 
study, we systematically examined the interactions of natural purine and pyrimidine 
nucleotides and several (M)ANT-substituted analogs with EF in terms of catalysis, 
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fluorescence changes and molecular modeling. 
 
3. Materials and Methods 
 
3.1 Materials:  
MANT-GTP, ANT-GTP, MANT-ATP and MANT-ADP were purchased from 
Jena Bioscience, Germany. PMEApp was supplied by Gilead Sciences, Foster 
City, CA. GTP, UTP and CTP were purchased from Roche, Mannheim, Germany. 
ITP, ampicillin, kanamycin, lysozyme enzyme, β- mercaptoethanol, Mes buffer (low 
moisture content) and dithiothreitol (for molecular biology) were purchased from 
Sigma-Aldrich, Steinheim, Germany. Tryptone and yeast were purchased from BD 
Biosciences (Franklin Lakes, NJ). [α−32P]ATP (800 Ci/mmol) was purchased from 
PerkinElmer, Rodgau Jügesheim, Germany. Aluminum oxide 90 active, (neutral, 
activity 1, particle size 0.06 - 0.2 mm) was purchased from Biomedicals 
(Eschwege, Germany). Bovine serum albumin (fraction V, highest quality) was 
bought from Sigma-Aldrich, Steinheim, Germany. Imidazole (highest quality), 
CaCl2, MnCl2 tetrahydrate and MgCl2 hexahydrate (highest quality) were 
purchased from Merck. For all experiments double-distilled water was used. 
 
3.2 (M)ANT-nucleotides  synthesis and analysis 
3.2.1 (M)ANT-nucleotides  synthesis:  general procedure 
MANT-CTP, MANT- CDP, MANT-UTP, MANT-UDP, MANT-ITP, MANT-IDP, 
ANT-ATP and ANT-ADP were synthesized according to Hiratsuka (1983) with 
modifications. The nucleotide (0.33 mmol, 1 eq) was propounded in a small two-
neck round flask and dissolved in a minimum amount of water (3 ml). Under 
continuous stirring a crystalline preparation of (methyl)isatoic anhydride (0.5 mmol, 
1.5 eq) was added. After heating to 38°C the pH-value was adjusted to 8.6 and 
maintained by titration of 1 N NaOH solution for 2 hours. The reaction mixture was 
extracted three times with chloroform (3 x 20 ml; only for MANT-nucleotides, not for 
ANT-nucleotides). The aqueous phase was dry- frozen. The received foam showed 
white to brown color and was applied to a Sephadex® LH-20 column (85 x 2 cm) 
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and subsequently eluted with double-distilled water. The desired product could be 
detected directly by its blue fluorescence in the collection tubes at λex of 366 nm 
and by TLC. For further purification, reversed-phase preparative HPLC was used 
to separate (M)ANT-NTP from (M)ANT-NDP. After final dry-freezing white solid 
compounds (purity >99%) were obtained. 
 
3.2.2 HPLC analysis of (M)ANT-nucleotides   
The samples were filtered using a PTFE filter (Chromafil, O-20/15, organic, 
pore size 0.2 mm; Machery-Nagel, Düren, Germany). A 10 µl sample was 
analyzed using a HPLC model 1100 (Agilent Technologies, Waldbronn, Germany) 
fitted with a C18 analytical column (Phenomenex Luna, particle size 3 µm, 150 x 
4.60 mm, Aschaffenburg, Germany) and DAD. Data were analyzed using a HPLC-
3D ChemStation Rev. A.10.01 [1635]. Gradient elution was performed with 0.05 M 
ammonium acetate (solvent A) and acetonitrile (solvent B) at a constant flow rate 
of 1.0 ml/min. A gradient profile with the following proportions of solvent B was 
applied [t (min), % B]: [0, 5], [10, 5], [30, 45]. [40, 80]. The chromatograms were 
monitored at UV absorption at 220 and 254 nm. In addition, a fluorescence 
detector was used for the analysis of the fluorescent anthraniloylic compounds at 
λex of 350 nm and λem of 450 nm. 
 
3.2.3 LC/MS online coupling 
All samples were filtered using a PTFE filter and injected into a HPLC 
model 1100 (Hewlett- Packard, Waldbronn, Germany). The compound to be 
analyzed was separated by a C18 column (Phenomenex luna, particle size 3 µm, 
150 x 2 mm, Aschaffenburg, Germany). A binary eluent mixture consisting of 
water (10 mM ammonium acetate) (eluent A) and acetonitrile (eluent B) was 
pumped with a constant flow of 0.3 ml/min. The following gradient profile was 
used t [min], % B: [0, 5], [10, 5], [30, 45]. [40, 80]. The injected volume was 3 µl. 
Using a triple stage mass spectrometer (TSQ 7000, Thermoquest Finnigan, 
Toronto, Canada) the mass of the respective compound was determined. 
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3.2.4 Preparative HPLC 
Compound mixtures were dissolved in water (concentration: 30-50 mg/ml) 
and filtered using a PTFE filter. Compounds were separated using a HPLC model 
1100 (Agilent Technologies, Waldbronn, Germany) fitted with a C18 preparative 
column (phenomenex Luna, particle size) 10 µm 21.2 mm). Gradient elution was 
performed with 0.05 M ammonium acetate (solvent A) and acetonitrile (solvent B) 
at a constant flow rate of 21 ml/min. The chromatograms were monitored by UV 
absorption at 220 and 254 nm. 
 
3.2.5 Synthesized nucleotides: 
  
MANT-UTP (N-methyl-2'(3‘)-O-anthraniloyl-uridine-5‘-triphospate) or 
[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxy-
phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-
methylaminobenzoate. 
182 mg of introduced disodium salt of UTP yielded over all purification 
steps 32 mg (52 µmol, 15%) pure product. Rf = 0.21 (1-propanol:H2O:NH3 (32%) = 
2:1:1). HPLC (analytic): Rt = 18.78 min, 19.15 min; k = 12.49, 12.75; LC/MS (ESI, 
H2O/CH3CN): m/z = 635.2 [M+NH4
+] (Rt = 19.69 min, 19.88 min, 100 %), 652.2 [M-
H+2NH4
+] (Rt = 20.15 min, 100%); (-ESI, H2O/CH3CN): m/z = 616.2 [M-H
-] 
(Rt:19.53 min, 20.01 min, 100 %); HPLC (preparative), gradient (t [min], % B: [0, 
14], [20, 14], [30, 80]): Rt = 6.07 min, 6.79 min; empirical formula: 17H22N3O16P3; 
MW = 617.29. 
 
MANT-UDP (N-methyl-2'(3‘)-O-anthraniloyl-uridine-5‘-diphospate) or 
[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4(3)-hydroxy-2-[(hydroxy- 
phosphonooxyphosphoryl)oxymethyl]oxolan-3(4)-yl]2-
methylaminobenzoate. 
182 mg of introduced disodium salt of UDP yielded over all purification 
steps 8 mg (15 µmol, 3.8%) pure product. Rf = 0.25 (1-propanol:H2O:NH3 (32 %) = 
2:1:1). HPLC (analytic): Rt = 19.75 min, 19.93 min; k = 13.19, 13.32; LC/MS (ESI, 
H2O/CH3CN): m/z = 555.2 [M + NH4
+
] (Rt = 20.64 min, 20.94 min, 100%), 572.2 [M-
H + 2NH4
+
] (Rt = 20.64 min, 20.94 min, 40 %); (-ESI, H2O/CH3CN): m/z = 536.2 [M-
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H-] (Rt: 20.50 min, 20.78 min, 100%); HPLC (preparative), gradient (t [min], % B: 
[0, 14], [20, 14], [30, 80]): Rt = 8.79 min, 9.49 min; empirical formula: 
C17H21N3O13P2; MW = 537.31. 
 
MANT-CTP (N-methyl-2'(3‘)-O-anthraniloyl-cytosine-5‘-triphospate) or 
[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4(3)-hydroxy-2-[[hydroxy- 
(hydroxy-phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)- 
yl]2-methylaminobenzoate.  
200 mg of introduced trisodium salt of CTP yielded over all purification steps 
30 mg (48 µmol, 14%) pure product. Rf = 0.24 (1- propanol:H2O:NH3  (32%) = 
2:1:1). HPLC (analytic): Rt = 16.86 min, 17.60 min; k = 11.17, 11.70; LC/MS (ESI, 
H2O/CH3CN): m/z = 634.2 [M+NH4
+] (Rt = 12.98 min, 16.98 min, 100%); (-ESI, 
H2O/CH3CN): m/z = 615.2[M-H
-] (Rt:13.75 min, 17.24 min, 100%); HPLC 
(preparative), gradient (t [min], % B: [0, 14], [20, 14], [30, 80]): Rt = 4.08 min, 4.61 
min; empirical formula: C17H23N4O15P3; MW = 616.30. 
 
MANT-CDP (N-methyl-2'(3‘)-O-anthraniloyl-cytosine-5‘-diphospate) or 
[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4(3)-hydroxy-2-[(hydroxy- 
phosphonooxyphosphoryl)oxymethyl]oxolan-3(4)-yl]2-
methylaminobenzoate. 
200 mg of introduced disodium salt of CDP yielded over all purification 
steps 2 mg (3.7 µmol, 1%) pure product. Rf = 0.28 (1-propanol:H2O:NH3 (32%) = 
2:1:1). HPLC (analytic): Rt =18.38 min; k = 12.27; LC/MS (ESI, H2O/CH3CN): m/z = 
554.2 [M+NH4
+ ] (Rt = 18.55 min, 100%); (-ESI, H2O/CH3CN): m/z = 535.2 [M-H
-
] 
(Rt:18.66 min, 100%); HPLC (preparative), gradient (t [min], % B: [0, 14], [20, 14], 
[30, 80]): Rt = 5.80 min; empirical formula: C17H22N4O12P2; MW = 536.32. 
 
MANT-ITP (N-methyl-2'(3‘)-O-anthraniloyl-inosine-5‘-triphospate) or 
[(2R,3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxy- 
phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2- 
methylaminobenzoate.   
189 mg of introduced trisodium salt of ITP yielded over all purification steps 
39 mg (61 µmol, 18%) pure product. Rf = 0.31 (1-propanol:H2O:NH3 (32%) = 2:1:1). 
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HPLC (analytic): Rt = 19.74 min, 19.86 min; k = 12.65, 12.73; LC/MS (ESI, 
H2O/CH3CN): m/z = 676.2 [M-H+2NH4
+] (Rt = 20.92 min, 100 %), 659.2  [M+NH4
+ ] 
(Rt = 20.92 min, 80%); (-ESI, H2O/CH3CN): m/z = 640.2 [M-H
-
] (Rt:20.92 min, 
100%); HPLC (preparative), gradient (t [min], % B: [0, 14], [20, 14], [30, 80]): Rt = 
8.03 min, 8.23 min; empirical formula: C18H22N5O15P3; MW = 641.31. 
 
MANT-IDP (N-methyl-2'(3‘)-O-anthraniloyl-inosine-5‘-diphospate) or 
[(2R,3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-4(3)-hydroxy-2-[(hydroxy- 
phosphonooxyphosphoryl)oxymethyl]oxolan-3(4)-yl]2- 
methylaminobenzoate. 
189 mg of introduced disodium salt of IDP yielded over all purification steps 
15 mg (27 µmol, 7%) pure product. Rf = 0.35 (1-propanol:H2O:NH3 (32%) = 2:1:1). 
HPLC (analytic): Rt = 20.34 min, 20.58 min; k = 13.07, 13.23; LC/MS (ESI, 
H2O/CH3CN): m/z = 596.3 [M-H+2NH4
+] (Rt = 21.38 min, 100%), 579.3 [M+NH4
+] 
(Rt = 21.38 min, 70%); (-ESI, H2O/CH3CN): m/z = 560.2[M-H
-] (Rt: 21.39 min, 21.55 
min, 100%); HPLC (preparative), gradient (t [min], % B: [0, 14], [20, 14], [30, 80]): 
Rt = 10.62 min, 11.36 min; empirical formula: C18H21N5O12P2; MW = 561.33. 
 
 
ANT-ATP (2'(3‘)-O-anthraniloyl-adenosine-5‘-triphospate) or [(2R,3S,4R,5R)-5-
(6-aminopurin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxy- 
phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2- 
aminobenzoate.  
189 mg introduced disodium salt of ATP yielded over all purification steps 
59 mg (94 µmol, 26%) pure product. Rf = 0.24 (1-propanol:H2O:NH3 (32%) = 
2:1:1). HPLC (analytic): Rt = 17.44 min; k = 10.07; LC/MS (ESI, H2O/CH3CN): m/z 
= 661.3 [M-H+2NH4
+] (Rt = 18.12 min, 18.32 min, 100%), 644.2 [M+NH4
+] (Rt = 
18.12 min, 18.32 min, 80%); (-ESI, H2O/CH3CN): m/z = 625.2 [M-H
-] (Rt = 18.12 
min, 18.33 min, 100%); HPLC (preparative), gradient (t [min], % B: [0, 11], [9, 11], 
[19, 80]): Rt = 7.07 min, 7.51 min; empirical formula: C17H21N6O14P3; MW = 626.30. 
 
ANT-ADP (2'(3‘)-O-anthraniloyl-adenosine-5‘-diphospate) or 
[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4(3)-hydroxy-2-[(hydroxy- 
phosphonooxyphosphoryl)oxymethyl]oxolan-3(4)-yl]2-aminobenzoate. 
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 200 mg introduced disodium salt of ADP yielded over all purification steps 8 
mg (15 µmol, 4%) pure product. Rf = 0.27 (1-propanol:H2O:NH3 (32%) = 2:1:1). 
HPLC (analytic): Rt = 18.09 min; k = 10.73; LC/MS (ESI, H2O/CH3CN): m/z = 564.3 
[M+NH4
+] (Rt = 18.81 min, 19.04 min, 100%); (-ESI, H2O/CH3CN): m/z = 545.2 [M-
H-] (Rt = 18.81 min, 19.04 min, 100%); HPLC (preparative), gradient (t [min], % B: 
[0, 11], [9, 11], [19, 80]): Rt = 8.99 min; empirical formula: C17H20N6O11P2; MW = 
546.32. 
 
3.3 Expression and purification of EF and EF3(F586A)  
The plasmids pProExH6-EF and pProExH6-EF3F586A were prepared as 
described and amplified in E. coli BL21 (DE3)/pUBS520 cells (3-5, 12). The EF3 
mutants (H577A, N583A, N583Q, N583H, K353A and K353R) were purified as 
described in references (3-5, 12). 
 
Expression and purification of EF was essentially performed as described in 
reference (4) with minor modifications. Specifically, the imidazole concentration in 
the elution buffer for the HisTrap fast flow rate Ni column was increased to 200 
mM. Moreover, imidazole (20 mM) was added into the sample, thus yielding the 
same imidazole concentration as in the second wash buffer of the Ni column. The 
following columns were used for EF protein purification; HisTrap fast flow rate 
affinity Ni column (5 ml) and resource Q (quaternary ammonium salt) strong 
anionic exchange column (6 ml) (GE Healthcare, Freiburg/Brsg., Germany). 
EF3(F586A) mutant was expressed and purified essentially as described i n  
r e f e r ence  (4) with minor modifications. Specifically, the imidazole concentration 
in the elution buffer for the Ni column was 200 mM, and imidazole (20 mM) was 
included in the sample. The HisTrap fast flow rate affinity Ni column (5 ml) was 
used for immobilized matrix affinity chromatography and the HiPrep 16/10 SP XL 
column (GE Healthcare) was used in cation exchange chromatography. CaM was 
extracted and purified from bovine brain as described in reference (13). The HiPrep 
16/10phenyl FF (high sub) column (GE Healthcare) was used in hydrophobic 
chromatography purification of CaM. 
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3.4 AC activity assay 
For the determination of the potency of AC toxin inhibitors, assay tubes 
contained 10 µl of MANT-nucleotides at final concentrations from 10 nM to 100 µM 
as appropriate to obtain saturated inhibition curves and 20 µl of EF, EF3 or 
EF3(F586A) (10 pM final concentration) in 75 mM Tris/HCl, pH 7.4, containing 
0.1% (m/v) bovine serum albumin. Tubes were preincubated for 2 min at 25°C, 
and reactions were initiated by the addition of 20 µL of reaction mixture consisting 
of the following components to yield the given final concentrations; 100 mM KCl, 
100 µM free Ca2+, 5 mM free Mn2+ or Mg2+, 100 µM EGTA, 100 µM cAMP, 100 nM 
CaM. ATP was added as non-labeled substrate at a final concentration of 40 µM 
and as radioactive tracer [α−32P]ATP (0.2 µCi/tube). For the determination of Km 
and Vmax values, 10 µM to 1 mM ATP/Mn
2+ or ATP/Mg2+  were added, plus 5 mM of 
free Mn2+ or Mg2+, respectively. Tubes were incubated for 10 min at 25°C, and 
reactions were stopped by the addition of 20 µL of 2.2 N HCl. Denaturated protein 
was sedimented by a 1-min centrifugation at 13,000 x g. [32P]cAMP was separated 
from [α−32P]ATP by transferring the samples to columns containing 1.4 g of neutral 
alumina. [32P]cAMP was eluted by the addition of 4 ml of 0.1 M ammonium acetate 
solution, pH 7.0. Blank values were about 0.02% of the total amount of [α−32P]ATP 
added; substrate turnover was < 3% of the total amount of [α−32P]ATP added. 
Samples collected in scintillation vials were filled up with 10 ml of double-distilled 
water and Čerenkov radiation was measured in a PerkinElmer Tricarb 2800TR 
liquid scintillation counter. Free concentrations of divalent cations were calculated 
with WinMaxC (http://www.stanford.edu/~cpatton/maxc.html). Vmax and Km values 
reported in Table 1 and Ki values reported in Tables 2 and 3 were calculated using 
the Prism 4.02 software (Graphpad, San Diego, CA, USA). 
 
For determination of the potency of AC toxin inhibitors at various EF3 
mutants (H577A, N583A, N583Q, N583H, K353A and K353R), the experiments 
were essentially performed as described for EF and EF3 with some modifications. 
Specifically, the final enzyme concentrations were increased up to 2 nM in order to 
account for the lower catalytic activity of the mutants. Moreover, the reaction time 
was prolonged to 20 min at 30°C. For the determination of Vmax and Km, the 
ATP/Mn2+ concentration ranged from 100 µM to 4 mM. The higher substrate 
concentrations compared to EF were essential in order to obtain saturated enzyme 
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kinetics. 
 
For determination of the potency of AC toxin inhibitors at EF3 in absence of 
both CaM and Ca2+, experiments were performed as described for standard 
experiments with some modifications in order to increase assay sensitivity. 
Specifically, the final enzyme concentration was increased up to 5 nM, and the 
reaction was stopped after 30 min incubation at 30°C. Moreover, in competition 
experiments, the concentration of unlabeled ATP was decreased to 20 µM and 
[α−32P]ATP was used at a high amount (1.0 µCi/tube). For the determination of 
Vmax and Km, the same modifications were performed, except that the ATP/Mn
2+ 
concentration was varied. 
 
For studying of the inhibition mechanism of the EF3 by MANT-nucleotides, 
enzyme saturation experiments were performed in the presence of various inhibitor 
concentrations as shown in Fig. 1. Assay tubes contained MANT-nucleotides at 
final concentrations from 0.5 µM to 20 µM as appropriate according to the potency 
of the inhibitor. For the basal saturation curve 5 µl of double-distilled water was 
added instead of the inhibitor. Next, 5 µl of 50 µM to 600 µM ATP/Mn2+, plus 20 µl of 
10 pM EF3 in 75 mM Tris/HCl, pH 7.4, containing 0.1% (m/v) bovine serum albumin 
were added. Tubes were preincubated for 2 min at 25°C, and reactions were initiated 
by the addition of 20 µL of reaction mixture consisting of the following components to 
yield the given final concentrations; 100 mM KCl, 100 µM free Ca2+, 5 mM free Mn2+, 
100 µM EGTA, 100 µM cAMP, 100 nM CaM, and [α−32P]ATP (0.2 µCi/tube). 
 
3.5 Fluorescence resonance energy transfer (FRET) experiments 
for monitoring inhibitor binding to EF 
Fluorescence experiments were performed using quartz UV ultra-
microcuvettes from Hellma (Müllheim, Germany, type 105.251- QS, light path 
length 3 x 3 mm, center 15 mm, total volume 70 µl and type 105.250- QS, light 
path length 10 x 2 mm, center 15 mm, total volume 150 µl) in a thermostated 
multicell holder at 25°C in a Varian Cary Eclipse fluorescence spectrometer 
(Varian, Darmstadt, Germany). In case of 150 µl cuvettes, 140 µl of buffer 
consisting of 100 mM KCl, 100 µM CaCl2, 10 mM MnCl2 and 25 mM 
HEPES/NaOH, pH 7.4, was added into the cuvette. Five µl of 10 µM full-length EF 
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(final concentration 300 nM), 5 µl of 10 µM CaM (final concentration 300 nM) and 
MANT-ATP or MANT-CTP (300 nM each) were added. In case of experiments with 
70 µl cuvettes, volumes were adjusted stoichiometrically. The results obtained with 
70 µl- and 150 µl-cuvettes were identical, with the 70 µl-cuvettes offering an 
opportunity to save EF/EF3 mutant protein.  
 
Steady-state fluorescence emission spectra of nucleotides were recorded at 
low speed in the scan mode from λem 300 nm to 550 nm with λex 280 nm. 
Fluorescence recordings were analyzed with the spectrum package of the Varian 
Cary Eclipse software version 1.1. Baseline fluorescence (buffer alone) and the 
baseline-corrected nucleotide-dependent emission of each concentration of the 
ligand (buffer + nucleotide) were subtracted from the spectra shown in Fig. 2. In 
the competition experiments shown in Fig. 3, MANT-nucleotides were displaced 
from the EF catalytic site using PMEApp. In some experiments, we also directly 
excited MANT-nucleotides at λex 350 nm and monitored fluorescence emission 
from 400-500 nm. 
 
3.6 Modeling of the nucleotide binding mode to EF-CaM  
Docking studies were performed with the molecular modeling package 
SYBYL 7.3 (Tripos International, St. Louis, MO) on a Silicon Graphics Octane 
workstation. An initial computer model was generated from the crystal structure of 
EF-CaM in complex with 2'-deoxy-3'ANT-ATP, PDB 1lvc, chain C (4). Yb2+ was 
replaced by Mg2+. Water molecules were added from the crystal structure of EF-
CaM in complex with 3'-deoxy-ATP, PDB 1k90 (3). Hydrogens were added and 
AMBER_FF99 charges assigned to the protein and the water. 2'-Deoxy-3'ANT-ATP 
was provided with Gasteiger-Hueckel-charges. The model was then pre-optimized 
with the AMBER_FF99 force field (14) (ligand and Mg2+ fixed, distant dependent 
dielectric constant ε = 4, 25 cycles steepest descent, followed by Powell conjugate 
gradient, end gradient of 0.1 kcal mole-1 Å-1) were performed. 
 
Initial docking positions of 2'-MANT-CTP, 3'-MANT-CTP and 3'-MANT-ATP 
were based on the localization and conformation of 2'-deoxy-3'-ANT-ATP  in this 
model, allowing the modification of rotatable bonds. Each complex was refined in a 
stepwise approach. Firstly, ~25 minimization cycles with fixed ligand 
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(AMBER_FF99 force field, steepest descent, ε = 4), secondly, minimization of the 
ligand and the surrounding  protein residues (distance up to 6 Å) with the Tripos 
force field (15), (Powell conjugate gradient, ε = 1, end gradient of 0.05 kcal mole-1 
Å-1), and, thirdly, final refinement with fixed ligand (AMBER_FF99 force field, 
Powell conjugate gradient, ε = 4, end gradient of 0.01 kcal mole-1 Å-1). The RMS 
deviation between the three minimized models amounts to 0.2 – 0.25 Å if all atoms 
of the protein are considered. 
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4. Results 
 
 
 
4.1 Kinetic analysis of the catalytic activities of EF, EF3 and 
various EF3 mutants 
  In Table 1, the Vmax and Km values of EF, EF3 and various EF3 mutants in 
the presence of Ca2+/CaM and Mn2+ are summarized. The difference between EF 
and EF3 is that EF3 does not contain the binding domain for protective antigen (3, 
5). The Vmax and Km values were very similar for EF and EF3. In EF3(F586A), Vmax 
decreased by about 50% compared to EF3 with little change in Km. The H577A 
mutation dramatically reduced Vmax and moderately decreased Km. Substitution of 
N583 with other hydrogen-bond-forming  residues such as Q583 or H583 
significantly reduced Vmax together with a 10-50-fold increase in Km. Mutation of 
K353 into A353 reduced Vmax 55-fold and increased Km 10-fold. EF(K353R) 
exhibited about 5-fold reduced Vmax and similar Km compared to the EF3. There are 
some differences in the kinetic parameters of EF3 and EF3 mutants in the 
presence of Mg2+ (3) and Mn2+ (Table 1), supporting the view that these divalent 
cations interact differentially with ACs (6-9). Since the FRET signals presented 
below were much smaller in the presence of Mg2+ than Mn2+ (data not shown), we 
decided to conduct all enzymatic studies in the presence of Mn2+ as well. 
 
We also determined the kinetic parameters of EF3 in the presence of Mn2+ 
but in the absence of Ca2+/CaM. By removing both CaM and Ca2+ from the reaction 
mixture, Vmax was reduced about 2000-fold, but there was no effect on Km. 
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Table 1: Km and Vmax values of EF, EF3 and various EF3 mutants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AC toxin activities were determined as described under “Materials and Methods”. Km and 
Vmax values were obtained by non-linear regression analysis of substrate-saturation 
experiments and are the means ± SD of at least 3 independent experiments performed 
in triplicates. For the determination of the Vmax and Km of EF, EF3 and EF3(F586A), 
reaction mixtures contained 100 µM free Ca2+, 5 mM free Mn2+, 100 µM EGTA, 0.2 
µCi/tube [α−32P]ATP, 100 µM cAMP, 100 nM calmodulin and 10 pM enzyme in 75 mM 
Tris/HCl, pH 7.4. In case of the other EF3 mutants, reaction mixtures contained 0.4 µCi 
[α−
32P]ATP per tube and 2 nM enzyme. For determination of Vmax and Km without CaM 
and Ca2+, the enzyme concentration was 5 nM. The unlabeled ATP/Mn2+ concentrations 
ranged from 100 nM to 4 mM as appropriate to obtain saturated curves. 
60.0 ± 0.890.11 ± 0.007-EF3
75.4 ± 1.3532.3 ± 0.06 +EF3(K353R)
804 ± 1373.93 ± 0.02 +EF3(K353A)
3,890 ± 1,22059.7 ± 10.4+EF3(N583H)
855 ± 3918.4 ± 0.08 +EF3(N583Q)
224 ± 7.3 15.4 ± 0.13 +EF3(N583A)
34.5 ± 9.7 0.013 ± 0.003 +EF3(H577A)
92.0 ± 14.7 128 ± 5.0+EF3(F586A)
82.6 ± 8.2223 ± 12 +EF3
84.5 ± 8.3232 ± 34+EF
Km (µM)Vmax (s
-1)Ca2+/CaMToxin
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4.2 Inhibition of the catalytic activity of EF, EF3 and various EF3 
mutants by (M)ANT-nucleotides 
Table 2 summarizes the Ki values of MANT-ATP and MANT- CTP at EF, 
EF3 and EF3 mutants in the presence of Mn2+. At EF and EF3, MANT- CTP was a 
5-10-fold more potent inhibitor than MANT-ATP. The F586A mutation reduced the 
inhibitory potencies of MANT-ATP and MANT-CTP by 5-6-fold, whereas the 
H577A mutation did not decrease inhibitor potency. The N583A mutation 
decreased nucleotide-potency by 90-100-fold. The N583Q substitution reduced the 
potency of MANT-ATP by 70-fold and the potency of MANT-CTP by 2,500-fold. 
For the N583H mutant, a 200-300-fold decrease in potency of MANT-ATP and 
MANT-CTP was observed. The K353A substitution reduced the potency of MANT-
ATP by less than 20-fold, whereas the potency of MANT-CTP was reduced by 
more than 500-fold. The Ki value of MANT-ATP at EF3(K353R) increased just 3-
fold, while the Ki value of MANT-CTP increased by 65-fold. The omission of 
Ca2+/CaM had only little effect on the Ki values of both MANT-ATP and MANT-CTP 
at EF3. 
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Table 2: Inhibitory potencies of MANT-ATP and MANT-CTP at EF, EF3 and EF3 
mutants in the presence of Mn2+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibitory potencies of MANT-ATP and MANT-CTP at EF, EF3 and various EF3 mutants 
were determined as described under “Materials and Methods”. Ki-values are given in µM and 
are the means ± SD of 3 experiments performed in triplicates. The relative potencies (rel. 
pot.) of MANT-ATP and MANT-CTP are given, too, EF3 being the reference. For 
determination of the inhibitory potencies of MANT-ATP and MANT-CTP at EF, EF3 and 
EF3(F586A), reaction mixtures contained100 µM free Ca2+, 5 mM free Mn2+, 100 µM EGTA, 
40 µM ATP, 0.2 µCi/tube [α−32P]ATP, 100 µM cAMP, 100 nM CaM and 10 pM enzyme in 75 
mM Tris/HCl, pH 7.4. For other EF3 mutants, reaction mixtures contained 0.4 µCi 
[α−
32P]ATP per tube. The enzyme concentration was 2 nM. For the determination of Ki-
values of MANT-ATP and MANT-CTP without CaM and Ca2+, the ATP/Mn2+ concentration 
was 20 µM and the enzyme concentration was 5 nM. Nucleotides were added at different 
concentrations as appropriate to obtain saturated concentration-response curves. Inhibition 
curves were analyzed by non-linear regression using the Prism 4.02 software. 
 
 
630.16921.07 ± 0.04-EF3
1.56.53 ± 0.26303.27 ± 0.08+EF3(K353R)
0.254.8 ± 0.835.617.4 ± 4.0+EF3(K353A)
0.522 ± 5.40.3308 ± 89+EF3(N583H)
0.04248 ± 231.567.4 ± 4.8+EF3(N583Q)
1.010.4 ± 0.021.191.7 ± 2.5+EF3(N583A)
910.11 ± 0.0171890.52 ± 0.05+EF3(H577A)
160.61 ± 0.11224.54 ± 1.15+E3(F586A)
1000.10 ± 0.0081000.98 ± 0.08+EF3
910.11 ± 0.041690.58 ± 0.13+EF
MANT-CTP
rel. pot.
MANT-CTP
K
i
(µM)
MANT-ATP
rel. pot.
MANT-ATP
K
i
(µM)
Ca2+/CaMToxin
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Fig. 1 shows the double-reciprocal analysis of EF3 inhibition kinetics by 
MANT-ATP and MANT-CTP according to Lineweaver-Burk. The linear regression 
lines intersected at the y-axis, i.e. Vmax remained constant, whereas Km increased 
with increasing inhibitor concentration. 
 
Table 3 summarizes the Ki values of various natural purine and pyrimidine 
nucleotides and various (M)ANT-NDPs and -NTPs at EF in the presence of Mn2+ 
and Mg2+. In general, inhibitor potencies were higher with Mn2+ than with Mg2+, but 
the impact of the cation varied with the nucleotide studied. For example, ANT-ATP, 
MANT-CTP and MANT-CDP were about 10-fold more potent in the presence of 
Mn2+ than in the presence of Mg2+, whereas for MANT-GTP, the affinity difference 
was less than 2-fold. A differential impact of Mg2+ and Mn2+ on MANT-nucleotide-
affinity was also noted for mAC and CyaA (6-9). 
 
All natural nucleoside 5’-triphosphates studied inhibited the catalytic activity 
of EF with CTP being the most potent inhibitor. Substitution of the 2’(3’)-O-ribosyl 
group with a (M)ANT group substantially increased inhibitor potency. For example, 
in the presence of Mn2+, MANT-CTP showed about 60-fold higher potency at EF 
than the unmodified nucleotide. The potency-increasing effect of the (M)ANT-group 
depended on the specific nucleotide examined. For example, in the presence of 
Mn2+, the potency of MANT-GTP was just 3.5-fold higher than the potency of GTP. 
(M)ANT- NDPs were less potent EF inhibitors than the corresponding (M)ANT-
NTPs. In the presence of Mn2+, MANT-ATP and ANT-ATP were similarly potent EF 
inhibitors, whereas in the presence of Mg2+, MANT-ATP was about 4-fold more 
potent than ANT-ATP. MANT-GTP was up to 2.5-fold more potent than ANT-GTP. 
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Table 3: Inhibitory potencies of NTPs and (M)ANT-nucleotides at EF in the 
presence of Mn2+ and Mg2+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibitory potencies of various purine and pyrimidine nucleotides at EF were determined as 
described under “Materials and Methods”. Ki values are given in µM and are the means ± 
SEM of 3-4 independent experiments performed in triplicates. The Km value of EF for ATP in 
the presence of Mg2+ was 120 ± 6.5 µM. Reaction mixtures contained 5 mM MnCl2 or 5 mM 
MgCl2, 100 mM KCl, 100 µM CaCl2, 40 µM ATP, [α−
32P]ATP (0.2-0.4 µCi/tube), 100 µM 
cAMP and 100 nM CaM. Nucleotides were added at different concentrations as appropriate 
to construct saturated concentration-response curves. Inhibition curves were analyzed by 
non-linear regression using the Prism 4.02 software. 
 
 
 
 
0.06±13.80.12±1.30MANT-CDP
0.09±1.260.01±0.10MANT-CTP
20.6±1070.48±38.7MANT-UDP
0.82±32.20.08±3.67MANT-UTP
3.16±48.51.89±11.0MANT-IDP
3.29±10.60.06±4.06MANT-ITP
1.86±13.01.09±4.10ANT-GTP
0.32±4.700.08±2.49MANT-GTP
25.1±57.91.25±3.85ANT-ADP
2.12±5.150.09±0.44ANT-ATP
3.34±34.70.50±3.26MANT-ADP
0.57±1.360.09±0.58MANT-ATP
9.18±45.20.38±5.10CTP
2.53±1389.21±63.9UTP
15.8±2333.60±45.4ITP
6.02±73.60.79±9.2GTP
Mg2+Mn2+
K
i
(µM)
Nucleotide
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Fig. 1: Lineweaver-Burk analysis of the inhibition of EF3 AC activity by 
MANT-ATP and MANT-CTP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AC activities were determined as described under “Materials and Methods” with the 
indicated concentrations of MANT-ATP (0 µM, 0.5 µM, 5 µM, 10 µM and 20 µM) (A) and 
MANT-CTP (0 µM, 0.5 µM, 1 µM and 5 µM) (B). Reaction mixtures contained 10 pM EF3, 
100 mM KCl, 100 µM free Ca2+, 5 mM free Mn2+, 100 µM EGTA, 100 µM cAMP, 100 nM 
calmodulin, 0.2 µCi/tube [α−32P]ATP and  unlabeled ATP/Mn2+  concentrations indicated in 
the graph. Data were plotted reciprocally and analyzed by linear regression according to 
Lineweaver- Burk. Shown are the results of a representative experiment performed in 
triplicates. Similar results were obtained in two independent experiments. 
 
 
                EF3
-0.005 0.000 0.005 0.010 0.015 0.020
0.01
0.02
0.03
0.04
0.05
0.06MANT-ATP (0 µM)
MANT-ATP (0.5 µM)
MANT-ATP (5 µM)
MANT-ATP (10 µM)
MANT-ATP (20 µM)
A
1/[ATP/Mn
+2
] (µM
-1
)
1
/V
e
lo
c
it
y
-0.005 0.000 0.005 0.010 0.015 0.020
0.025
0.050
0.075
0.100
0.125
0.150MANT-CTP (0 µM)
MANT-CTP (0.5 µM)
MANT-CTP (1 µM)
MANT-CTP (5 µM)
EF3B
1/[ATP/Mn
2+
] (µM
-1
)
1
/V
e
lo
c
it
y
1
/V
e
lo
c
it
y
1
/V
e
lo
c
it
y
Chapter III                                                                                                                      Results 
 
 93 
4.3 Analysis of the interaction of MANT-nucleotides with EF3 in 
FRET experiments  
At an excitation wavelength of 280 nm, tryptophan and tyrosine residues in 
proteins are excited, emitting light at 350 nm (16) which can then excite the 
(M)ANT group of nucleotides (17), provided sufficient proximity between donor and 
acceptor. Such energy transfer results in increased fluorescence of the MANT-
group at 420-450 nm in mAC and CyaA, reflecting the fact that the MANT-group is 
in a hydrophobic environment (7-9). Previous studies with mAC showed that in the 
presence of Mn2+, FRET signals were much larger than in the presence of Mg2+ 
(7). Preliminary studies with EF3 showed that the Mn2+-preference also applies to 
the toxin (data not shown). Therefore, all subsequent FRET studies with EF3 were 
conducted in the presence of Mn2+ (see Materials and Methods). 
 
In the absence of CaM, EF3 exhibits a strong emission peak at 350 nm 
when excited at 280 nm under steady-state conditions (Figs. 2A and 2C). Upon 
addition of the EF activator CaM, an additional prominent fluorescence peak with 
an emission maximum at 440 nm appeared with MANT-ATP (Fig. 2A), reflecting 
FRET from tryptophan and tyrosine residues to the MANT-group. In EF(F586A), 
the endogenous tryptophan and tyrosine fluorescence was similar as in EF3, but 
the FRET signal (difference in fluorescence at an emission wavelength of 440 nm 
in the presence and absence of calmodulin) was reduced by 55% (Fig. 2B). With 
MANT-CTP, only a small FRET signal was apparent with EF3 upon addition of 
CaM (Fig. 2C). Even an increase of the final CaM concentration to 3 µM, yielding a 
10-fold molar excess of CaM relative to EF3, did not increase FRET with MANT-
CTP (data not shown). The small FRET signal with MANT-CTP was reduced by 
43% in EF(F586A) (Fig. 2D). Analysis of the EF mutants H577A, N583A, N583Q, 
N583H and K353A with MANT- ATP and MANT-CTP revealed no FRET at all 
(data not shown). With CaM and MANT-nucleotides alone, i.e. in the absence of 
EF3, no FRET signal was observed (data not shown). 
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Fig. 2: Analysis of MANT-nucleotide binding to the catalytic site of EF3 and 
EF3(F586A) using FRET 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FRET experiments were performed as described under “Materials and Methods”. The 
assay buffer consisted of 75 mM HEPES/NaOH, 100 µM CaCl2, 100 mM KCl and 5 mM 
MnCl2, pH 7.4. Nucleotides were added to the buffer to yield 300 nM final concentrations. 
EF3/EF3(F586A) (300 nM final concentration) was added followed by the addition of CaM 
(1 µM final concentration). Emission was scanned at an excitation wavelength of 280 nm 
after each addition. The buffer and the MANT-nucleotide basal fluorescence was 
subtracted from the fluorescence after addition of EF3/EF3(F586A) (dotted purple line) 
and CaM (solid blue line). Shown are superimposed recordings of a representative 
experiment. Similar data were obtained in 5 independent experiments. a.u., arbitrary unit. 
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In FRET experiments, the appearance of the new fluorescence peak at λem 
440 nm would have been expected to be accompanied by a decrease in 
fluorescence at λem 350 nm as was the case for mAC (7, 8) and CyaA (9). Rather, 
a small increase in EF3 fluorescence upon CaM addition was observed (Fig. 2). 
An explanation for these findings could be that the endogenous tyrosine and 
tryptophan fluorescence of EF3 is quenched by surrounding polar amino acids 
such as aspartate, glutamate and histidine (16). Upon addition of CaM, a large 
conformational change occurs in EF3 (3, 4), abrogating the quenching effects of 
polar amino acids and, thereby, masking the expected decrease in fluorescence at 
λem 350 nm.  
 
Control experiments with dimethyl sulfoxide ranging from 0-100% (v/v) (17) 
revealed that MANT-ATP and MANT-CTP possess similar relative increases in 
fluorescence upon exposure to a hydrophobic environment (λex 350 nm; λem 400-
500 nm) (data not shown). Thus, differences in biophysical properties of 
nucleotides do not account for the different FRET responses observed with MANT- 
ATP and MANT-CTP upon interaction with EF. We also studied the interaction of 
EF with MANT-nucleotides by exciting nucleotides directly at λem 350 nm. As was 
true in the FRET experiments (Fig. 2), the response observed with MANT-ATP at 
λem 450 nm was greater than with MANT-CTP (data not shown). 
 
Fig. 3 shows the kinetics of FRET experiments with MANT-ATP and MANT- 
CTP at a fixed emission wavelength of 440 nm. Sequential addition of EF3 and 
CaM resulted only in small fluorescence increases, reflecting the far end of the 
tryptophan/tyrosine emission spectrum (see Fig. 2). Addition of MANT-nucleotides 
to cuvettes instantaneously resulted in substantial fluorescence increases, 
reflecting FRET. Addition of the high-affinity EF inhibitor and non-fluorescent 
nucleotide analog PMEApp (1 µM) (18) to cuvettes reduced the fluorescence 
signals with both MANT-nucleotides (300 nM each), but the inhibitory effect of 
PMEApp was more pronounced and more rapid in onset with MANT-ATP than with 
MANT-CTP. 
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Fig. 3: Kinetic analysis of the interaction of EF3 with MANT-nucleotides and 
CaM in FRET experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kinetic experiments were performed as described in “Materials and Methods”. The 
excitation wavelength was 280 nm and emission was detected at 430 nm over time. 
Successively, buffer (1), 300 nM EF3 (2), 1 µM CaM (3), nucleotide (A: MANT-ATP, B: 
MANT-CTP, 300 nM each) (4) and PMEApp (1 µM) (5) were added. A recording of a 
representative experiment is shown. Similar data were obtained in 4 independent 
experiments. a.u., arbitrary unit. 
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4.4 Modeling of the binding modes of MANT-nucleotides to EF-
CaM.  
The crystal structure of EF in complex with CaM and 2'-deoxy-3'-ANT-ATP  
(PDB 1lvc, (4)) served as basis for the docking of MANT-CTP and MANT-ATP. 
Fig. 4A shows that the nucleotide binding site of EF is a spacious cavity located 
at the interface of two structural domains, CA (D294 – N349, A490 – K622) and 
CB (V350 – T489). Three switches, A (Q507 – L549), B (G578 – N591), and C 
(R630 – T659), which strongly change their conformation and position on the 
transition from EF alone to EF-CaM (3, 4) cover the catalytic site in the EF-CaM 
state. A metal cation (Yb2+ in the template, replaced by Mg2+ in the models) is 
involved in ionic interactions with D491, D493 and the α-phosphate of the 
nucleotides. The MANT group is aligned in parallel with the phenyl ring of F586. 
Thus, hydrophobic interactions account for the generally higher potency of the 
ANT- and MANT-derivatives compared to their natural parent nucleotides (Table 
3). 
 
The docking approaches were performed to suggest possible reasons why 
MANT-CTP inhibits EF-CaM more potently than MANT-ATP. Fig. 4B and 4D 
compare the putative binding mode of 3'-MANT-CTP and 3’-MANT-ATP in more 
detail. The common structures of both molecules interact with EF-CaM in the 
same manner. In the minimized models, the ribosyl rings adopt a 3'-exo 
conformation like the ribosyl moiety of 3'-MANT-ATP in complex with mAC (8). The 
triphosphate moieties fit into a deep polar pocket forming ionic interactions with the 
lysines 346, 353 and 372 as well as an H bond with S354 (γ-phosphate). These 
interactions account for the higher inhibitory potencies of the triphosphates 
compared to the diphosphate analogs in Table 3. The ring oxygens of the ribosyl 
moieties are hydrogen-bonded to the amide NH2 of N583. The 2'-OH groups 
approach the side chain of L348. Additionally to the parallel fit to F586, the 3'-
MANT Substituents interact via their amino function with H351. 
 
The nucleobases show both shared and different interactions. Most striking 
is the flat alignment with the side chain of N583. In the case of 3'-MANT-CTP, 
such type of interaction is more favorable since the oxygen in 2'-position of the 
base may align with the positive pole of the amide dipole. However, this difference 
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cannot be the only reason for the higher potency compared to MANT-ATP, 
because also on the N583A mutant, MANT-CTP is more potent than its ATP 
analog (Table 3). 
 
Considering the farther environment of the cytosine oxygen, additional 
reasons can be suggested. In the minimized model, it is in a 3.3 Å distance from 
the guanidino group of R329. Moreover, a water molecule can be placed in an 
ideal position into the EF-MANT-CTP model where it forms three H bonds, bridging 
the cytosine oxygen with the side chains of R329 and E580. The NH2 groups of the 
cytosine and adenine moieties interact similarly with EF-CaM via H bonds to 
backbone oxygens (3'-MANT- CTP to G578 and/or T579, 3'MANT-ATP to T548 
and T579). The signifinace of these interactions is confirmed by the lower potency 
of MANT-UTP and MANT-GTP (Table 3). Interestingly, the N583H mutant 
disproportionately reduces the potency of MANT- ATP, whereas on the N583Q 
species, MANT-CTP is even less potent than its ATP analog. In the former case, 
an alignment of the heterocycles should be still possible. However, the larger 
glutamine side chain in N583Q restricts the binding cavity for the nucleobases so 
that the mode of interaction changes. As suggested for MANT-CTP, also the 
affinity of the other nucleotides to EF3 and EF mutants may be affected by a 
specific arrangement of water molecules. 
 
The MANT nucleotides used in the assays are mixtures of 2'-MANT and 3'- 
MANT isomers, and there is spontaneous isomerization between the two species 
under physiological conditions (17, 19, 20). So far, only the putative binding mode 
of 3’-MANT-isomers has been considered. The question arises whether the MANT 
group may fit to the same EF- CaM site in both isomers as shown for the binding 
of MANT-nucleotides to CyaA (9). Fig. 4C indicates that 2'-MANT-CTP may indeed 
interact with EF-CaM in a very similar position like its 3'-MANT analog. The main 
difference is a 3'- endo conformation of the ribosyl moiety, present also in the 
complex of 3'-deoxy-ATP with EF-CaM (3). This geometry implies an axial position 
of the 2'- MANT group which may then project to the space between H351 and 
F586. Additionally, an intramolecular H bond between the 3'-hydroxy group and 
the proximal α-phosphate oxygen is possible. Fig. 4E, showing the alignment of 2'- 
MANT-CTP, 3'-MANT-CTP and 3'-MANT-ATP in the docked poses, indicates a 
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close fit of the 2'-MANT and 3'-MANT isomers. Only the positions of the MANT 
groups themselves are slightly different (variability of the triphosphate conformation 
is due to the individual minimization courses). 
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Fig. 4: Docking of MANT- CTP and MANT-ATP on EF-CaM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The minimized models are based on the crystal structure of EF-CaM-3'ANT-2'deoxy-ATP, 
PDB 1lvt (Shen et al., 2002). Colors of atoms, unless otherwise indicated: P – orange, O – 
red, N – blue, C, H –grey, Mg2+ – purple spheres. A, topology diagram of the EF domains 
surrounding the binding site with docked 3'-MANT-CTP (represented as transparent CPK 
model). Domains CA – green, CB – greenblue, switch A – red, switch B – orange, switch C 
– yellow. Amino acids subjected to mutation – balls and sticks models. B-D, detailed 
representation of interactions of MANT-nucleotides with EF-CaM. The side chains of 
amino acids within a sphere of 3 Å around the ligand and Mg2+ are drawn as sticks (C 
atoms – cyan) and labeled. For clarity, repeating labels are omitted in panels C and D 
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(see panel B). Cα-trace – cyan line. B, docking of 3´-MANT-CTP. C, docking of 2´-MANT-
CTP. D, docking of 3´-MANT-ATP. E, superposition of the docked MANT nucleotides 
based on alignment of the three EF models (all heavy protein atoms considered). Colors 
of C and essential H atoms: 3´-MANT-CTP – green, 2´-MANT-CTP – purple, 3´-MANT-
ATP – yellow. 
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5. Discussion 
 
 
The major goal of the present study was to characterize the interaction of 
the catalytic site of EF with (M)ANT-nucleotides  possessing various purine and 
pyrimidine bases in order to better understand the molecular mechanisms of EF 
inhibition and to provide the basis for the rational development of potent and 
selective EF inhibitors. Such EF inhibitors could be useful compounds to treat EF 
toxinemia and antibiotic-resistant Bacillus anthracis strains (1). 
 
In previous studies, we developed a three-site pharmacophore model for 
mAC and CyaA toxin with binding regions for the base, the MANT-group and the 
polyphosphate chain (8-11). Those studies revealed that the MANT-group and the 
polyphosphate chain are the major determinants of inhibitor potency, whereas the 
base plays a relatively small role in this respect. This is reflected by the fact that 
the catalytic sites of mAC and CyaA are conformationally flexible and 
accommodate both purine and pyrimidine nucleotides. 
 
Likewise, in EF, the (M)ANT-group and the length of the polyphosphate 
chain have a substantial impact on inhibitor potency, and EF accommodates 
various purine and pyrimidine bases (Table 3). These data indicate that the three-
site binding model developed for mAC and CyaA can also be extended to EF. The 
structure/activity relationships of (MANT)-nucleotides at EF, CyaA and mAC are 
different, indicating that in principle, the development of potent and AC isoform-
specific inhibitors is feasible. Most strikingly, CTP inhibited EF more than 400-fold 
more potently than mAC (Table 3)(10). Substitution of the 2’(3’)-O-ribosyl position 
of CTP with a MANT group decreased the Ki value from 5 µM to 100 nM, yielding 
an EF inhibitor that is even 5-10-fold more potent than MANT-ATP in the presence 
of Mn2+  (Tables 2 and 3). 
 
The highly unexpected preference of EF for the base cytosine prompted us 
to analyze EF inhibition by MANT-CTP and MANT-ATP in more detail. The 
analysis of enzyme inhibition kinetics revealed that both MANT-CTP and MANT-
ATP are competitive EF inhibitors; i.e., they bind to the same site as, and freely 
compete with, the substrate ATP (Fig. 1). These data ruled out the existence of a 
hitherto unidentified cytosine base-preferring nucleotide-binding site in the 
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structurally very complex EF protein (Fig. 4A) (3, 4). Kinetic FRET competition 
experiments with the non-fluorescent ATP analog PMEApp revealed that both 
MANT- ATP and MANT-CTP reversibly bind to the catalytic site (Fig. 3), 
corroborating the competitive inhibition mode and the existence of a single 
nucleotide-binding site in EF. The faster displacement of MANT-ATP from EF by 
PMEApp compared to the displacement of MANT-CTP is explained by the higher 
affinity of EF for MANT-CTP. 
 
To dissect possible differences in the binding modes of MANT-ATP and 
MANT-CTP to EF, we studied their interaction with several EF mutants in terms of 
enzyme inhibition and fluorescence spectroscopy. A previous study had shown 
that F586 mediates π-stacking interactions with 2’-deoxy-3’-ANT-ATP, resulting in 
a fluorescence increase upon excitation of the ANT-group (4). In agreement with 
those data, mutation of F586 reduced the potency of MANT-ATP and largely 
reduced the CaM-dependent FRET of MANT-ATP (Table 2 and Fig. 2). F586 is 
also important for the interaction with MANT-CTP as is revealed by the 6-fold 
reduction in potency. However, compared to MANT-ATP, the FRET signal with 
MANT-CTP in EF was much smaller, and the F586A mutation had a smaller 
inhibitory effect on the FRET. This difference in FRET cannot be explained by a 
lower CaM-affinity of EF bound to MANT-CTP compared to the protein complex 
bound to MANT-ATP since a 10-fold molar excess of CaM relative to EF did not 
yield a larger FRET with MANT-CTP. The models shown in Fig. 4 suggest a similar 
binding mode of MANT-CTP and its ATP analog. However, subtle differences due 
to the nucleobases occur and may account for the higher potency and the small 
FRET signal of MANT-CTP. In particular, the cytosine moiety may form water-
mediated hydrogen bonds with R329 and E580 and favorably fit to the amide 
dipole of N583. Additionally, the flexibility of the bound cytosine should be greater 
than in the case of the bulkier adenine ring. Together with the specific charge 
distribution in the vicinity of the nucleobase, this may lead to absorption and thus 
attenuation of the FRET energy which is mainly due to tyrosine and tryptophan 
residues in switch C. 
 
H577 plays a crucial role in catalysis as is reflected by the very low catalytic 
activity of the H577A mutant (Table 1) (3, 12). Nonetheless, the catalytic activity of 
the H577A mutant was sufficiently large to determine substrate- and MANT-
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nucleotide affinity. Indeed, this mutation does not exert detrimental effect on 
substrate- and inhibitor binding per se (Tables 1 and 2). 
 
N583 forms a crucial hydrogen bond with the ribosyl moiety of nucleotides 
bound to the catalytic site of EF (3). Accordingly, replacement of N583 by a non-
hydrogen bond-forming amino acid (N583A) or hydrogen bond- forming amino 
acid with a different spatial arrangement of the bonding partners (N583Q and 
N383H) substantially decreases catalytic activity of the resulting EF mutants and 
also increases Km (Table 1) (3). Thus, it was also not surprising that N583 mutants 
substantially reduced the potencies of MANT-ATP and MANT-CTP (Table 2). 
However, whereas the N583A mutation and the N583H mutation affected inhibitor 
potencies to a similar extent, the potency of MANT-CTP was much more strongly 
reduced by the N583Q mutation than the potency of MANT- ATP. These findings 
suggest that the binding of MANT-CTP is severely impaired by the longer side 
chain of Q as compared to N, indicative for a substantial spatial constraint in this 
part of the binding pocket. 
 
The carboxyl group of E588 and the amino group of K353 form an ionic 
bond that locks the base into the catalytic site (3). Disruption of this ionic bond by 
the K353A mutation largely reduces catalytic activity and lowers substrate affinity 
(3) (Table 1). The K353R mutation that alters the spatial arrangement of the 
catalytic site but still allows ionic bridge formation displays less severe impairment 
of catalysis and no change in Km (Table 1). Intriguingly, binding of MANT-CTP to 
the catalytic site is much more sensitive to disruption of ionic bond formation 
between E588 and K353 and reorientation of the ionic bond than binding of MANT-
ATP (Table 2), further corroborating the notion that there are subtle differences in 
the binding modes of MANT-ATP and MANT-CTP. 
 
The high sensitivity of our AC assay, largely due to very low blank values 
(see Materials and Methods) allowed us not only to precisely determine the kinetic 
parameters of EF mutants but also of wild-type EF in the absence of CaM. In fact, 
the catalytic activity of EF is not absolutely CaM-dependent. Even in the absence 
of CaM, we could accurately determine kinetic parameters using appropriate 
experimental conditions, i.e. higher protein and [α-32P]ATP amounts, higher 
incubation temperature and longer incubation time. The fact that in the absence of  
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CaM, EF displays unaltered substrate- and inhibitor affinity despite the largely 
reduced catalytic activity was rather surprising. Even the MANT-CTP/MANT-ATP 
potency ratio is conserved. Comparing the crystal structures of EF-CaM (PDB 
1lvc, (4)) and EF alone (PDB 1k8t, (3)), 13 mutually resolved amino acids of the 
MANT-nucleotide binding sites (Fig. 4B) fit very well (RMSD of the backbone 
atoms 0.99 Å, only G578 and T579 at the N-terminus of switch B are outliers with 
distances of greater than 1.5 Å). However, switch B stabilized by switch C in EF-
CaM is disordered in the structure of EF alone and contains amino acids involved 
in substrate- and MANT-nucleotide binding to EF-CaM (T579, E580, N583, F586, 
E588) or in the stabilization of residues that participate in catalysis (e.g., D590 
forming a salt bridge with R329). To explain the unaltered potency of the MANT 
inhibitors at EF alone, we postulate that the nucleotides stabilize switch B in a 
conformation like that in EF-CaM. The substrate may act similarly in terms of 
affinity, but the resulting switch B conformation is insufficient for high catalytic 
activity. Experiments with membrane-permeable CaM inhibitors (21) will have to 
answer the question whether the CaM-independent catalytic activity of EF is of 
pathophysiological relevance. 
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6. Summary and conclusion 
In conclusion, through a combination of enzymological, fluorescence 
spectroscopy, mutagenesis and molecular modeling approaches, we have shown 
that there are subtle differences in the binding modes of MANT-ATP and MANT-
CTP to EF. EF, unlike all other ACs studied so far including mAC and CyaA toxin 
from Bordetella pertussis, exhibits a unique preference for the base cytosine, 
offering an excellent starting point for the development of EF inhibitors with 
specificity for the toxin relative to mAC. Finally, our studies also raise the intriguing 
question whether CTP, exhibiting an unusually high affinity for EF is not only an 
inhibitor of cAMP synthesis but, perhaps, a substrate itself. 
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IV. Molecular Analysis of the Interaction of Anthrax 
Adenylyl Cyclase Toxin, Edema Factor, with Bis- 
2’,3’-O-(N- (propyl)/(methyl)anthraniloyl)-Substituted 
Purine and Pyrimidine Nucleotides 
 
1. Abstract 
Bacillus anthracis causes anthrax disease and exerts its deleterious effects by 
the release of three exotoxins, i.e. lethal factor, protective antigen and edema factor 
(EF), a highly active calmodulin-dependent adenylyl cyclase (AC). However, 
conventional antibiotic treatment is ineffective against either toxemia or antibiotic-
resistant strains. Thus, more effective drugs for anthrax treatment are needed. The 
studies reported in Chapter III showed that EF is differentially inhibited by various 
purine and pyrimidine nucleotides modified with N-methylanthraniloyl (MANT)- or 
anthraniloyl (ANT) groups at the 2’(3’)-O-ribosyl position, with the unique preference 
for the base cytosine. MANT-CTP was the most potent EF inhibitor (Ki, 100 nM) 
among 16 compounds studied. In this Chapter, we examined the interaction of EF 
with 2’,3’-O-bis-(M)ANT-substituted nucleotides. Bis-MANT-ATP and Bis-MANT-CTP 
were the most potent EF inhibitors among nucleotides studied (Ki, 210 nM for both 
nucleotides). Bis-MANT-nucleotides inhibited EF competitively. Propyl-ANT-ATP was 
more potent than Bis-propyl-ANT-ATP and MANT-ATP. Activation of EF by 
calmodulin resulted in effective fluorescence resonance energy transfer (FRET) from 
tryptophan and tyrosine residues located in the vicinity of the catalytic site to Bis-
MANT-ATP, but FRET to Bis-MANT-CTP was only small. Mutagenesis studies 
revealed that F586 is crucial for FRET to Bis-MANT-ATP and Bis-MANT-CTP and 
that the mutations N583Q, K353A and K353R differentially alter the inhibitory 
potencies of Bis-MANT-ATP and Bis-MANT-CTP. We conclude that the nucleotide 
binding site of EF is spacious and readily accommodates bulky Bis-(M)ANT-
substituted purine and pyrimidine nucleotides. Longer aliphatic chain substitution at 
N-position of ANT-ATP may increase the potency of EF inhibition. These data 
provide a solid basis for future structure/activity relationship studies aiming at the 
development of potent EF inhibitors with high selectivity relative to mammalian ACs.                         
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2.  Introduction 
The spore-forming Bacillus anthracis secretes three major toxins: edema 
factor (EF), protective antigen (PA), and lethal factor (LF) (1, 2). As an adenylyl 
cyclase, EF raises the concentration of a second messenger, cyclic AMP (cAMP), 
inside host cells to supraphysiological levels (3, 4). EF is the key virulence factor for 
anthrax pathogenesis. An inactivating mutation in EF results in reduced survival of 
germinated anthrax spores in macrophages, indicating an active role for EF at early 
stages of anthrax infection (5). Moreover, EF modulates the profile of cytokines such 
as tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6) produced by human 
monocytes, which impair cellular antimicrobial responses (6). In addition, a strain of 
anthrax with a defective EF gene has 100-fold reduced lethality in mice (7). 
 
EF enters host cells via a complex with PA, which is a pH-dependent protein 
transporter (8). LF, a zinc metalloprotease that inactivates mitogen-activated protein 
kinase kinase, also enters into host cells by its association with PA (9, 10). LF works 
coordinately with EF to facilitate bacterial survival in macrophages and to impair host 
innate immunity (5-7, 11, 12). The combination of toxemia caused by anthrax toxins 
and bacteremia due to the rapid growth of anthrax bacteria in vital organs can result 
in sepsis, pulmonary edema, and/or meningitis within few days, making inhalational 
anthrax a deadly disease. 
 
Natural isolates of Bacillus anthracis are sensitive to a broad spectrum of 
antibiotics; thus antibiotics have been the primary recourse for therapy (13). 
However, antibiotics are ineffective against either toxemia or antibiotic-resistant 
strains of anthrax. The antibiotic treatment used for victims of the 2001 bioterrorism-
related anthrax attack in the United States resulted in a survival rate of slightly better 
than 50% for cases of inhalational anthrax. Some survivors have experienced illness 
with symptoms such as fatigue, shortness of breath, chest pain, and memory loss. 
This situation highlights an urgent need for a more effective treatment to improve the 
survival rate and quality of life of Anthrax patients (14).  
 
Previous studies resolved several crystal structures of nucleotide-EF-CaM 
complexes and characterized the amino acids that are important for binding of the 
substrate ATP and catalysis (4, 15, 16). Additionally, we showed that mAC and 
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bacterial AC toxins are potently inhibited by MANT-substituted nucleoside 5’-
triphosphates (17-20). Those (M)ANT-nucleotides are environmentally sensitive 
fluorescence probes that show an increase in fluorescence upon interaction with a 
hydrophobic environment (21, 22). We exploited this property to suggest 
conformational changes associated with activation in purified catalytic subunits of 
mAC (18, 19), the Bordetella pertussis AC toxin, CyaA (20) and Bacillus anthracis AC 
toxin EF (23). In addition, by combining crystallographic and molecular modeling 
approaches, we developed a three-site pharmacophore model for mAC, CyaA, and 
EF with binding domains for the base, the MANT-group and the polyphosphate chain 
(19, 20, 24, 25). 
 
In our recent study, we systematically examined the interactions of natural 
purine and pyrimidine nucleotides and several (M)ANT- substituted analogues with 
EF in terms of catalysis, fluorescence changes and molecular modeling. This study 
revealed that the structure/activity relationships of (MANT)-nucleotides at EF, CyaA 
and mAC are different; indicating that in principle, the development of potent and 
specific E F - inhibitors is feasible. Additionally, EF exhibited a highly unexpected and 
unique preference for the base cytosine. MANT-CTP was the most potent EF-
inhibitor among the studied nucleotides, 5-10-fold more potent than MANT-ATP (23). 
 
Moreover, we found that MANT-CTP and MANT-ATP are competitive EF 
inhibitors, i.e. they bind to the same site as, and freely compete with, the substrate 
ATP. These data ruled out the existence of a hitherto unidentified cytosine base-
preferring nucleotide-binding site in the structurally very complex EF protein (4, 15). 
Kinetic FRET competition experiments with the non-fluorescent ATP analog PMEApp 
revealed that both MANT- ATP and MANT-CTP reversibly bind to the catalytic site, 
corroborating the competitive inhibition mode and the existence of a single 
nucleotide-binding site in EF. Mutagenesis studies revealed that F586 is crucial for 
FRET to MANT-ATP and MANT-CTP and that the mutations N583Q, K353A and 
K353R differentially alter the inhibitory potencies of MANT-ATP and MANT-CTP (23). 
 
In our previous studies, we have also shown that the catalytic sites of both 
CyaA and EF are spacious and readily accommodate a broad variety of 2’,3’-
substituted nucleotides. The catalytic site of CyaA even accommodates a bis-
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substituted MANT-nucleotide. Interestingly, Bis-MANT-IMP exhibited higher potency 
at CyaA in comparison to the corresponding mono-substituted MANT-nucleotide (23). 
These data prompted us to study systematically the interactions of several newly 
synthesised mono- and bis-substituted (M)ANT-nucleotides with EF and several EF 
mutants in terms of catalysis, fluorescence changes and molecular modeling, 
Focusing on Bis-MANT-ATP and Bis-MANT-CTP to better dissect the unique 
preference of EF for the base cytosine. The major goal of the present study was to 
provide the basis for the rational development of potent and selective EF inhibitors. 
Such EF inhibitors could be useful compounds to treat EF toxemia and antibiotic-
resistant Bacillus anthracis strains. 
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3. Materials and Methods 
 
3.1 Materials:  
Expression and purification of EF was performed as described in Chapter II. 
The following columns were used for EF protein purification; HisTrap fast flow rate 
affinity Ni column (5 ml) and resource Q (quaternary ammonium salt) strong 
anionic exchange column (6 ml) (GE Healthcare, Freiburg/Brsg., Germany). 
EF3(F586A) mutant was expressed and purified as described in Chapter II. The 
HisTrap fast flow rate affinity Ni column (5 ml) was used for immobilized matrix 
affinity chromatography and the HiPrep 16/10 SP XL column (GE Healthcare) was 
used in cation exchange chromatography. CaM was extracted and purified from 
bovine brain as described i n  Chapter II. The HiPrep 16/10phenyl FF (high sub) 
column (GE Healthcare) was used in hydrophobic chromatography purification of 
CaM. PMEApp was supplied by Gilead Sciences, Foster City, CA. ATP, ITP, CTP, 
IMP, ampicillin, kanamycin, lysozyme enzyme, β-mercaptoethanol, Mes buffer (low 
moisture content) and dithiothreitol (for molecular biology) were purchased from 
Sigma-Aldrich, Steinheim, Germany. Tryptone and yeast were purchased from BD 
Biosciences (Franklin Lakes, NJ). [α−32P]ATP (800 Ci/mmol) was purchased from 
PerkinElmer, Rodgau Jügesheim, Germany. Aluminum oxide 90 active, (neutral, 
activity 1, particle size 0.06 - 0.2 mm) was purchased from Biomedicals 
(Eschwege, Germany). Bovine serum albumin (fraction V, highest quality) was 
bought from Sigma-Aldrich, Steinheim, Germany. Imidazole (highest quality), 
CaCl2, MnCl2 tetrahydrate and MgCl2 hexahydrate (highest quality) were 
purchased from Merck. For all experiments double-distilled water was used. 
 
3.2 Mono- and bis-(M)ANT-nucleotides  synthesis and analysis 
3.2.1 General procedure for mono- and bis- (M)ANT-nucleotides  
synthesis  
(M)ANT-nucleotides were synthesized according to Hiratsuka (1983) with 
modifications. In general, mono- and bis-substituted (M)ANT-nucleotides could be 
achieved both in an one pot synthesis procedure. The nucleotide (0.33 mmol, 1 eq) 
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was propounded in a small two-neck round flask and dissolved in a minimum 
amount of water (3 ml). Under  continuous  stirring  a  crystalline  preparation  of  
the  appropriate  isatoic anhydride derivative (0.5 mmol, 1.5 eq) was added. After 
heating to 38 °C the pH- value was adjusted to 8.6 and maintained by titration of 1 
N NaOH solution for 2 hours. The reaction mixture was extracted three times by 20 
ml chloroform (only for MANT-nucleotides). The aqueous phase was dry-frozen. The 
received foam showed white to brown color. The crude reaction mixture was purified 
by preparative reversed phase high pressure liquid chromatography. Especially for 
the sensitive separation of mono- and bis-(M)ANT-NTPs from mono- and  bis-
(M)ANT-NDPs this purification strategy was required. In case of monophosphate 
derivatives only size-exclusion chromatography with a long Sephadex® LH-20 
column (85 x 2 cm) and subsequently elution with double-distilled water was  
app l i ed .  The desired product could be  detected directly by its blue fluorescence 
in the collection tubes at λex of 366 nm and by TLC. After final dry-freezing white to 
brown solid compounds (purity > 98 %) were obtained. For  all derivatives yields 
were determined by analytical HPLC measurements of crude reaction mixtures and 
correlate with the maximal accessible yield. Because of the time consuming and 
costly preparative HPLC purification separation was stopped after obtaining 
approximate 5 mg pure compound. 
 
Synthesis of isatoic anhydride precursors 
For the propyl- and acetylated amino-ANT-nucleotide derivatives the 
corresponding isatoic anhydrides were easily accessible by nucleophilic substitution 
with propyliodide and for acetylation with acetic acid anhydride by standard protocol 
respectively. 
 
3.2.2 HPLC analysis of bis-(M)ANT-nucleotides   
The samples were filtered using a PTFE filter (Chromafil, O-20/15, organic, 
pore size 0.2 mm; Machery-Nagel, Düren, Germany). A 10 µl sample was 
analyzed using a HPLC model 1100 (Agilent Technologies, Waldbronn, Germany) 
fitted with a C18 analytical column (Phenomenex Luna, particle size 3 µm, 150 x 
4.60 mm, Aschaffenburg, Germany) and DAD. Data were analyzed using a HPLC-
3D ChemStation Rev. A.10.01 [1635]. Gradient elution was performed with 0.05 
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ammonium acetate (solvent A) and acetonitrile (solvent B) at a constant flow rate 
of 1.0 ml/min. A gradient profile with the following proportions of solvent B was 
applied [t (min), % B]: [0, 5], [10, 5], [30, 45]. [40, 80]. The chromatograms were 
monitored at UV absorption at 220 and 254 nm. In addition, a fluorescence 
detector was used for the analysis of the fluorescent anthraniloylic compounds at 
λex of 350 nm and λem of 450 nm. 
 
3.2.3 LC/MS online coupling 
All samples were filtered using a PTFE filter and injected into a HPLC 
model 1100 (Hewlett- Packard, Waldbronn, Germany). The compound to be 
analyzed was separated by a C18 column (Phenomenex luna, particle size 3 µm, 
150 x 2 mm, Aschaffenburg, Germany). A binary eluent mixture consisting of 
water (10 mM ammonium acetate) (eluent A) and acetonitrile (eluent B) was 
pumped with a constant flow of 0.3 ml/min. The following gradient profile was 
used t [min], % B: [0, 5], [10, 5], [30, 45]. [40, 80]. The injected volume was 3 µl. 
Using a triple stage mass spectrometer (TSQ 7000, Thermoquest Finnigan, 
Toronto, Canada) the mass of the respective compound was determined. 
 
3.2.4 Preparative HPLC 
Compound mixtures were dissolved in water (concentration: 30-50 mg/ml) 
and filtered using a PTFE filter. Compounds were separated using a HPLC model 
1100 (Agilent Technologies, Waldbronn, Germany) fitted with a C18 preparative 
column (phenomenex Luna, particle size) 10 µm 21.2 mm). Gradient elution was 
performed with 0.05 M ammonium acetate (solvent A) and acetonitrile (solvent B) 
at a constant flow rate of 21 ml/min. The chromatograms were monitored by UV 
absorption at 220 and 254 nm. 
 
3.2.5 NMR spectrometry 
 Bruker Avance 400 (1H: 400.1 MHz, 13C: 100.6 MHz, 31P-NMR: 161.9 
MHz, T = 300 K), Bruker Avance 300 (1H: 300.1 MHz, 13C: 75.5 MHz, T = 300 K). 
The chemical shifts are reported in δ [ppm] relative to external standards (solvent 
residual peak). The spectra were analysed by first order, the coupling constants are 
given in Hertz [Hz]. Characterisation of the signals: s = singlet, d = doublet, t = 
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triplet, m = multiplet, dd = double doublet, ddd = double double doublet. Integration 
is determined as the relative number of atoms. Assignment of signals in 13C-spectra 
was determined with DEPT-technique (pulse angle: 135°) and given as (+) for CH or 
CH3, (-) for CH2 and (Cquat) for quaternary C. Error of reported values: chemical shift: 
0.01 ppm for 1H- NMR, 0.1 ppm for 13C-NMR and 0.1 Hz for coupling constants. The 
solvent used is reported for each spectrum. 
 
3.2.6 Spectroscopy 
 Absorption spectroscopy was performed using a Varian Cary BIO 50 
UV/VIS/NIR spectrometer with a 1 cm quartz cuvette (Hellma) and Uvasol solvents 
(Merck or Baker). IR spectra were recorded by a Bio-Rad FTS 2000 MX FT-IR. 
Further mass spectrometry measurements with electron ionization technique were 
applied by a Varian CH-5. 
 
3.2.7 Synthesized nucleotides: 
 
Cl-ANT-ATP (2’(3’)-O-5-chloroanthraniloyl-adenosine-5’-triphosphate) or 
[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxyl-
phosphonooxy-phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-amino-
5-chlorobenzoate 
For the procedure see general prescription. 100 mg (0.17 mmol) introduced 
disodium salt of ITP yielded 47 mg (71 µmol, 42 %) pure product after purification. Rf 
= 0.27 (1- propanol:H2O:NH3 (32%) = 2:1:1). HPLC (analytic): Rt = 20.59 min, 20.84 
min; k = 13.24, 13.39; LC/MS (ESI, H2O/CH3CN): m/z = 96.0 [M+NH3NH4
+] (Rt = 
16.77 min,  100 %),  679.0  [M+NH4
+]  (Rt = 16.77 min,  90 %),  662.1 [M+H
+] (Rt = 
16.77 min, 5 %); (-ESI, H2O/CH3CN): m/z = 660.1 [M-H
-] (Rt = 16.77 min, 100 %); 
HPLC (preparative), gradient (t [min], % B: [0, 14], [6, 14], [15, 38], [20, 80]): Rt = 
7.71 min,  8.44 min;  UV/Vis  (H2O)  λmax   (log  ε)  =  255  nm  (14,600),  348  nm 
(4,500); empirical formula: C17H19ClN5O15P3; MW = 661.73. 
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Br-ANT-ATP (2’(3’)-O-5-bromoanthraniloyl-adenosine-5’-triphosphate)  or  
[(2R,3S, 4R,5R)-5-(6-aminopurin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxyl-
phosphonooxy- phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-amino-
5-bromobenzoate   
 For the procedure see general prescription. 100 mg (0.18 mmol) introduced 
disodium salt of ATP led to 36 mg (50 µmol, 28 %) pure product after purification. Rf 
= 0.24 (1- propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt  = 20.24 min,  
20.39  min; k = 12.18, 12.28; LC/MS (ESI, H2O/CH3CN): m/z = 724.1 [M+NH4
+] (Rt 
= 21.21 min, 100 %), 741.2 [M+NH3+NH4
+] (Rt = 21.21 min, 40%); (-ESI,  
H2O/CH3CN): m/z = 705.1 [M-H
-] (Rt = 21.21 min, 100 %); HPLC (preparative), 
gradient (t [min], % B: [0, 17], [8, 17], [10, 25], [15, 38], [20, 80]): Rt = 6.32 min; 
UV/Vis (H2O) λmax  (log ε) = 256 nm (16,400), 332 nm (3,300); empirical formula: 
C17H20BrN6O14P3; MW = 705.20. 
 
Br-ANT-ITP (2’(3’)-O-5-bromoanthraniloyl-inosine-5’-triphosphate) or 
[(2R,3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxyl-
phosphonooxy-phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-amino-
5-bromobenzoate 
 For the procedure see general prescription. 100 mg (0.17 mmol) introduced 
disodium salt of ITP yielded 48 mg (68 µmol, 40 %) pure product after purification. Rf 
= 0.25 (1- propanol:H2O:NH3  (32 %)  =  2:1:1).  HPLC  (analytic):  Rt   =  21.16 min,  
21.45 min; k = 13.63, 13.83; LC/MS (ESI, H2O/CH3CN): m/z = 725.1 [M+NH4
+] (Rt 
= 18.81 min, 100 %), 742.2 [M+NH3+NH4
+] (Rt = 18.81 min, 35 %); (-ESI, 
H2O/CH3CN) : m/z = 706.1 [M-H
-] (Rt = 18.81 min, 100 %); HPLC (preparative), 
gradient (t [min], % B: [0, 18], [15, 38], [20, 80]): Rt = 4.27 min, 4.53 min; UV/Vis 
(H2O) λmax  (log ε) = 248 nm (15,000), 328 nm (4,300); empirical formula: 
C17H19BrN5O15P3; MW = 706.18. 
 
Pr-ANT-ATP  (N-propyl-2’(3’)-O-anthraniloyl-adenosine-5’-triphosphate)  or  
[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxy-
phosphonooxy- phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-
propylaminobenzoate 
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 For the procedure see general prescription. 100 mg (0.18 mmol) introduced 
disodium salt of ATP yielded 29 mg (43 µmol, 24 %) pure product after 
purification. Rf = 0.31 (1-propanol:H2O:NH3  (32 %) = 2:1:1). HPLC (analytic): Rt  = 
24.93 min, 25.67 min; k = 15.29, 15.78;  LC/MS  (ESI,  H2O/CH3CN):  m/z = 669.0  
[M+H+]  (Rt = 23.12 min, 100 %), 686.0 [M+NH4
+] (Rt = 23.12 min, 15 %); (-ESI, 
H2O/CH3CN): m/z = 667.0 [M- H
-] (Rt = 23.12 min, 100 %); HPLC (preparative), 
gradient (t [min], % B: [0, 5], [20, 45], [25, 80]): Rt = 13.33 min; UV/Vis (H2O) λmax  
(log ε) = 257 nm (17,500), 359 nm (4,600); empirical formula: C20H27N6O14P3; MW 
= 668.38. 
 
Pr-ANT-ITP   (N-propyl-2’(3’)-O-anthraniloyl-inosine-5’-triphosphate) or 
[(2R,3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxy-
phosphonooxy-phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-
propylaminobenzoate 
 For the procedure see general prescription. 100 mg (0.17 mmol) introduced 
disodium salt of ITP yielded 25 mg (37 µmol, 22 %) pure product after purification. Rf 
= 0.32 (1- propanol:H2O:NH3  (32 %)  =  2:1:1).  HPLC  (analytic):  Rt   =  24.73 min,  
25.16 min; k = 16.10, 16.40; LC/MS (ESI, H2O/CH3CN): m/z = 687.0 [M+NH4
+] (Rt 
= 22.87 min, 100 %), 669.8 [M+H+] (Rt = 22.87 min, 20 %); (-ESI, H2O/CH3CN): m/z 
= 668.0 [M-H-] (Rt = 22.87 min, 100 %); HPLC (preparative), gradient (t [min], % B: 
[0, 5], [20, 45], [25, 80]): Rt = 13.12 min; UV/Vis (H2O) λmax   (log ε) = 257 nm 
(17,500), 359 nm (4,600); empirical formula: C20H26N5O15P3; MW = 669.37. 
 
Ac-NH2-ANT-ATP  (2’(3’)-O-5-acetylaminoanthraniloyl-adenosine-5’- 
triphosphate)  or [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4(3)-hydroxy-2-
[[hydroxy-(hydroxyl-phosphono- oxyphosphoryl)oxyphosphoryl]- 
oxymethyl]oxolan-3(4)-yl]2-amino-5-acetylamino- benzoate 
For the procedure see general prescription. 100 mg (0.18 mmol) introduced 
disodium salt of ATP yielded 57 mg (84 µmol, 46 %) pure product after 
purification. Rf = 0.21 (1-propanol:H2O:NH3  (32 %)  =  2:1:1).  HPLC  (analytic):  Rt   
=  8.39 min,  8.75 min; k = 4.48,  4.72;  LC/MS  (ESI,  H2O/CH3CN):  m/z = 683.9  
[M+H+]  (Rt = 3.34 min, 100 %), 701.0 [M+NH4
+] (Rt = 3.34 min, 70 %); (-ESI, 
H2O/CH3CN): m/z = 682.0 [M- H
-] (Rt = 3.34 min, 100 %); HPLC (preparative), 
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gradient (t [min], % B: [0, 6], [5, 7], [23, 14], [24, 80], [29, 80]): Rt = 12.06 min; 
UV/Vis (H2O) λmax   (log ε) = 259 nm (17,200), 349 nm (3,100);empirical formula: 
C19H24N7O15P3; MW = 683.35. 
 
Ac-NH2-ANT-ITP (2’(3’)-O-5-acetylaminoanthraniloyl-inosine-5’-triphosphate) 
or [(2R,3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxy- 
phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3(4)-yl]2-amino-5-
acetyl- aminobenzoate 
For the procedure see general prescription. 100 mg (0.17 mmol) introduced 
disodium salt of ITP yielded 60 mg (88 µmol, 52 %) pure product after purification. Rf 
= 0.22 (1- propanol:H2O:NH3 (32 %) = 2:1:1). HPLC (analytic): Rt = 7.63 min, 7.99 
min; k = 4.28, 4.53; LC/MS (ESI, H2O/CH3CN): m/z = 702.0 [M+NH4
+] (Rt = 1.91 min, 
100 %), 719.0 [M+NH3+NH4
+]  (Rt = 1.91 min,  40 %),  684.9  [M+H
+]  (Rt = 1.91 
min,  25 %);  (-ESI, H2O/CH3CN): m/z = 683.0 [M-H
-] (Rt = 1.91 min, 100 %); HPLC 
(preparative), gradient (t [min], % B: [0, 5.8], [11, 5.8], [12, 10], [18, 13], [20, 80]): 
Rt = 9.50 min; UV/Vis (H2O) λmax  (log ε) = 248 nm (11,400; shoulder), 345 nm 
(2,500); empirical formula: C19H23N6O16P3; MW = 684.34. 
 
Bis-MANT-ATP (N-methyl-2’,3’-bis-O-anthraniloyl-adenosine-5’-
triphosphate) or [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-2-[[hydroxy-(hydroxy-
phosphonooxy- phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-
methylaminobenzoate 
For the procedure see general prescription. 100 mg (0.18 mmol) introduced 
disodium salt of ATP led over all purification steps to 21 mg (27 µmol, 15 %) 
pure product. Rf = 0.32  (1-propanol:H2O:NH3 (32 %)  =  2:1:1).  HPLC  (analytic):  
Rt = 26.95 min; k = 16.61; LC/MS (ESI, H2O/CH3CN): m/z = 791.2 [M+NH4
+] (Rt = 
28.58 min, 100 %), 774.2  [M+H+]  (Rt = 28.58 min,  40 %);  (-ESI,  H2O/CH3CN):  
m/z  =  772.3 [M-H-] (Rt = 28.58 min, 100 %); HPLC (preparative), gradient (t [min], 
% B: [0, 11], [2, 11], [5, 30], [15, 31.5], [18, 80]): Rt = 9.91 min; UV/Vis (H2O) 
λmax   (log ε)  = 255 nm (18,000), 359 nm (7,300); empirical formula: C26H30N7O15P3; 
MW = 773.48. 
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Bis-MANT-ITP (N-methyl-2’,3’-bis-O-anthraniloyl-inosine-5’-triphosphate) or 
[(2R,3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-2-[[hydroxy-(hydroxy-
phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-
methylaminobenzoate 
For the procedure see general prescription. 100 mg introduced trisodium salt 
of ITP (0.17 mmol) yielded over all purification steps 18 mg (23 µmol, 14 %) pure 
product. Rf  = 0.33 (1-propanol:H2O: NH3  (32 %) = 2:1:1) HPLC (analytic): Rt = 
26.74 min; k = 16.52; LC/MS (ESI, H2O/CH3CN): m/z = 792.3 [M+NH4
+] (Rt = 28.02 
min, 100 %), 775.2  [M+H+]  (Rt = 28.58 min,  15 %);  (-ESI,  H2O/CH3CN):  m/z  =  
773.3 [M-H-] (Rt = 28.08 min, 100 %); HPLC (preparative), gradient (t [min], % B: 
[0, 11], [2, 11], [5, 30], [15, 31.5], [18, 80]): Rt = 9.72 min; UV/Vis (H2O) λmax   
(log ε)  = 251 nm (16,400), 358 nm (6,400); empirical formula: C26H29N6O16P3; MW 
= 774.46. 
 
Bis-MANT-CTP (N-methyl-2’,3’-bis-O-anthraniloyl-cytosine-5’-triphosphate) 
or [(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[hydroxy-(hydroxy-
phosphonooxy- phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-
methylaminobenzoate 
100 mg introduced trisodium salt of CTP (0.18 mmol) yielded 35 mg (46 
µmol, 26 %) pure product.  Rf   = 0.29 (1-propanol:H2O:NH3   (32 %)  =  2:1:1).  
HPLC  (analytic): Rt = 26.83 min;  k  =  16.60;  LC/MS  (ESI,  H2O/CH3CN):  m/z  
=  750.0  [M+H+] (Rt = 25.37 min, 100 %), 767.1 [M+NH4
+] (Rt = 25.37 min, 10 %); 
(-ESI, H2O/CH3CN): m/z = 748.0 [M-H
-] (Rt = 25.37 min, 100 %); HPLC 
(preparative), gradient (t [min], % B: [0, 14], [6, 14], [11, 35], [15, 40], [20, 80]): 
UV/Vis (H2O) λmax  (log ε) = 253 nm (14,500),  359  nm  (6,600);  Rt   =  13.19  min;  
empirical  formula:  C25H30N5O16P3; MW = 749.45. 
 
Bis-Cl-ANT-ATP  (2’,3’-bis-O-5-chloroanthraniloyl-adenosine-5’-triphosphate) 
or [(2R, 3S,4R,5R)-5-(6-aminopurin-9-yl)-2-[[hydroxy-(hydroxy-
phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-
amino-5-chlorobenzoate 
For the procedure see general prescription. 100 mg (0.18 mmol) introduced 
disodium salt of ATP yielded 31 mg (38 µmol, 21 %) pure product after 
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purification. Rf = 0.32 (1-propanol:H2O:NH3  (32 %) = 2:1:1). HPLC (analytic): Rt = 
27.79 min; k = 17.10; LC/MS (ESI, H2O/CH3CN): m/z = 831.0 [M+NH4
+] (Rt = 
26.24 min, 100 %), 814.1 [M+H+]  (Rt = 26.24 min,  10 %);  (-ESI,  H2O/CH3CN):  
m/z  =  812.0 [M-H-]  (Rt = 26.24 min, 100 %); HPLC (preparative), gradient (t 
[min], % B: [0, 14], [6, 14], [11, 37], [15, 40], [20, 80]): Rt = 13.26 min; UV/Vis 
(H2O) λmax  (log ε) = 255 nm (16,900), 350 nm (5,100); empirical formula: 
C24H24Cl2N7O15P3; MW = 814.31. 
 
Bis-Cl-ANT-ITP   (2’,3’-bis-O-5-chloroanthraniloyl-inosine-5’-triphosphate) or 
[(2R,3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-2-[[hydroxy-(hydroxy-
phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-
methyl-5-chloroaminobenzoate 
For the procedure see general prescription. 100 mg introduced trisodium salt 
of ITP (0.17 mmol) yielded over all purification steps 30 mg (37 µmol, 22 %) pure 
product. Rf  = 0.35 (1-propanol:H2O: NH3  (32 %) = 2:1:1) HPLC (analytic): Rt = 
27.46 min; k = 17.99; LC/MS (ESI, H2O/CH3CN): m/z = 849.1 [M+NH4
+] (Rt = 25.90 
min, 100 %), 832.0  [M+H+]  (Rt = 25.90 min,  90 %);  (-ESI,  H2O/CH3CN):  m/z  =  
830.0 [M-H-] (Rt: 25.90 min, 100 %); HPLC (preparative), gradient (t [min], % B: 
[0, 14], [6, 14], [15, 38], [20, 80]): Rt = 15.65 min; UV/Vis (H2O) λmax  (log ε) = 249 
nm (19,700), 350 nm (6,200); empirical formula: C24H23Cl2N6O16P3; MW = 815.30. 
 
Bis-Br-ANT-ATP (2’,3’-bis-O-5-bromoanthraniloyl-adenosine-5’-triphosphate) 
or (2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-2-[[hydroxy-(hydroxy-
phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-
amino-5-bromobenzoate 
For the procedure see general prescription. 100 mg introduced disodium salt 
of ATP yielded 1 8  mg ( 20 µmol, 1 1  %) p u r e  p r o d u c t  a f t e r  
p u r i f i c a t i o n . Rf = 0.31 ( 1- propanol:H2O:NH3   (32 %)  =  2:1:1).  HPLC  
(analytic):  Rt = 26.72  min;  k = 16.41; LC/MS  (ESI,  H2O/CH3CN):  m/z = 920.9 
[M+NH4
+]  (Rt = 26.24 min,  100 %),  904.0 [M+H
+] (Rt = 26.24 min, 10 %) (-ESI, 
H2O/CH3CN): m/z = 90.9 [M-H
-] (Rt: 26.24 min, 100 %); HPLC (preparative), 
gradient (t [min], % B: [0, 17], [8, 17], [10, 25], [15, 38], [20, 80]): Rt = 16.14 
min; UV/Vis (H2O) λmax   (log ε) = 255 nm (14,600), 348 nm (4,500); empirical 
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formula: C24H24Br2N7O15P3; MW = 903.21. 
 
Bis-Br-ANT-ITP (2’,3’-bis-O-5-bromoanthraniloyl-inosine-5’-triphosphate) or 
[(2R,3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-2-[[hydroxy-(hydroxy-
phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-
methyl-5-bromoaminobenzoate 
For the procedure see general prescription. 100 mg introduced trisodium 
salt of ITP (0.17 mmol) yielded over all purification steps 32 mg (36 µmol, 21 %) 
pure product. Rf  = 0.33 (1-propanol:H2O: NH3  (32 %) = 2:1:1) HPLC (analytic): 
Rt = 28.16 min; k = 18.47; LC/MS (ESI, H2O/CH3CN): m/z = 921.9 [M+NH4
+] (Rt = 
25.89 min, 100 %), 905.0  [M+H+]  (Rt = 25.89 min,  15 %);  (-ESI,  H2O/CH3CN):  
m/z  =  903.0 [M-H-] (Rt: 25.89 min, 100 %); HPLC (preparative), gradient (t [min], 
% B: [0, 18], [15, 38], [20,  80]: Rt = 12.39 min;  UV/Vis  (H2O)  λmax   (log  ε)  =  249  
nm  (19,000),  348  nm (5,600);empirical formula: C24H23Br2N6O16P3; MW = 904.20. 
 
Bis-Pr-ANT-ATP (N-propyl-2’,3’-bis-O-anthraniloyl-adenosine-5’-triphosphate) 
or [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-2-[[hydroxy-(hydroxy-phosphonooxy 
phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-
propylaminobenzoate 
For the procedure see general prescription. 100 mg introduced disodium salt 
of ATP (0.18 mmol) yielded over all purification steps 21 mg (25 µmol, 14 %) pure 
product. Rf  = 0.34 (1-propanol:H2O: NH3  (32 %) = 2:1:1) HPLC (analytic): Rt = 
33.04 min; k = 20.59; LC/MS (ESI, H2O/CH3CN): m/z = 830.2 [M+H
+] (Rt = 30.63 
min, 100 %), 847.2  [M+NH4
+]  (Rt = 30.63 min,  30 %);  (-ESI,  H2O/CH3CN):  m/z  
=  828.1 [M-H-] (Rt = 30.63 min, 100 %); HPLC (preparative), gradient (t [min], % 
B: [0, 5], [20, 45], [25, 80]): Rt = 20.14 min; UV/Vis (H2O) λmax   (log ε) = 255 nm 
(16,800), 359 nm (5,800); empirical formula: C30H37N6O16P3; MW = 829.58. 
 
Bis-Pr-ANT-ITP  (N-propyl-2’,3’-bis-O-anthraniloyl-inosine-5’-triphosphate)  or  
[(2R,3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-2-[[hydroxy-(hydroxy-
phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-
propylaminobenzoate 
For the procedure see general prescription. 100 mg introduced trisodium salt 
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of ITP (0.17 mmol) yielded over all purification steps 15 mg (19 µmol, 11 %) pure 
product. Rf  = 0.35 (1-propanol:H2O: NH3  (32 %) = 2:1:1) HPLC (analytic): Rt = 
30.57 min; k = 20.14; LC/MS (ESI, H2O/CH3CN): m/z = 848.1 [M+NH4
+] (Rt = 30.60 
min, 100 %), 831.1  [M+H+]  (Rt = 30.60 min,  20 %);  (-ESI,  H2O/CH3CN):  m/z  =  
829.1 [M-H-] (Rt = 30.60 min, 100 %); HPLC (preparative), gradient (t [min], % B: 
[0, 5], [20, 45], [25, 80]): Rt = 19.58 min; UV/Vis (H2O) λmax   (log ε) = 255 nm 
(14,600), 359 nm (5,300); empirical formula: C30H37N6O16P3; MW = 830.57. 
 
Bis-Ac-NH2-ANT-ATP (2’,3’-bis-O-5-acetylaminoanthraniloyl-adenosine-5’- 
triphosphate) or [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-2-[[hydroxy-(hydroxy- 
phosphonooxyphosphoryl)oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-
amino-5-acetylaminobenzoate 
For the procedure see general prescription. 100 mg introduced disodium salt 
of ATP (0.18 mmol) yielded over all purification steps 27 mg (32 µmol, 18 %) pure 
product. Rf  = 0.27 (1-propanol:H2O: NH3  (32 %) = 2:1:1) HPLC (analytic): Rt = 
20.05 min; k = 12.10; LC/MS (ESI, H2O/CH3CN): m/z = 860.1 [M+H
+] (Rt = 16.79 
min, 100 %), 877.2  [M+NH4
+]  (Rt = 16.79 min,  30 %);  (-ESI,  H2O/CH3CN):  m/z  
=  858.1 [M-H-] (Rt = 16.79 min, 100 %); HPLC (preparative), gradient (t [min], % B: 
[0, 6], [5, 7], [23, 14], [24, 80], [29, 80]): Rt = 21.49 min; UV/Vis (H2O) λmax  (log ε) = 
261 nm (23,500), 350 nm (5,700); empirical formula: C28H32N9O17P3; MW = 859.53. 
 
Bis-Ac-NH2-ANT-ITP (2’,3’-bis-O-5-acetylaminoanthraniloyl-inosine-5’-
triphosphate) or [(2R,3S,4R,5R)-5-(6-oxo-1H-purin-9-yl)-2-[[hydroxy-(hydroxy-
phosphonooxy- phosphoryl)oxyphosphoryl]oxymethyl]oxolan-3,4-bis-yl]2-
amino-5-acetylamino- benzoate 
For the procedure see general prescription. 100 mg introduced trisodium salt 
of ITP (0.17 mmol) yielded over all purification steps 16 mg (19 µmol, 11 %) pure 
product. Rf  = 0.29 (1-propanol:H2O: NH3  (32 %) = 2:1:1) HPLC (analytic): Rt = 
18.80 min; k = 12.00; LC/MS (ESI, H2O/CH3CN): m/z = 878.1 [M+NH4
+] (Rt = 8.85 
min, 100 %), 895.1  [M+NH3+NH4
+]  (Rt = 8.85 min,  35 %),  861.1  [M+H
+]  (Rt = 
8.85 min,  30 %); (-ESI, H2O/CH3CN): m/z = 859.1 [M-H
-] (Rt = 8.85 min, 100 %); 
HPLC (preparative), gradient (t [min], % B: [0, 5.8], [11, 5.8], [12, 10], [18, 13], [20, 
80]): Rt = 18.43 min; UV/Vis (H2O) λmax  (log ε) = 259 nm (14,300; shoulder), 348 
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nm (5,200); empirical formula: C28H31N8O18P3; MW = 860.51. 
 
 
3.3 AC activity assay 
For the determination of the potency of AC toxin inhibitors, assay tubes 
contained 10 µl of (bis)-(M)ANT-nucleotides at final concentrations from 10 nM to 
100 µM as appropriate to obtain saturated inhibition curves and 20 µl of EF3 or 
EF3(F586A) (10 pM final concentration) in 75 mM Tris/HCl, pH 7.4, containing 
0.1% (m/v) bovine serum albumin. Tubes were preincubated for 2 min at 25°C, 
and reactions were initiated by the addition of 20 µL of reaction mixture consisting 
of the following components to yield the given final concentrations; 100 mM KCl, 
10 µM free Ca2+, 5 mM free Mn2+, 100 µM EGTA, 100 µM cAMP, 100 nM CaM. 
ATP was added as non-labeled substrate at a final concentration of 40 µM and as 
radioactive tracer [α−32P]ATP (0.2 µCi/tube). For the determination of Km and Vmax 
values, 10 µM to 1 mM ATP/Mn2+ were added, instead of inhibitor, plus 5 mM of 
free Mn2+, respectively. Tubes were incubated for 10 min at 25°C, and reactions 
were stopped by the addition of 20 µL of 2.2 N HCl. Denaturated protein was 
sedimented by a 1-min centrifugation at 13,000 x g. [32P]cAMP was separated from 
[α−32P]ATP by transferring the samples to columns containing 1.4 g of neutral 
alumina. [32P]cAMP was eluted by the addition of 4 ml of 0.1 M ammonium acetate 
solution, pH 7.0. Blank values were about 0.02% of the total amount of [α−32P]ATP 
added; substrate turnover was < 3% of the total amount of [α−32P]ATP added. 
Samples collected in scintillation vials were filled up with 10 ml of double-distilled 
water and Čerenkov radiation was measured in a PerkinElmer Tricarb 2800TR 
liquid scintillation counter. Free concentrations of divalent cations were calculated 
with WinMaxC (http://www.stanford.edu/~cpatton/maxc.html). Ki values reported in 
Tables 1, 2 and 3 were calculated using the Prism 4.02 software (Graphpad, San 
Diego, CA, USA). 
 
For determination of the potency of AC toxin inhibitors at various EF3 
mutants (H577A, N583A, N583Q, N583H, K353A and K353R), the experiments 
were essentially performed as described for EF3 with some modifications. 
Specifically, the final enzyme concentrations were increased up to 2 nM in order to 
account for the lower catalytic activity of the mutants. Moreover, the reaction time 
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was prolonged to 20 min at 30°C. For the determination of Vmax and Km, the 
ATP/Mn2+ concentration ranged from 100 µM to 4 mM. The higher substrate 
concentrations compared to EF were essential in order to obtain saturated enzyme 
kinetics 
 
For studying of the inhibition mechanism of the EF3 by Bis-MANT-
nucleotides, enzyme saturation experiments were performed in the presence of 
various inhibitor concentrations as shown in Fig. 3. Assay tubes contained B is -
MANT-nucleotides at final concentrations from 0.5 µM to 10 µM as appropriate 
according to the potency of the inhibitor. For the basal saturation curve 5 µl of 
double-distilled water was added instead of the inhibitor. Next, 5 µl of 50 µM to 600 
µM ATP/Mn2+, plus 20 µl of 10 pM EF3 in 75 mM Tris/HCl, pH 7.4, containing 0.1% 
(m/v) bovine serum albumin were added. Tubes were preincubated for 2 min at 25°C, 
and reactions were initiated by the addition of 20 µL of reaction mixture consisting of 
the following components to yield the given final concentrations; 100 mM KCl, 10 µM 
free Ca2+, 5 mM free Mn2+, 100 µM EGTA, 100 µM cAMP, 100 nM CaM, and 
[α−
32P]ATP (0.2 µCi/tube). 
 
3.5 Fluorescence resonance energy transfer (FRET) experiments 
for monitoring inhibitor binding to EF3 and various EF3 mutants 
Fluorescence experiments were performed using quartz UV ultra-
microcuvettes from Hellma (Müllheim, Germany, type 105.251- QS, light path 
length 3 x 3 mm, center 15 mm, total volume 70 µl and type 105.250- QS, light path 
length 10 x 2 mm, center 15 mm, total volume 150 µl) in a thermostated multicell 
holder at 25°C in a Varian Cary Eclipse fluorescence spectrometer (Varian, 
Darmstadt, Germany). In case of 150 µl cuvettes, 140 µl of buffer consisting of 100 
mM KCl, 100 µM CaCl2, 10 mM MnCl2 and 25 mM HEPES/NaOH, pH 7.4, was 
added into the cuvette. Five µl of 10 µM EF3/EF3 mutants (final concentration 300 
nM), 5 µl of 10 µM CaM (final concentration 300 nM) and Bis-MANT-ATP or Bis-
MANT-CTP (300 nM each) were added. In case of experiments with 70 µl cuvettes, 
volumes were adjusted stoichiometrically. The results obtained with 70 µl- and 150 
µl-cuvettes were identical, with the 70 µl-cuvettes offering an opportunity to save 
EF3/EF3 mutants proteins.  
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Steady-state fluorescence emission spectra of nucleotides were recorded at 
low speed in the scan mode from λem 300 nm to 550 nm with λex 280 nm. 
Fluorescence recordings were analyzed with the spectrum package of the Varian 
Cary Eclipse software version 1.1. Baseline fluorescence (buffer alone) and the 
baseline-corrected nucleotide-dependent emission of each concentration of the 
ligand (buffer + nucleotide) were subtracted from the spectra shown in panel A 
and B of Figs. (4-11). In the competition experiments shown in Fig. 13, bis-MANT-
nucleotides were displaced from the EF3 catalytic site using PMEApp.  
 
In direct fluorescence experiments, bis-MANT-nucleotides were excited at 
λex 350 nm and emission spectra were recorded from 380 nm to 550 nm. For an 
estimation of the hydrophobic properties of the binding site interacting with the 
MANT-group shown in Fig. 12, direct fluorescence control experiments of the bis-
MANT-nucleotides were conducted in the presence of dimethyl sulfoxide ranging 
from 0 to 100% (v/v). 
 
3.6 Data analysis 
 All monophasic inhibition and saturation curves summarized in Table 1, 2 and 
3 were analyzed by non-linear regression using the Prism 4.0 software (Graphpad, 
San Diego, CA, USA). Fluorescence spectra were analyzed using the spectrum 
package of the Varian Cary Eclipse 1.1 software. For the generation of graphs shown 
in Figs. (4-13), fluorescence data were imported into the Prism software. 
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4. Results 
 
 
4.1 Inhibition of the catalytic activity of EF3 by Bis-MANT-
nucleotides  
 The Ki values of various mono- and bis-MANT-NTPs and NMP at EF3 in 
the presence of Mn2+ are summarized in Table 1. In general, t he  inhibitory 
potencies o f  MANT-nucleotides were lower than those of the corresponding bis-
MANT-nucleotides except for the base cytosine. For example, Bis-MANT-ATP was 3-
fold more potent than MANT-ATP. In contrast, Bis-MANT-CTP was 2-fold less potent 
than MANT-CTP. Moreover, Bis-MANT-NTPs were more potent than Bis-MANT-
NMP. The most striking results was the higher potency of both Bis-MANT-ATP and Bis-
MANT-CTP among the studied compounds 
 
Table 1: Inhibitory potencies of Mono- and Bis-MANT-nucleotides at EF3 in the 
presence of Mn2+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibitory potencies of various mono- and bis-MANT-nucleotides at EF3 were determined as 
described under “Materials and Methods”. Ki values are given in µM and are the means ± 
SD of 3-4 independent experiments performed in triplicates. The Km value of EF3 for ATP in 
the presence of Mn2+ was 82.6 ± 8.2 µM. Reaction mixtures contained 5 mM MnCl2 or 5 mM 
MgCl2, 100 mM KCl, 10 µM free Ca
2+, 40 µM ATP, [α−32P]ATP (0.2-0.4 µCi/tube), 100 µM 
cAMP and 100 nM CaM. Nucleotides were added at different concentrations as appropriate 
to construct saturated concentration-response curves. Inhibition curves were analyzed by 
non-linear regression using the Prism 4.02 software. 
 
 
 
 
0.11 ± 0.04
35.60 ± 0.13  
5.90  ± 0.69
0.58 ± 0.13
Mono -
Ki (µM)
0.21 ± 0.01 MANT -CTP
8.66 ± 0.14MANT -IMP
4.42 ± 0.2MANT -ITP
0.21 ± 0.02MANT -ATP
Bis-
Ki (µM)
Nucleotides
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4.2 Inhibition of the catalytic activity of EF, EF3 and various EF3 
mutants by Bis-MANT-nucleotides 
Table 2 summarizes the Ki values of Bis-MANT-ATP and Bis-MANT-CTP at 
EF3 and EF3 mutants (H577A, N583A, N583Q, N583H, K353A and K353R) in the 
presence of Mn2+. Both Bis-MANT-ATP and Bis-MANT-CTP possesses the same 
inhibitory potencies at EF3. The F586A mutation reduced the inhibitory potencies of 
Bis-MANT-ATP and Bis-MANT-CTP by 5-6-fold, whereas the H577A mutation did 
not decrease inhibitor potency. The N583A mutation decreased nucleotide-
potency by 6-12-fold. The N583Q substitution reduced the potency of Bis-MANT-
ATP by 60-fold and the potency of Bis-MANT-CTP by 120-fold. For the N583H 
mutant, a 130-230-fold decrease in potency of Bis-MANT-ATP and Bis-MANT-
CTP was observed. The K353A substitution reduced the potency of Bis-MANT-
ATP and Bis-MANT-CTP by 40-50-fold. The Ki value of Bis-MANT-ATP and Bis-
MANT-CTP at EF3(K353R) increased about just 3-fold. The relative potencies of 
Bis-MANT-ATP and Bis-MANT-CTP at various EF3/EF3 mutants are represented 
in Fig. 2 taking EF3 as a reference. It is clear that both Bis-MANT-ATP and Bis-
MANT-CTP behaved similarly at EF3 and various EF3 mutants. In addition, both 
F586 and K353 amino acid residues that located at EF3 binding site are critical for 
Bis-MANT-ATP and Bis-MANT-CTP binding.  
 
Fig. 3 shows the double-reciprocal analysis of EF3 inhibition kinetics by Bis-
MANT-ATP and Bis-MANT-CTP according to Lineweaver-Burk. The linear 
regression lines intersected at the y-axis, i.e. Vmax remained constant, whereas Km 
increased with increasing inhibitor concentration. 
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Table 2: Inhibitory potencies of Bis-MANT-ATP and Bis-MANT-CTP at EF, EF3 
and EF3 mutants in the presence of Mn
2+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibitory potencies of Bis-MANT-ATP and Bis-MANT-CTP at EF, EF3 and various EF3 
mutants were determined as described under “Materials and Methods”. Ki-values are given in 
µM and are the means ± SD of 3 experiments performed in triplicates. The relative potencies 
(rel. pot.) of Bis-MANT-ATP and Bis-MANT-CTP are given, too, EF3 being the reference. For 
determination of the inhibitory potencies of Bis-MANT-ATP and Bis-MANT-CTP at EF, EF3 
and EF3(F586A), reaction mixtures contained 10 µM free Ca2+, 5 mM free Mn2+, 100 µM 
EGTA, 40 µM ATP, 0.2 µCi/tube [α−32P]ATP, 100 µM cAMP, 100 nM CaM and 10 pM 
enzyme in 75 mM Tris/HCl, pH 7.4. For other EF3 mutants, reaction mixtures contained 0.4 
µCi [α−32P]ATP per tube. The enzyme concentration was 2 nM. Nucleotides were added at 
different concentrations as appropriate to obtain saturated concentration-response curves. 
Inhibition curves were analyzed by non-linear regression using the Prism 4.02 software. 
 
420.50 ± 0.00141.180.51 ± 0.001 EF3 K353R
2.647.96 ± 0.152.129.90 ± 0.24EF3 K353A
0.7627.68 ± 0.470.4546.30 ± 17.95EF3 N583H
0.8624.49 ± 0.321.2816.38 ± 0.14EF3 N583Q
8.172.57 ± 0.02916.281.29 ± 0.02EF3 N583A
123.530.17 ± 0.026110.530.19 ± 0.02EF3 H577A
17.651.19 ± 0.00112.731.65 ± 0.08EF3 F586A
1000.21 ± 0.0051000.21± 0.02EF3 wild type
Bis-MANT-CTP
rel. pot.
Bis-MANT-CTP
K
i
(µM)
Bis-MANT-ATP
rel. pot.
Bis-MANT-ATP
K
i
(µM)
Toxin
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 Fig. 2: Inhibitory potencies of Bis-MANT-ATP and Bis-MANT-CTP at EF3 and 
various EF3 mutants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The relative potencies (rel. pot.) of Bis-MANT-ATP (blue columns) and Bis-MANT-CTP 
(purple columns) are shown, too, EF3 being the reference. For determination of the inhibitory 
potencies of Bis-MANT-ATP and Bis-MANT-CTP at EF, EF3 and EF3(F586A), reaction 
mixtures contained 10 µM free Ca2+, 5 mM free Mn2+, 100 µM EGTA, 40 µM ATP, 0.2 
µCi/tube [α−32P]ATP, 100 µM cAMP, 100 nM CaM and 10 pM enzyme in 75 mM Tris/HCl, pH 
7.4. For other EF3 mutants, reaction mixtures contained 0.4 µCi [α−32P]ATP per tube. The 
enzyme concentration was 2 nM. Nucleotides were added at different concentrations as 
appropriate to obtain saturated concentration-response curves. Inhibition curves were 
analyzed by non-linear regression using the Prism 4.02 software. 
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4.3 Inhibition of the catalytic activity of EF3 by various mono- 
and bis-(propyl)(M)ANT-nucleotides  
 Table 3 summarizes the Ki values of mono- and bis- propyl-ANT-NTPs and 
various mono-and bis-MANT-NTPs (substituted at position number 5 of the 
anthraniloyl ring) at EF3 in the presence of Mn2+. In general, ATP-analogues were 
about 2-fold more potent than the corresponding ITP-analogues. Moreover, the 
inhibitory potencies of position-5-substituted-MANT-nucleotides were slightly 
higher than those of the corresponding bis-MANT-nucleotides. Propyl-ANT-
nucleotides were more potent than the corresponding Bis-propyl-ANT-analogues. 
For example, propyl-ANT-ATP was 13-fold more potent than Bis-propyl-ANT-ATP.  
 
4.4 Direct fluorescence and FRET studies of bis-MANT-
nucleotides with EF3  
Tryptophan ( and tyrosine) residues in proteins are excited at an excitation 
wavelength of 280 nm (18, 19, 23), resulting in substantial endogenous 
fluorescence of EF3 with an emission maximum of λem 350 nm (22) which can then 
excite the (M)ANT group of nucleotides (26), provided sufficient proximity between 
donor and acceptor. Such energy transfer results in increased fluorescence of the 
MANT-group at 420-450 nm in mAC, CyaA and EF3 reflecting the fact that the 
MANT-group is in a hydrophobic environment (23, 27-29). Previous studies with 
mAC showed that in the presence of Mn2+, FRET signals were much larger than in 
the presence of Mg2+(27). All subsequent FRET studies with EF3 were conducted 
in the presence of Mn2+ (see Materials and Methods). 
 
At λex 280 and 350 nm, bis-MANT-nucleotides exhibited only minimal 
endogenous fluorescence, providing an excellent signal-to-noise ratio for FRET 
studies. In the absence of CaM, EF3/EF3 mutants exhibit a strong emission peak at 
350 nm when excited at 280 nm under steady-state conditions (panels A and B of 
Figs. 4-11). Following the addition of CaM, with Bis-MANT-nucleotides examined, 
new fluorescence peaks with a maximum of λem 425–430 nm became apparent. 
These new peaks reflect FRET from tryptophan and tyrosine residues to the MANT 
group and were the result of the substantial CaM-induced conformational change in 
EF (4, 23).  
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Table 3: Inhibitory potencies of mono- and bis-ANT-nucleotides at EF3 in the 
presence of Mn2+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibitory potencies of various newly synthesized mono- and bis-ANT-nucleotides at EF3 
were determined as described under “Materials and Methods”. Ki values are given in µM and 
are the means ± SD of 3 independent experiments performed in triplicates. The Km value of 
EF3 for ATP in the presence of Mn2+ was 82.6 ± 8.2 µM. Reaction mixtures contained 10 µM 
free Ca2+, 5 mM free Mn2+, 100 µM EGTA, 40 µM ATP, 0.2 µCi/tube [α−32P]ATP, 100 µM 
cAMP, 100 nM CaM and 10 pM enzyme in 75 mM Tris/HCl, pH 7.4. Nucleotides were added 
at different concentrations as appropriate to obtain saturated concentration-response curves. 
Inhibition curves were analyzed by non-linear regression using the Prism 4.02 software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3 ± 0.25Bis-AC-NH-ANT-ITP0.67 ± 0.03Bis-AC-NH-ANT-ATP
1.0 ± 0.13AC-NH-ANT-ITP0.55 ± 0.01AC-NH-ANT-ATP
0.4 ± 0.09Bis-Cl-ANT-ITP0.22 ± 0.02Bis-Cl-ANT-ATP
0.3 ± 0.05Cl-ANT-ITP0.17 ± 0.02Cl-ANT-ATP
0.5 ± 0.1Bis-Br-ANT-ITP0.26 ± 0.04Bis-Br-ANT-ATP
0.4 ± 0.25Br-ANT-ITP0.20 ± 0.01Br-ANT-ATP
1.9 ± 0.01Bis- Propyl-ANT-ITP1.02 ± 0.15Bis- Propyl-ANT-ATP
0.2 ± 0.02Propyl-ANT-ITP0.08 ± 0.01Propyl-ANT-ATP
Ki (µM)NucleotidesKi (µM)Nucleotides
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Interestingly, In the FRET experiments of Bis-MANT-ATP and Bis-MANT-CTP, 
we found a good relation between the maximum intensity of the FRET signal in the 
FRET assay and the Ki values in the AC assay; i.e., the higher the intensity of the 
FRET signal, the higher the affinity of the probed Bis-MANT-nucleotides to the binding 
sites of the EF3/EF3mutants and vice versa. Also, it is noteworthy that the FRET 
signal with Bis-MANT-CTP was moderately smaller than with Bis-MANT-ATP. Our 
previous study of EF3/EF3 mutants with MANT-nucleotides showed that in presence 
of Mn2+, FRET signal with MANT-CTP was moderately smaller than with MANT-ATP 
(23). These differences in fluorescence were not due to the endogenous differences in 
responsiveness to hydrophobic environments between nucleotides since hydrophobic 
environments in the presence of dimethyl sulfoxide ranging from 0 to 100% (v/v)  
yielded similar relative fluorescence increases with the Bis-MANT-ATP and Bis-
MANT-CTP Fig. 12.  
 
In FRET experiments of EF3 (Fig. 4, A and B) and various EF3 mutants (Figs. 
5-11, A and B) with bis-MANT-.nucleotides, the signal intensities of endogenous 
tryptophan and tyrosine fluorescence were similar. The mutations F586A, H577A, 
N586A, N583Q, N583H and K353A differentially alter the FRET signals intensities 
(difference in fluorescence at an emission wavelength of 427 nm in the presence 
and absence of calmodulin) of Bis-MANT-ATP and Bis-MANT-CTP. In EF3(F586A), 
the FRET signal was reduced by 23% (Fig. 5A) with Bis-MANT-ATP and 17% With 
Bis-MANT-CTP (Fig. 5B). Moreover, the FRET signal of Bis-MANT-ATP and Bis-
MANT-CTP was reduced by 41% and 15% in EF3(N583A) (Fig. 7A and B). In 
addition, in EF3(N583Q) and EF3(K353A), the FRET signals with Bis-MANT-ATP 
were reduced by 45% and 27% (Figs. 8A and 10A), while with Bis-MANT-CTP no 
FRET signal was observed (8B and 10B). The analysis of the EF3 mutants H577A 
and N583H with Bis-MANT-ATP and Bis-MANT-CTP revealed no FRET at all (Figs. 6 
and 9, A and B), while in K353R mutant, the FRET signal was similar to that in EF3 
(Fig. 11, A and B).  
 
In a classic FRET experiment, the appearance of the new emission peak at 
λem 425–430 nm should be accompanied by a corresponding decrease in the 
endogenous tryptophan- and tyrosine-fluorescence peak at λem 350 nm (18, 19, 30). 
However, for bis-MANT-nucleotides, the appearance of the fluorescence peak at λem 
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425–430 nm was not accompanied by a decrease at λem 350 nm. These findings are 
explained by a model in which part of the endogenous tryptophan and tyrosine 
fluorescence of EF3 is quenched by surrounding polar amino acids such as 
aspartate, glutamate and histidine (23, 30). Upon EF3 activation by CaM, a large 
conformational change in EF3 occurs (4, 23), annihilating, to a large extent, the 
quenching effects of polar amino acids and masking the predicted decrease in 
fluorescence at λem 350 nm.  
 
We also examined the direct bis-MANT-nucleotide fluorescence by using an 
excitation wavelength of λex 350 nm (Figs. 4–11, C and D) (4, 21-23). At λex 350 nm, 
Bis-MANT-nucleotides exhibited a very low endogenous fluorescence with a 
maximum at λem 445-450 nm. Bis-MANT-ATP and Bis-MANT-CTP did not differ from 
each other in their endogenous fluorescence properties. Moreover, the addition of 
EF3 to samples did not significantly change this basal fluorescence. However, upon 
addition of CaM, we observed very large increases in the intensity of the 
fluorescence signals, about 6-7-fold with Bis-MANT-ATP and 2-3-fold with Bis-MANT-
CTP at λem 440 nm. 
 
In EF3(F586A), the emission maximum  at λem 440 nm was reduced by 35% 
(Fig. 5C) with Bis-MANT-ATP and 15% with Bis-MANT-CTP (Fig. 5D). Moreover, the 
Fluorescence signal of Bis-MANT-ATP and Bis-MANT-CTP was reduced by 50% and 
22% in EF3(N583A) (Fig. 7C and D). In addition, in EF3(N583Q) and EF3(K353A), 
the fluorescence signals with Bis-MANT-ATP were reduced by 57% and 43% (Figs. 
8C and 10C), while with Bis-MANT-CTP were reduced by 44% and 28% (8D and 
10D) respectively. The analysis of the EF3 mutants H577A and N583H with Bis-
MANT-ATP and Bis-MANT-CTP at an excitation wavelength λex 350 revealed a large 
reduction in the intensity of fluorescence signal (60%-90%) at λem 440 (Figs. 6 and 9, 
C and D). In the K353R mutant, the fluorescence signal was nearly the same as in 
case of EF3 (Fig. 11, A and B).  
 
 Increases in direct fluorescence were accompanied by decreases of the 
emission maximum by about 5 nm, referred to as blue-shift, reflecting transfer of the 
MANT group into a more hydrophobic environment (21, 23). Previous studies have 
already shown that MANT-nucleotides are highly sensitive at detecting small 
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differences in the interaction of ligands with the catalytic site of bacterial AC toxins 
including EF and mammalian AC (18-20, 23). 
               
Fig. 3: Lineweaver-Burk analysis of the inhibition of EF3 AC activity by Bis-
MANT-ATP and Bis-MANT-CTP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AC activities were determined as described under “Materials and Methods” with the 
indicated concentrations of Bis-MANT-ATP (0 µM, 0.5 µM, 2.5 µM and 5 µM) (A) and 
MANT-CTP (0 µM, 0.5 µM, 2.5 µM, 5 µM and 10 µM) (B). Reaction mixtures contained 10 
pM EF3, 100 mM KCl, 10 µM free Ca2+, 5 mM free Mn2+, 100 µM EGTA, 100 µM cAMP, 
100 nM calmodulin, 0.2 µCi/tube [α−32P]ATP and  unlabeled ATP/Mn2+  concentrations 
indicated in the graph. Data were plotted reciprocally and analyzed by linear regression 
according to Lineweaver-Burk. Shown are the results of a representative experiment 
performed in triplicates. Similar results were obtained in two independent experiments. 
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Fig. 4: Analysis of the interaction of EF3 with Bis-MANT-ATP and Bis-MANT-
CTP in fluorescence experiments  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FRET and direct f luorescence experiments were performed as described under 
“Materials and Methods”. The assay buffer consisted of 75 mM HEPES/NaOH, 100 µM 
CaCl2, 100 mM KCl and 5 mM MnCl2, pH 7.4. Nucleotides were added to the buffer to 
yield 300 nM final concentrations. EF3 (300 nM final concentration) was added followed 
by the addition of CaM (1 µM final concentration). Steady state emission spectra were 
recorded. In FRET studies (panels A and B) emission was scanned at an excitation 
wavelength of 280 nm after each addition. In direct fluorescence studies (panels C and D) 
emission was scanned at an excitation wavelength of 350 nm after each addition. In 
panels A and B, the buffer and the MANT-nucleotide basal fluorescence were subtracted 
from the fluorescence after addition of EF3 (green line) and CaM (blue line). Shown are 
superimposed recordings of a representative experiment. Similar data were obtained in 5 
independent experiments. a.u., arbitrary unit. 
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Fig. 5: Analysis of the interaction of EF3(F586A) with Bis-MANT-ATP and Bis-
MANT-CTP in fluorescence experiments 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FRET and direct f luorescence experiments were performed as described under 
“Materials and Methods”. The assay buffer consisted of 75 mM HEPES/NaOH, 100 µM 
CaCl2, 100 mM KCl and 5 mM MnCl2, pH 7.4. Nucleotides were added to the buffer to 
yield 300 nM final concentrations. EF3(F586A) (300 nM final concentration) was added 
followed by the addition of CaM (1 µM final concentration). Steady state emission spectra 
were recorded. In FRET studies (panels A and B) emission was scanned at an excitation 
wavelength of 280 nm after each addition. In direct fluorescence studies (panels C and 
D), emission was scanned at an excitation wavelength of 350 nm after each addition. In 
panels A and B, the buffer and the MANT-nucleotide basal fluorescence were subtracted 
from the fluorescence after addition of EF3(F586A) (green line) and CaM (blue line). 
Shown are superimposed recordings of a representative experiment. Similar data were 
obtained in 5 independent experiments. a.u., arbitrary unit. 
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Fig. 6: Analysis of the interaction of EF3(H577A) with Bis-MANT-ATP and 
Bis-MANT-CTP in fluorescence experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FRET and direct f luorescence experiments were performed as described under 
“Materials and Methods”. The assay buffer consisted of 75 mM HEPES/NaOH, 100 µM 
CaCl2, 100 mM KCl and 5 mM MnCl2, pH 7.4. Nucleotides were added to the buffer to 
yield 300 nM final concentrations. EF3(H577A) (300 nM final concentration) was added 
followed by the addition of CaM (1 µM final concentration). Steady state emission spectra 
were recorded. In FRET studies (panels A and B) emission was scanned at an excitation 
wavelength of 280 nm after each addition. In direct fluorescence studies (panels C and 
D), emission was scanned at an excitation wavelength of 350 nm after each addition. In 
panels A and B, the buffer and the MANT-nucleotide basal fluorescence were subtracted 
from the fluorescence after addition of EF3(H577A) (green line) and CaM (blue line). 
Shown are superimposed recordings of a representative experiment. Similar data were 
obtained in 5 independent experiments. a.u., arbitrary unit. 
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Fig. 7: Analysis of the interaction of EF3(N583A) with Bis-MANT-ATP and 
Bis-MANT-CTP in fluorescence experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FRET and direct f luorescence experiments were performed as described under 
“Materials and Methods”. The assay buffer consisted of 75 mM HEPES/NaOH, 100 µM 
CaCl2, 100 mM KCl and 5 mM MnCl2, pH 7.4. Nucleotides were added to the buffer to 
yield 300 nM final concentrations. EF3(N583A) (300 nM final concentration) was added 
followed by the addition of CaM (1 µM final concentration). Steady state emission spectra 
were recorded. In FRET studies (panels A and B) emission was scanned at an excitation 
wavelength of 280 nm after each addition. In direct fluorescence studies (panels C and 
D), emission was scanned at an excitation wavelength of 350 nm after each addition. In 
panels A and B, the buffer and the MANT-nucleotide basal fluorescence were subtracted 
from the fluorescence after addition of EF3(N583A) (green line) and CaM (blue line). 
Shown are superimposed recordings of a representative experiment. Similar data were 
obtained in 5 independent experiments. a.u., arbitrary unit. 
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Fig. 8: Analysis of the interaction of EF3(N583Q) with Bis-MANT-ATP and 
Bis-MANT-CTP in fluorescence experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FRET and direct f luorescence experiments were performed as described under 
“Materials and Methods”. The assay buffer consisted of 75 mM HEPES/NaOH, 100 µM 
CaCl2, 100 mM KCl and 5 mM MnCl2, pH 7.4. Nucleotides were added to the buffer to 
yield 300 nM final concentrations. EF3(N583Q) (300 nM final concentration) was added 
followed by the addition of CaM (1 µM final concentration). Steady state emission spectra 
were recorded. In FRET studies (panels A and B) emission was scanned at an excitation 
wavelength of 280 nm after each addition. In direct fluorescence studies (panels C and 
D), emission was scanned at an excitation wavelength of 350 nm after each addition. In 
panels A and B, the buffer and the MANT-nucleotide basal fluorescence were subtracted 
from the fluorescence after addition of EF3(N583Q) (green line) and CaM (blue line). 
Shown are superimposed recordings of a representative experiment. Similar data were 
obtained in 5 independent experiments. a.u., arbitrary unit. 
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Fig. 9: Analysis of the interaction of EF3(N583H) with Bis-MANT-ATP and 
Bis-MANT-CTP in fluorescence experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FRET and direct f luorescence experiments were performed as described under 
“Materials and Methods”. The assay buffer consisted of 75 mM HEPES/NaOH, 100 µM 
CaCl2, 100 mM KCl and 5 mM MnCl2, pH 7.4. Nucleotides were added to the buffer to yield 
300 nM final concentrations. EF3(N583H) (300 nM final concentration) was added followed 
by the addition of CaM (1 µM final concentration). Steady state emission spectra were 
recorded. In FRET studies (panels A and B) emission was scanned at an excitation 
wavelength of 280 nm after each addition. In direct fluorescence studies (panels C and D), 
emission was scanned at an excitation wavelength of 350 nm after each addition. In panels 
A and B, the buffer and the MANT-nucleotide basal fluorescence were subtracted from the 
fluorescence after addition of EF3(N583H) (green line) and CaM (blue line). Shown are 
superimposed recordings of a representative experiment. Similar data were obtained in 5 
independent experiments. a.u., arbitrary unit. 
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Fig. 10: Analysis of the interaction of EF3(K353A) with Bis-MANT-ATP and 
Bis-MANT-CTP in fluorescence experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FRET and direct f luorescence experiments were performed as described under 
“Materials and Methods”. The assay buffer consisted of 75 mM HEPES/NaOH, 100 µM 
CaCl2, 100 mM KCl and 5 mM MnCl2, pH 7.4. Nucleotides were added to the buffer to yield 
300 nM final concentrations. EF3(K353A) (300 nM final concentration) was added followed 
by the addition of CaM (1 µM final concentration). Steady state emission spectra were 
recorded. In FRET studies (panels A and B) emission was scanned at an excitation 
wavelength of 280 nm after each addition. In direct fluorescence studies (panels C and D), 
emission was scanned at an excitation wavelength of 350 nm after each addition. In panels 
A and B, the buffer and the MANT-nucleotide basal fluorescence were subtracted from the 
fluorescence after addition of EF3(K353A) (green line) and CaM (blue line). Shown are 
superimposed recordings of a representative experiment. Similar data were obtained in 5 
independent experiments. a.u., arbitrary unit. 
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Fig. 11: Analysis of the interaction of EF3(K353R) with Bis-MANT-ATP and 
Bis-MANT-CTP in fluorescence experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FRET and direct f luorescence experiments were performed as described under 
“Materials and Methods”. The assay buffer consisted of 75 mM HEPES/NaOH, 100 µM 
CaCl2, 100 mM KCl and 5 mM MnCl2, pH 7.4. Nucleotides were added to the buffer to yield 
300 nM final concentrations. EF3(K353R) (300 nM final concentration) was added followed 
by the addition of CaM (1 µM final concentration). Steady state emission spectra were 
recorded. In FRET studies (panels A and B) emission was scanned at an excitation 
wavelength of 280 nm after each addition. In direct fluorescence studies (panels C and D), 
emission was scanned at an excitation wavelength of 350 nm after each addition. In panels 
A and B, the buffer and the MANT-nucleotide basal fluorescence were subtracted from the 
fluorescence after addition of EF3(K353R) (green line) and CaM (blue line). Shown are 
superimposed recordings of a representative experiment. Similar data were obtained in 5 
independent experiments. a.u., arbitrary unit. 
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Fig. 12: Direct fluorescence experiments of Bis-MANT-ATP and Bis-MANT-CTP 
in the presence of water and different DMSO concentrations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Direct fluorescence experiments of Bis-MANT-nucleotides were performed as described 
under “Materials and Methods”. The excitation wavelength was 350 nm, and emission was 
scanned from 380 nm to 550 nm. Nucleotides were added to the water and DMSO to yield 
300 nM final concentrations. To mimic binding of the Bis-MANT-group to a hydrophobic 
binding pocket, Bis-MANT-ATP (A) and Bis-MANT-CTP (B) were directly excited in water 
plus dimethyl sulfoxide DMSO (10%-100%) (v/v). Shown are superimposed recordings of a 
representative experiment. Similar data were obtained in 5 independent experiments. a.u., 
arbitrary unit. 
 
 
Fig. 13 shows the kinetics of FRET experiments with Bis-MANT-ATP and 
Bis-MANT- CTP at a fixed emission wavelength of 440 nm. Sequential addition of 
EF3 and CaM resulted only in small fluorescence increases, reflecting the far end 
of the tryptophan/tyrosine emission spectrum (see Figs. 4-11). Addition of bis-
MANT-nucleotides to cuvettes instantaneously resulted in substantial fluorescence 
increases, reflecting FRET. Addition of the high-affinity EF inhibitor and non-
fluorescent nucleotide analog PMEApp (1 µM) (20, 23) to cuvettes reduced the 
fluorescence signals with both bis-MANT-nucleotides (300 nM each). 
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Fig. 13: Kinetic analysis of the interaction of EF3 with Bis-MANT-nucleotides 
and CaM in FRET experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FRET kinetic experiments were performed as described under “Materials and Methods”. 
The excitation wavelength was 280 nm and emission was detected at 430 nm over time. 
Successively, buffer (1), 300 nM EF3 (2), 1 µM CaM (3), nucleotide (A: Bis-MANT-ATP, 
B: Bis-MANT-CTP, 300 nM each) (4) and PMEApp (1 µM) (5) were added. A recording 
of a representative experiment is shown. Similar data were obtained in 4 independent 
experiments. a.u., arbitrary unit. 
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5. Discussion 
 In a previous study, the unexpected by-product Bis-MANT-IMP, 
obtained in synthesis scheme of MANT-ITP, was serendipitously found to possess 
higher affinity to the nucleotide-binding site of CyaA than the corresponding MANT-
IMP (20). The higher affinity of the Bis-MANT-IMP compared with MANT-IMP was 
attributed to interactions of the 2´MANT-group with a hydrophobic site consisting of 
P305 and F261 (20). undoubtedly, the introduction of a second MANT-group 
increased the inhibitor affinity to CyaA. In addition, the introduction of a second 
MANT-group to MANT-ATP exhibited clear differences in fluorescence responses of 
MANT- ATP and Bis-MANT-ATP with EF3 in both direct fluorescence and FRET 
studies.  
 
These findings prompted us to characterize the interaction of the catalytic 
site of EF with bis-MANT-nucleotides possessing various purine and pyrimidine 
bases, specifically, Bis-MANT-ATP and Bis-MANT-CTP in order to better dissect 
the unique preference of EF to base cytosine and better understand the molecular 
mechanisms of EF inhibition and to provide the basis for the rational development 
of potent and selective EF inhibitors. Such EF inhibitors could be useful 
compounds to treat EF toxinemia and antibiotic-resistant Bacillus anthracis strains 
(31). 
 
The structure/activity relationships of (MANT)-nucleotides at EF, CyaA and 
mAC are different, indicating that in principle, the development of potent and 
selective EF and AC isoform-specific inhibitors is feasible. Our recent study showed 
that CTP inhibited EF more than 400-fold more potently than mAC (23, 24). 
Substitution of the 2’(3’)-O-ribosyl position of CTP with a MANT group decreased 
the Ki value from 5 µM to 100 nM, yielding an EF inhibitor that is even 5-10-fold 
more potent than MANT-ATP in the presence of Mn2+; i.e., EF exhibited high 
unexpected preference for the base cytosine (23). Surprisingly, among the studied 
bis-MANT-nucleotides only Bis-MANT-CTP exhibited a lower potency than the 
corresponding MANT-CTP. 
 
These data prompted us to analyze EF inhibition by Bis-MANT-CTP and 
Bis-MANT-ATP in more detail. The analysis of enzyme inhibition kinetics revealed 
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that both Bis-MANT-CTP and Bis-MANT-ATP are competitive EF inhibitors; i.e., 
they bind to the same site as, and freely compete with, the substrate ATP (Fig. 4). 
These data ruled out the existence of a hitherto unidentified cytosine base-
preferring nucleotide-binding site in the structurally very complex EF protein (4, 
15). Kinetic FRET competition experiments with the non-fluorescent ATP analogue 
PMEApp revealed that both Bis-MANT- ATP and Bis-MANT-CTP reversibly bind 
to the EF-catalytic site (Fig. 13), corroborating the competitive inhibition mode and 
the existence of a single nucleotide-binding site in EF. The slower displacement of 
both Bis-MANT-ATP and Bis-MANT-CTP from EF by PMEApp is explained by the 
higher affinity of EF for bis-MANT-nucleotides. 
 
Our study demonstrates a noteworthy dissociation between ligand-affinity for 
EF as assessed by the inhibition of catalysis and FRET on one hand and both the 
maximum stimulation of direct fluorescence and FRET upon activation of CaM on the 
other hand. Most notably, both Bis-MANT-ATP and Bis-MANT-CTP possess the 
same Ki value at EF3 Table 1 and 2. However, in terms of maximum direct 
fluorescence and FRET signals, Bis-MANT-CTP is clearly surpassed by Bis-MANT-
ATP (Fig. 4).In Chapter III, similar dissociations between affinity and maximum 
fluorescence signals were observed for the comparison of MANT-ATP and MANT-
CTP at EF (23). An explanation for these discrepancies could be differences in 
mobility of the various fluorescence probes, with the more rigidly bound ligands being 
more effective in terms of direct MANT fluorescence and FRET (20, 23). 
 
A previous study had shown that F586 mediates π-stacking interactions with 
2’-deoxy-3’-ANT-ATP, resulting in a fluorescence increase upon excitation of the 
ANT-group (15). Our previous study also showed that the mutation of F586 resulted 
in 5-6-fold reduction in potencies of both MANT-ATP and MANT-CTP and largely 
reduced the CaM-dependent FRET of MANT-ATP. However, the small FRET signal 
intensity of MANT-CTP with EF3 was slightly reduced in EF3(F586A). The models of 
the MANT-nucleotides binding mode suggested a similar binding mode of MANT-
CTP and its ATP analogue with subtle differences due to the nucleobases occur and 
may account for the higher potency and the small FRET signal of MANT-CTP. In 
particular, the cytosine moiety formed water-mediated hydrogen bonds with R329 
and E580 and favourably fit to the amide dipole of N583. Additionally, the flexibility of 
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the bound cytosine was greater than in the case of the bulkier adenine ring. 
Together with the specific charge distribution in the vicinity of the nucleobase, these 
might lead to absorption and thus attenuation of the FRET energy which is mainly 
due to tyrosine and tryptophan residues in switch C.  
 
In agreement with those data, the interaction of Bis-MANT-ATP and Bis-
MANTCTP with several EF mutants in terms of enzyme inhibition and fluorescence 
spectroscopy showed that F586 is also important for the interaction with Bis-MANT-
ATP and Bis-MANT-CTP as is revealed by the 5-6-fold reduction in potency (Table 
2). Nonetheless, the small FRET and direct fluorescence signal intensities with Bis-
MANT-CTP in EF, compared to MANT-ATP, was much smaller, and the F586A 
mutation had a smaller inhibitory effect on the FRET and direct fluorescence signal 
intensities (Fig. 5). 
 
H577 plays a crucial role in catalysis as is reflected by the very low catalytic 
activity of the H577A mutant (4, 23, 32). In addition, Bis-MANT-ATP and Bis-
MANT-CTP exhibited no FRET signal at all in H577A mutant (Fig. 6, A and B), and 
largely reduced signal intensities in direct fluorescence studies (Fig. 6, C and D). 
Nonetheless, this mutation did not exert detrimental effect on substrate- and 
inhibitor binding per se (Tables 2) (23). 
 
N583 forms a crucial hydrogen bond with the ribosyl moiety of nucleotides 
bound to the catalytic site of EF (4, 23). Accordingly, replacement of N583 by a 
non-hydrogen bond-forming amino acid (N583A) or hydrogen bond- forming amino 
acid with a different spatial arrangement of the bonding partners (N583Q and 
N383H) substantially decreases catalytic activity of the resulting EF mutants (4,  
23 ) . Moreover, N583 mutants substantially reduced the potencies of MANT-ATP 
and MANT-CTP (23). Similarly, N583 mutants substantially reduced the potencies 
of Bis-MANT-ATP and Bis-MANT-CTP. Interestingly, N583 mutants reduced the 
inhibitor potencies of both bis-MANT-nucleotides to a similar extent. Moreover, in 
N583 mutants, the FRET and direct fluorescence signals intensities were markedly 
reduced (Figs. 7-9). In addition, the bis-MANT-nucleotides potencies were more 
strongly reduced by the N583Q and N583H than by N583A mutation. These 
findings imply a substantial spatial constraint in this part of the binding pocket and 
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highlight the importance of the spatial arrangement of N583 for the binding of bis-
MANT-nucleotides.  
 
We showed previously that the base is locked into the catalytic site by 
the ionic bond formed between the carboxyl group of E588 and the amino 
group of K353 (4, 23). In addit ion,  disruption of this ionic bond by the K353A 
mutation largely reduces catalytic activity and lowers substrate affinity (4, 23) but 
K353R displayed less severe impairment of catalysis and no change in Km (23). In 
the present study, the affinity of Bis-MANT-ATP and Bis-MANT-CTP to the EF-
catalytic site is obviously reduced in EF3(K353A) mutant as revealed by higher Ki 
values (Table 2) and lower intensities of FRET and direct fluorescence signals 
(Fig. 10). The K353R mutation had only a small effect on inhibitor affinity as 
revealed by AC and fluorescence assays (Table 2 and Fig. 11).   The binding of 
bis-MANT-nucleotides to the EF-catalytic site was largely affected by disruption of 
the ionic bond by the K353A mutation. The K353R mutation that alters the spatial 
arrangement of the catalytic site but still allows ionic bridge formation did not affect 
the inhibitor potency substantially. 
 
The inhibitory potencies of position-5-substituted-MANT-nucleotides were 
slightly higher than those of the corresponding bis-MANT-nucleotides (Table 3). 
Similar data were obtained in case of propyl-ANT-nucleotides; i.e., propyl-ANT-
nucleotides were more potent than the corresponding Bis-propyl-ANT-analogues. 
For example, propyl-ANT-ATP was 13-fold more potent than Bis-propyl-ANT-ATP 
(Table 3). The most interesting finding is the higher potency of N-propyl-ANT-
nucleotides compared to the corresponding MANT-analogues. H351 amino acid 
interacts with amino function of MANT Substituents. These interactions my 
account for the higher potency of the compounds possess longer aliphatic chain at 
the N-position of anthraniloyl ring. It will also be very interesting to examine the 
effects of the longer aliphatic chain at the N-position of anthraniloyl ring.   
 
Our data have important conceptual implications for future drug development. 
These results are valuable for the development of potent EF inhibitors with selectivity 
relative to mammalian membranous ACs. Considering the fact EF exhibits a uniquely 
high affinity for base cytosine. The analysis of the interaction of PMECpp with EF will 
be particularly interesting.    
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Our present data have also practical implications for future EF inhibitor 
development. Specifically, the lower basal fluorescence of bis-MANT-analogues and 
the higher CaM-dependent fluorescence signals at the excitation wave length 350 nm 
(Figs. 4-11, C and D), could be used as non-radioactive high-throughput screening 
assay for EF inhibitors, including compounds binding to the catalytic site as well as 
compounds impeding with the interaction of EF and CaM. The establishment of such 
an assay will be facilitated by the fact that EF can be purified in large quantities. Such 
FRET assay constitutes a valuable complementation of the sensitive radiometric AC 
assay. 
 
To the best of our knowledge, this is the first study that systematically 
compares the interaction of bis-MANT-nucleotides with EF3 and EF3 mutants, using 
enzymological and biophysical analysis. 
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6. Conclusion 
In conclusion, using enzymatic and fluorescence spectroscopy approaches, 
our present study shows that bulky bis-MANT- and bis-propyl-ANT-substituted purine 
and pyrimidine nucleotides are readily accommodated by the nucleotide-binding-site 
of EF. Thus, the results of this study lend further support to the broad hypothesis that 
the catalytic sites of various structurally unrelated ACs including mammalian 
membranous ACs and bacterial AC toxins exhibit substantial degrees of 
conformational flexibility, allowing for numerous structural modifications in nucleotide 
inhibitors and the development of EF-potent and selective inhibitors. Our present 
study also provides valuable insights into the molecular mechanisms of ligand/EF 
interactions, yields highly sensitive fluorescence probes for EF analysis and 
facilitates the design of potent and selective EF inhibitors.  
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2. Abbreviation List
AC Adenylyl cyclase
Ac-NH2 Acetylamino
Ac Acetyl
AMPCPP Adenosine 5’-(α, β-methylene)-triphosphate
ANT Anthraniloyl
ATP Adenosine 5’-triphosphate
ANTXR1 Anthrax toxin receptor 1
ANTXR2 Anthrax toxin receptor 2
AVA Anthrax Vaccine Adsorbed
a.u Arbitrary unit
CaM Calmodulin
cAMP Adenosine 3’,5’-cyclic monophosphate
CDC Centers for Disease Control and Prevention
CTP Cytidine 5’-triphosphate
CyaA Exotoxin AC of Bordetella pertussis
d- Deoxy
DAD Diode array detector
DNA Deoxyribonucleic acid
EDTA Ethylene diaminetetraacetic acid disodium salt
EF Full length edema factor, anthrax adenylyl cyclase toxin
EF3 Calmodulin-activated catalytic domain of EF
EGTA Ethylene glycol tetraacetic acid
EI Electronic ionisation
eq Equivalents
EPR Electron Paramagnetic Resonance
ESI Electronic spray ionisation
ET Edema toxin (edema factor and protective antigen)
FDA Food and drug administration
Fig. Figure
FPLC Fast Protein Liquid Chromatography system
FRET Fluorescent resonance energy transfer
FS Forskolin
GMPPNP Guanosine 5’-[ β, γ-imido]triphosphate
GPCR G-protein coupled receptor
GTP Guanosine 5’-triphosphate
GTP γS Guanosine 5’-(γ-thio) triphosphate
HEPES 4-(2-hydroxyethyl)- piperazine-1-ethane sulfonic acid
HPLC High performance liquid chromatography
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IC50 Half-maximal inhibition concentration
IR Infrared spectroscopy
IMAC Immobilized metal ion-affinity chromatography
IMP Inosine 5’-monophosphate
IPTG Isopropyl-1-thio galactopyranoside
ITP Inosine 5’-triphosphate
ITPγS Inosine 5’-(γ-thio) triphosphate
J Coupling constant
K Capacity factor
kDa Kilodalton
Kd Dissociation constant
Ki Inhibition constant
Km Michaelis Menten constant
KO Knockout
LB medium Luria-Bertani medium
LC Liquid chromatography
LF Lethal factor
LRP6 Low density lipoprotein receptor-related protein 6
LT Lethal toxin (lethal factor and protective antigen)
LTP Long-term potentiation
mAC Membranous adenylyl cyclase
MANT Methyl anthraniloyl
MAPK Mitogen–activated protein kinase
mAU Milli absorbance unit
MEKs Mitogen–activated protein kinase Kinases
MES 2-(N-morpholino)ethanesulfonic acid
Mp Melting point
mRNA Messenger ribonucleic acid
MS Mass spectroscopy
MW Molecular weight
m/v Mass per volume
NDP Nucleoside 5’-diphosphate
NMP Nucleoside 5’-mono phosphate
NMR Nuclear magnetic resonance
NTP Nucleoside 5’-triphosphate
PA Protective antigen
PDB Protein data bank
PKA Protein kinase A
PKC Protein kinase C
PMEApp 9-[2-(phosphonomethoxy) ethyl]adenine diphosphate
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PMNS Polymorphonuclear cells
PMSF Phenyl methyl sulfonyl fluoride
PMT Photomultiplier
PPi Pyrophosphate
PTFE Polytetrafluorethylene
RAP1 Small GTPase protein
ROS Reactive oxygen species
rpm Rrevolution per minute
rPA Recombinant protective antigen
Rf Retention factor
Rt Retention time
sAC Soluble adenylyl cyclase
SD Standard deviation
SDS-PAGE Sodium dodecyl sulfate; polyacrylamide gel electrophoresis
Sf Spodoptera frugiperda
TNP 2,4,6 trinitrophenyl
Tris Tris(hydroxymethyl)aminomethane
tRNA Transfere ribonucleic acid
UTP Uridine 5’-triphosphate
v/v Volume per volume
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